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ABSTRACT 
 
Arginine metabolism and creatine biosynthesis in Yucatan Miniature piglets 
 
Creatine and creatine phosphate are amino acid-derived compounds that are necessary to 
meet short-term energy requirements. Creatine is a potent neuromodulator such that it is 
critical for neurological development in neonates. Neonates receive creatine in mother's 
milk. However, up to 77% of the daily creatine requirement must be synthesized 
endogenously. Creatine synthesis involves the conversion of arginine to guanidinoacetic 
acid (GAA) via L-arginine:glycine amidinotransferase (AGAT). The subsequent 
conversion of GAA to creatine requires methionine and guanidinoacetate N-
methyltransferase (GAMT). Following preterm birth, total parenteral nutrition (PN) is often 
required as a means of nutritional support. However, creatine is not a component of 
pediatric PN. In this situation, the entire creatine requirement must be met by de novo 
synthesis which consequently must create considerable demand for the amino acid 
precursors. Poor arginine status is common in neonates during PN, and this may 
compromise optimal creatine accretion. In this thesis, the capacity of the neonatal piglet to 
synthesize creatine was addressed, particularly when dietary creatine was not supplied. The 
data from first experiment demonstrated that PN support with creatine led to greater 
creatine concentrations in plasma and tissues, suggesting that neonates receiving PN may 
not be able to sustain optimal creatine accretion. The second major objective of this thesis 
was to investigate whether the low creatine accretion in piglets fed creatine-free diets was 
due to limited enzyme capacity or limited substrate availability. Using a multiple isotope 
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tracer method, we determined that inadequate dietary arginine and methionine, not enzyme 
capacity, limits GAA and creatine biosynthesis. Lastly, because we measured high AGAT 
activity in kidney and pancreas, we investigated how the plasma concentrations of 
precursor amino acids (arginine/citrulline) and creatine affected the release of GAA and 
creatine from these organs as well as from the intestine. We determined both arginine and 
citrulline can provide precursors for renal GAA synthesis. However, in the pancreas and 
intestine, citrulline cannot provide arginine to serve as a precursor for GAA. Overall, the 
results of this thesis clearly demonstrate that dietary concentrations of arginine and 
methionine are important mediators of creatine synthesis; the absence of dietary creatine, 
such as during PN feeding, must be taken into consideration when determining dietary 
requirements of neonates.   
 
Key words: Arginine, citrulline, methionine, creatine, AGAT, GAMT, tracer: tracee, 
enrichment, flux, organ balance 
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CHAPTER ONE 
 
1.0 Introduction 
1.1 Creatine  
 
Creatine is an amino acid-derived nitrogenous compound which occurs naturally in food, 
particularly in meat products and fish. Creatine and phosphocreatine together serve as a 
short-term energy reservoir in tissues with high and variable energy demands such as 
cardiac and skeletal muscles. Creatine is critical for brain function and neurological 
development in neonates. Severe creatine deficiency secondary to inborn errors of creatine 
synthesis or transport results in profound neurological defects, demonstrating its 
importance in brain development (Leuzzi et al, 2000, Battini et al, 2002, deGrauw et al, 
2002, Royes et al, 2006). Creatine can also be synthesized endogenously by a dual-organ 
process involving the kidneys and the liver. In terms of loss, creatine is subjected to 
continuous degradation and is excreted as creatinine at a daily rate of approximately 1.7% 
in adult humans (Wyss et al, 2000), which represents the maintenance cost of creatine in 
the body. In addition to fulfilling the maintenance requirement, rapidly growing neonates 
must accrue creatine as lean tissue pools expand. A factorial assessment in piglets 
suggested that the absolute creatine need in growing neonates is greater than that supplied 
by porcine milk (~12.7 versus 2.8 mmol.wk-1, respectively); consequently, neonates rely 
on de novo creatine synthesis to supply approximately 75% of the daily requirement 
(Brosnan et al, 2009).  
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1.1.1 Creatine biosynthesis 
 
Endogenous creatine synthesis is a simple two-step multi-organ reaction involving the 
kidney and the liver (FIGURE 1.1). Creatine synthesis requires three amino acids 
(arginine, glycine and methionine) and two enzymes (Walker et al, 1979). The first enzyme, 
L-arginine: glycine amidinotransferase [AGAT, EC number 2.1.4.1] is expressed in the 
kidney and pancreas and transfers the amidino compound from arginine to glycine in order 
to synthesize ornithine and guanidinoacetic acid (GAA). It has been postulated by Wyss et 
al (2000) that GAA is then transported to the liver where the methyl group of S-adenosyl-
L-methionine (SAM), which was donated by methionine, is transferred to 
guanidinoacetate. The enzyme guanidinoacetate N-methyltransferase [GAMT, EC 2.1.1.2], 
the second enzyme in the creatine synthesis pathway, is responsible for this methylation 
reaction.    
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FIGURE 1.1 Creatine biosynthesis pathway    
Abbreviations in the figure include, AGAT: L-arginine: glycine amidinotransferase, GAA: 
guanidinoacetic acid, GAMT: guanidinoacetate N-methyltransferase, HA: hepatic artery, 
HV:  hepatic vein, PV: portal vein, SAM: S-adenosyl-L-methionine, SAH: S-adenosyl-L-
homocysteine, Arg: arginine, Gly: Glycine.  
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The newly synthesized creatine is transported into the circulation via a sodium 
dependent creatine transporter (Fitch & Shields, 1966) for delivery to tissues and organs. 
Creatine is reversibly phosphorylated to phosphocreatine via creatine kinase. The larger 
pools of creatine and phosphocreatine are stored in tissues with high energy demands such 
as skeletal muscle, cardiac muscle and brain tissue (Wyss et al, 2000).   
 
1.1.1.1 AGAT  
 
The AGAT protein is highly expressed in the mammalian kidney and pancreas. A much 
lower level was reported in the brain, heart, lung, muscles, spleen and testes (Wyss et al, 
2000, Braissant et al, 2005). According to early studies in the literature, AGAT is the rate-
limiting enzyme for creatine biosynthesis and is subjected to end-product repression by 
ornithine and creatine (Sipila, 1980, McGuire et al, 1984).  
 
1.1.1.2 Kidney and pancreatic AGAT activity 
 
In the kidney, AGAT is predominantly bound to the external side of the mitochondrial inner 
membrane with a lesser amount located in the cytoplasm (Magri et al, 1975). According to 
immunochemical studies with monoclonal antibodies, the majority of transaminidase 
activity occurs in the proximal tubules of the kidney (McGuire 1984, Takeda et al, 1992). 
In the pancreas, immune-reactive transamidinase was detected only in acinar cells. The 
AGAT activity in pancreatic islet cells was below the detectable limit. Furthermore, the 
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whole pancreas AGAT activity was similar to that of the remaining pancreatic tissues after 
the islets had been separated from the acinar cells (Sorenson et al, 1995, da Silva, 2014).  
 
1.1.1.3 Interorgan creatine biosynthesis in adults 
 
In rats, the highest AGAT activity has been reported in kidney and pancreas; in contrast, a 
relatively high GAMT activity has been reported in the liver, and intermediate activity has 
been measured in the pancreas, compared to kidney and muscles (Walker et al, 1979). 
Furthermore, recent in-vivo studies have demonstrated the release of GAA by the kidneys 
in rats and humans (Edison et al, 2007). The conversion of GAA into creatine was further 
demonstrated in isolated rat hepatocytes (Edison et al, 2007, da Silva et al, 2009). 
Therefore, it is likely that a renal-hepatic axis for creatine biosynthesis is present in adults. 
A recent study by da Silva et al (2014) demonstrated that in pancreatic tissues from rats, 
GAMT activity was only 30% that of the specific activity of AGAT. This suggests that the 
capacity for GAA synthesis by the pancreas is greater than the capacity for creatine 
synthesis in this organ, and that the pancreas releases GAA into the portal blood (da Silva 
et al, 2014). However, no in vivo evidence for the role of the pancreas in whole body GAA 
and creatine supply currently exists to our knowledge.  
 
1.1.1.4 Creatine biosynthesis in neonates  
 
Neonates acquire only 23% of their creatine requirement via mother’s milk (Brosnan et al, 
2009). This means that the remaining 77% of the creatine requirement must be synthesized 
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by the neonate. In 7 – 8 d old sow-reared neonatal piglets, Brosnan et al (2009) studied the 
liver, kidney, pancreas, intestine, brain and muscle specific AGAT and GAMT activities. 
Pancreas had the highest AGAT specific activity among the organs they measured, with 
the kidney having the second highest. The AGAT activity in the pancreas was five times of 
that measured in the kidney on a per g of tissue basis. Liver had the highest specific GAMT 
activity among the tissues studied followed by pancreas and then kidney. The GAMT 
activity in liver tissue was four times higher than pancreas GAMT activity, and the pancreas 
GAMT activity was three times higher than the kidney. Based on carcass analysis, piglets 
between the ages of 4 and 11 days accrued 12.5 mmol creatine, and spontaneous loss was 
estimated as 2.3 mmol per week. Therefore, neonates must experience a high rate of de 
novo creatine synthesis, supported by high rates of activity by creatine synthesizing 
enzymes (Brosnan et al, 2009). Similar to adults, the highest AGAT activity appears to 
exist in the kidney and pancreas compared to liver, intestine, brain and muscle, whereas the 
highest GAMT activity occurs in the liver in neonatal piglets (Brosnan et al, 2009). 
However, in neonatal piglets, the existence of a renal-hepatic axis for the creatine 
biosynthesis has yet to be identified. The role of the pancreas in creatine synthesis also 
remains unknown in neonatal piglets. A direct measurement of GAA and creatine inter-
organ fluxes in piglets is required to confirm the importance of the kidney, pancreas and 
liver for creatine bio-synthesis.  
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1.1.1.5 Interactions between creatine supplementation and AGAT and GAMT activity 
 
In adult humans and rodents, creatine synthesis appears to be regulated by the activity of 
AGAT. Studies in rats that were fed diets supplemented with creatine reported lower 
AGAT activity and lower expression of AGAT mRNA compared to controls (McGuire et 
al., 1984, da Silva et al, 2014), demonstrating that creatine synthesis appears to be regulated 
via lower GAA production. In healthy adults, dietary creatine lowers the circulating GAA 
levels, suggesting dietary creatine inhibits endogenous GAA synthesis (Derave et al, 2004). 
In recent studies conducted in healthy rodents, kidney AGAT activity was lowered by more 
than 80% when creatine was provided in the diet at a concentration that was four-fold 
higher than the daily requirement (da Silva et al, 2009, 2014 & Deminice et al, 2011). 
However, the GAMT activity was not altered with creatine supplements. Therefore, AGAT 
is considered to be the rate limiting step in the creatine biosynthesis pathway in adult 
humans and rodents (Walker et al, 1979, McGuire et al, 1984). The capacity for creatine 
biosynthesis has not be been studied in neonates, nor has the AGAT and GAMT activities 
in response to creatine supplementation. In an acute study with neonatal piglets, GAA was 
infused intravenously to measure the effect of high circulating GAA on GAMT activity. It 
was demonstrated that the GAMT activity was driven by the GAA concentration, with no 
apparent feed back regulation via creatine (McBreairty et al, 2013). The effects of dietary 
creatine supplementation on the activities of AGAT and GAMT must be explored to 
elucidate the factors that affect the regulation of creatine biosynthesis in neonates. 
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1.1.1.6 Differential regulation of AGAT activity in the kidney and pancreas 
 
The regulation of kidney and the pancreatic AGAT activity in response to dietary creatine 
may differ between tissues. A recent publication by da Silva et al (2014) supports the idea 
that the feeding of creatine induces a reduction of AGAT activity in both kidney and 
pancreas in adult rats. In addition to the reduction of AGAT activity, the kidney had lower 
AGAT mRNA expression and lower AGAT protein abundance in rats fed creatine 
compared to rats fed a creatine-free diet. In contrast to this, pancreatic AGAT mRNA levels 
and AGAT protein abundance were not different between creatine-fed and creatine-free 
groups. Thus, kidney AGAT was likely regulated by a pre-translational mechanism while 
this mechanism seemed to be absent in pancreas. Furthermore, the reduction of rat 
pancreatic AGAT activity was only 30% compared to 80% in the kidney (da Silva et al 
2014). The different responses to creatine supplementation in kidney versus pancreas may 
be due to different roles for these organs in creatine homoeostasis. The kidney and 
pancreatic responses to creatine supplementation should be addressed in future studies of 
neonates. 
 
1.1.2 Creatine transporter (CT) 
 
In various tissues, cellular creatine uptake occurs via a sodium and chloride ion dependent 
creatine transporter protein (SLC6A8). The CT expresses in most tissues, with the highest 
levels found in skeletal muscle (Murphy et al, 2001), brain, kidneys and the intestine 
(Brosnan et al, 2007). Based on the intra-cellular to extra-cellular creatine gradient, the 
9 
 
same creatine transporter (SLC6A8) does not seems to be responsible for creatine release 
from the liver as is found in skeletal muscle (da Silva, 2009).  This suggests the expression 
of different creatine transporters.  
 
1.1.3 Creatine availability during fetal development 
 
In a spiny mouse model, the concentration of creatine in the kidney, liver, heart and brain 
of the fetus gradually increases during gestation, especially during the second half of the 
pregnancy (Ireland et al, 2009). Placental creatine concentrations also increase similarly to 
the fetal pattern. The placenta expresses relatively high amounts of creatine transporters 
and the transporter mRNA expression level peaks during late gestation in full-term 
pregnancies (Ireland et al, 2009). mRNA and protein levels for kidney AGAT and liver 
GAMT peak at 37 d or immediately after birth of a full-term pregnancy (Ireland et al, 2009) 
suggesting that the fetus relies on a supply of creatine from the placenta during fetal 
development. Growing neonates must accumulate substantial amounts of creatine; 
however, in a study using rats, only 12% of the total creatine accrued originated from rat 
milk (Lamarre et al, 2010). This suggests that the capacity for creatine synthesis gradually 
increases during fetal development and reaches a mature level sometime after birth to 
facilitate the shift from maternal dependency to endogenous synthesis of the creatine 
required. It is yet to be explored whether a premature birth interrupts the maturing of 
enzymes involved in creatine biosynthesis compared to that in a full-term birth.  
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1.1.4 Brain creatine homeostasis 
 
The source of creatine for the brain was thought, for many years, to come from the 
periphery (Wyss et al, 2000). However, it was more recently determined that AGAT and 
GAMT expresses within the brain, and within the brain, AGAT and GAMT express in a 
dissociated manner (Braissant et al, 2016). This suggests that within the central nervous 
system, GAA must be transported to GAMT expressing cells. Isotopic kinetic experiments 
demonstrated that GAA transported from AGAT expressing brain cells to GAMT 
expressing cells via the same transporter as creatine, SLC6A8 (Braissant et al, 2016). The 
transporter SLC6A8, is expressed by microcapillary endothelial cells at the blood-brain-
barrier (BBB) but is absent from surrounding astrocytes (Braissant et al, 2016). This 
suggests that the BBB may have a limited permeability for peripheral creatine. The 
literature suggests that no transport of GAA occurs at the BBB under normal physiological 
conditions. However, a net exit of GAA appears to occur at the blood-cerebrospinal-fluid-
barrier (BCSFB) most probably though the taurine transporter TauT (Braissant et al, 2016). 
 
1.1.5 Creatine deficiency and neurological disorders 
 
The brain creatine pool is relatively insignificant compared to the whole-body creatine 
pool, representing less than 2% of the entire body pool in neonatal piglets (Brosnan et al, 
2009). However, adequate brain creatine is of physiological importance and is critical to 
neurological developmental processes in neonates. Profound negative neuro-
developmental effects have been reported secondary to inborn errors of the enzymes 
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involved in creatine synthesis or defects in the creatine transporter. Infants with these 
genetic abnormalities exhibit neurological symptoms, including epilepsy, speech delay and 
mental retardation, if left untreated. Studies using magnetic resonance imaging (MRI) has 
revealed a profound depletion of brain creatine in infants with these genetic abnormalities 
(Clark et al, 2015). Case studies of infants suffering from creatine deficiency syndromes 
(ie. GAMT deficiency), have reported slow and variable recovery of cerebral creatine 
concentrations with creatine supplementation (Leuzzi et al, 2000; Stockler et al, 1996). 
Low permeability of the blood-brain-barrier to creatine has been suggested as the reason 
for the slow recovery of brain creatine levels (Hanna-El-Daher & Braissant, 2016). Creatine 
supplementation does not entirely reverse the pathology; however, very early provision of 
creatine appears to be beneficial for preventing negative neurological effects (Item et al, 
2001). Evidence from rodent models and humans supports the capacity for brain de novo 
creatine synthesis. However, in neonatal piglets, brain AGAT activity was not detected and 
GAMT activity was very low (Brosnan et al, 2009). The precise mechanisms by which 
GAA and creatine are made available to the brain are not clear. The recovery of brain 
creatine levels in infants who suffer creatine deficiency syndromes suggests that the healthy 
developing brain has the capacity to capture creatine from the periphery (Stockler-Ipsiroglu 
et al, 1996). However, the complete recovery of brain creatine concentrations may take one 
to two years following the initiation of supplementation (Stockler-Ipsiroglu et al, 2015). 
Therefore, the accrual of brain creatine seems to be a very slow process, even in a 
pathophysiological state of compromised creatine synthesis. Whether human neonates are 
capable of de novo creatine synthesis in the brain is unclear.  
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Accretion of creatine in the fetal brain likely depends on both the maternal supply 
and endogenous de novo synthesis in the fetus (Hanna-El-Daher & Braissant, 2016). In the 
first weeks after birth, piglets grow remarkably fast, demanding a high rate of creatine 
accretion for the expanding muscle mass. In the study on creatine accretion in early life, 
the piglets’ body weight increased by 50% between 4 and 11 days of age but there was no 
change in the brain weight (Brosnan et al, 2009). The total body creatine pool increased by 
71% over 7 days and the circulating creatine pool increased by 171%. In contrast, the brain 
creatine pool did not change. Therefore, unlike muscle, the brain does not appear to have 
the same need for rapid creatine accretion in the neonatal period. The rate of creatine 
degradation in the neonatal brain is also unknown but is likely very slow. In infants with 
AGAT deficiency, neurological symptoms do not become apparent until the second year of 
life (Mercimek-Mahmutoglu et al, 2009). Thus, brain creatine likely degrades too slowly 
to create a deficit until the second year of life. Based on current knowledge, it is unclear 
whether the brain synthesizes its own creatine locally or takes it up from the periphery, or 
whether both synthesis and uptake contribute to maintain the brain creatine equilibrium in 
neonatal piglets. Creatine deficiency disorders secondary to inborn errors in creatine 
metabolism have been shown to result in profound neurological defects, demonstrating the 
importance of creatine in brain metabolism. Under normal health conditions, neonates 
receive a dietary supply of creatine. However, certain dietary treatments, such as the use of 
soy-based infant formulas or pediatric parenteral nutrition (PN), are devoid of creatine. In 
these circumstances, the requirement for creatine must be met entirely by de novo synthesis 
from the amino acids arginine, glycine and methionine.  
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1.2 Arginine 
 
Arginine is an aliphatic straight chain amino acid with a guanidine group at the distal end 
of the chain. As the guanidine group is positively charged in neutral, acidic and even 
somewhat basic environments, arginine shows basic chemical properties.  
 
1.2.1 Biological importance of arginine 
 
Arginine is an important and abundant amino acid. It constitutes approximately 6.9% of 
total body proteins in fetal and neonatal piglets (Williams et al, 1954) and 7.7% in the 
human fetus (Widdowson et al, 1979). Arginine is also involved in the synthesis of other 
biologically important molecules such as nitric oxide (NO), polyamines and creatine. 
Arginine plays a critical role as a urea cycle metabolite and is therefore important for 
ammonia detoxification. The fate of arginine catabolism via the urea cycle or through NO 
or creatine synthesis depends on the cellular activities of the enzymes involved in the 
different synthetic pathways, as well as the availability of substrates.  
 
Nitric oxide is an end product of arginine metabolism whereby arginine is converted 
into citrulline and nitric oxide. NO acts as a vasodilator which modulates blood pressure 
and thus blood flow. NO also acts as a neurotransmitter and mediator of the immune 
response (Homer & Wanstall, 2000). The amount of arginine utilized for NO synthesis 
accounts for a small amount in adult man, such that the fraction of whole-body arginine 
flux associated with NO synthesis in healthy humans was 1.2% (Castillo et al, 1996). 
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Furthermore, whole-body arginine flux associated with urea synthesis is 15% in healthy 
humans (Castillo et al, 1996). Currently, there are no data available for neonates to describe 
the proportion of arginine flux dedicated to urea and NO synthesis.  
 
Arginine is also a precursor of ornithine, which is the amino acid precursor for 
polyamine synthesis. Polyamines (putrescine, spermidine and spermine) regulate gene 
expression, DNA and protein syntheses, apoptosis, cell proliferation and differentiation, 
and thus are essential for growth and differentiation of cells in many tissues including 
intestinal epithelial cells (Johnson, 1988; Blachier et al, 1995).  
 
The necessity for de novo creatine synthesis may place a significant demand on 
arginine, potentially limiting the partitioning of arginine towards growth or other metabolic 
pathways. However, the proportion of arginine flux required to meet the demands for 
creatine synthesis have not yet been empirically determined in human infants or neonatal 
piglets.   
 
1.2.2 Arginine de novo synthesis 
1.2.2.1 Arginine de novo synthesis in adults  
 
In an in-vitro experiment, it was determined that the small intestine of adults converts 
proline, glutamate and glutamine effectively into citrulline (Jones, 1985), a precursor for 
arginine. This is due to high activities of pyrroline-5-carboxylate synthase (P5CS) (Jones, 
1985), ornithine aminotransferase (OAT), carbamoyl phosphate synthetase (CPS-1) and 
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ornithine transcarbamylase (OTC) activities in adult intestinal mucosa (Wu, 1998) 
(FIGURE 1.2). However, a study by Marini et al (2010) demonstrated that the dietary 
glutamine and proline made only a minor contribution to the synthesis of citrulline in mice, 
even when the mice were fed an arginine-free diet. The extraction of plasma arginine and 
ornithine by the small intestine was adequate to support citrulline synthesis even with the 
arginine-free diet. In another study conducted in mice, using multiple isotope tracers, 
Marini et al (2012) showed that dietary and plasma arginine were the main precursors for 
citrulline synthesis in the gut during feeding and food deprivation, respectively (Marini et 
al, 2012). 
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Used with permission from the Journal of Nutrition (Bertolo & Burrin, 2008). 
 
FIGURE 1.2: Metabolic pathway of arginine    
This figure represents arginine metabolism in adult human (small intestinal-renal axis).  
Abbreviations ASL: argininosuccinate lyase; ASS: argininosuccinate synthetase; CPS-I: 
carbamoyl phosphate synthetase; OAT: ornithine aminotransferase; OTC: ornithine 
transcarbamylase; P5C: pyrroline-5-carboxylate; P5CDH: pyrroline-5-carboxylate 
dehydrogenase.  
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Low intestinal activities of argininosuccinate synthetase (ASS) and argininosuccinate lyase 
(ASL), and high activity of arginase results in the net release of citrulline into the portal 
vein (Cynober et al, 2002). In contrast, appreciable ASS and ASL enzyme activities in the 
kidney in conjunction with very low renal arginase activity facilitate net arginine release 
into the peripheral circulation (Brosnan et al, 2003; Dhanakoti et al, 1990). Therefore, small 
intestinally-derived citrulline is the major precursor for renal de novo arginine synthesis; 
thus, the small intestinal–renal axis is considered to be the major pathway for arginine de 
novo synthesis in adult humans. Using an in-vivo amino acid tracer technique, Ligthart-
Melis et al (2007; 2008) reported that arginine was synthesized from glutamate and 
glutamine in adult humans. However, those results were obtained using nitrogen-labelled 
tracers, which have been criticized because the movement of the tracer could potentially 
reflect transamination. Recently, a study by Tomlinson et al (2011a) used multiple carbon 
labelled tracers (arginine and proline) to determine whether dietary proline is a precursor 
for de novo arginine synthesis in adult humans. They demonstrated that 40% of newly 
synthesized arginine was derived from dietary proline. Thus, proline is considered an 
important dietary precursor for arginine synthesis in the adult human. A subsequent study 
by the same research group also clearly identified glutamine as a precursor for arginine, by 
using multiple glutamine tracers (13C and 15N). Based on the 13C tracer enrichments and 
flux, 50% of newly synthesized arginine was derived from glutamine (Tomlinson et al, 
2011b).   
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1.2.2.2 Arginine de novo synthesis in neonatal piglets 
 
Arginine is a metabolically important amino acid for neonates during the rapid growth 
period, and the consequences of limited arginine availability have captured the attention of 
clinicians and researchers.  
 
Arginine concentration in sow milk is relatively low (4.4% of total amino acids at 
d 21 of lactation) compared to the concentration of some other indispensable and 
conditionally indispensable amino acids such as proline (11.7%), leucine (8.9%), lysine 
(7.9%) or glutamate and glutamine (20.8%) (Davis et al, 1994). Mature sow milk provides 
approximately 0.47 g.kg-1.d-1 of arginine to the suckling neonatal piglet (Moughan et al, 
1992). According to the NRC recommendations (1998), the dietary requirement for 
arginine for a healthy neonatal piglet is 0.38 g.kg-1. d-1; as such, it is met by the arginine 
concentration in sow milk. However, Brunton et al (2003) measured protein synthesis rates 
as a functional determinant of the adequacy of arginine intake in parenterally-fed piglets; 
the intravenous arginine supply necessary to maximize muscle protein synthesis was 
greater than 1.2 g.kg-1.d-1. Sow milk is a relatively poor source of arginine as sow milk 
provides only 40% of the arginine required by the neonate. However, sow milk contains 
substantial amounts of the arginine precursors glutamine, glutamate and proline and trace 
amounts of citrulline and ornithine (Wu et al, 1994). Thus, sow-reared, neonatal piglets 
must synthesize a significant portion of their daily requirement of arginine to maximize 
growth. 
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De novo arginine synthesis in neonates does not follow the same intestinal-renal 
axis as has been described in adults. A series of studies in neonatal piglets have clearly 
shown that arginine synthesis occurs in the small intestine (Brunton et al, 1999; Bertolo et 
al, 2003; Wilkinson et al, 2004). Brunton et al (1999) were the first to demonstrate in 
neonatal piglets that feeding an arginine-free diet intravenously resulted in the rapid onset 
of severe hyperammonemia, despite the presence of proline in the diet. The same diet 
delivered intragastrically resulted in only moderate hyperammonemia after eight hours of 
feeding, indicating that de novo arginine synthesis occurred from dietary proline only when 
delivered into the gut. Bertolo et al (2003) used isotope kinetic analyses to isolate the 
metabolic roles of the small intestine in the inter-conversions of arginine, proline and 
ornithine in neonatal piglets. This study isolated intestinal metabolism from hepatic and 
peripheral metabolism by infusing isotopes into the portal vein. They observed an absence 
of proline to ornithine conversion and very low ornithine tracer conversion into arginine 
during intraportal compared to intragastric tracer infusions. Furthermore, there was no 
difference in arginine to ornithine or ornithine to proline conversion between the two routes 
of feeding. Only 10% of proline requirement was synthesized in the small intestine 
compared to 50% of arginine requirement (Bertolo et al, 2003). Accordingly, near absence 
of small intestinal proline de novo synthesis facilitated a net positive release of arginine 
into the portal blood. Bertolo et al (2003) were the first to use multiple tracers to estimate 
the arginine de novo synthesis in the small intestine. Wilkinson et al (2004) also found 42–
63% of whole-body arginine synthesis occurred during the first pass intestinal metabolism 
in neonatal piglets. Later, Urschel et al (2005) demonstrated that the hepatic contribution 
to net arginine synthesis is negligible. Indeed, they found that net arginine de novo 
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synthesis is dominated by the small intestinal mucosa of neonatal piglets by isolating the 
first pass hepatic metabolism through the infusion of intraportal and intravenous tracers. 
Based on the enzyme activities (in-vitro) measured in mucosal tissues in humans and piglets 
(Kohler et al, 2008; Wu, 1998), and in-vivo multi-tracer studies using various routes of 
administration in neonatal piglets (Bertolo et al, 2003; Wilkinson et al, 2004), it is clear 
that arginine de novo synthesis occurs in the small intestinal enterocytes in neonates.  
 
1.2.2.3 Intestinal-renal axis for arginine synthesis in neonates 
 
In the early stages of neonatal life, the functionality of the intestinal-renal axis for the 
arginine de novo synthesis is doubted. Urschel et al (2007) conducted a study in piglets 
which provided citrulline in the diet in an amount that was equimolar to a high arginine 
intake (1.8 arginine g.kg-1d-1) along with an arginine deficient diet (0.2 g arginine.kg-1d-1) 
fed intragastrically. Normal plasma ammonia and urea concentrations were sustained; 
however, compared to piglets fed the arginine deficient diet, the whole-body arginine flux 
was more than two-fold higher in piglets supplemented with citrulline. Interestingly, 
arginine fluxes did not differ between piglets fed high arginine and those supplemented 
with citrulline. Further studies are warranted to explore whether citrulline is a potent 
precursor for arginine synthesis in neonatal piglets and whether the conversion of citrulline 
to arginine occurs in the renal tissues of neonatal piglets.  
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1.2.3 Arginine as a semi-indispensable amino acid for sow-reared neonatal piglets 
 
In contrast to healthy adults, healthy neonatal piglets have been shown to require at least 
part of their whole-body arginine requirement from diet. Apparently, the capacity for de 
novo synthesis is not sufficient to meet the whole-body needs during rapid growth and 
development (Wilkinson et al, 2004; Kim & Wu, 2004). A study by Kim & Wu (2004) 
demonstrated that even with relatively normal feeding circumstances, dietary arginine 
intake at a concentration delivered in sow milk might be inadequate. In that study, a sow 
milk replacer was used to feed piglets. The formulas contained arginine at either the sow 
milk level or was supplemented with arginine at 0.2% and 0.4%. The piglets fed arginine 
at the sow-milk level had significantly lower plasma arginine, citrulline and ornithine 
concentrations by days 14 and 21 of age; this was accompanied by significantly higher 
plasma ammonia (Kim & Wu, 2004). Arginine supplementation enhanced daily weight 
gain by 28 and 66% in the two groups, compared to control piglets who received arginine 
at the sow milk level. The authors suggested that even normal, healthy neonatal piglets 
cannot synthesize adequate amounts of arginine to meet the requirement for rapid growth 
during early life. However, it is important to note that colostrum and sow milk are also 
important sources of polyamines and other growth factors (Kelly et al, 1991; Cheng et al, 
2006) as well as providing exogenous creatine (Brosnan et al, 2009). Thus, a formula diet 
containing arginine at the concentration found in sow milk may not produce a rate of growth 
that is truly reflective of the sow-reared piglet.  
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1.2.4 Arginine partitioning into NO and urea  
 
Arginine is the precursor for NO synthesis. The fraction of whole-body arginine flux 
associated with NO synthesis in healthy adult humans is small (1.2%) (Castillo et al, 1996). 
In healthy adults, the first-pass splanchnic use of dietary arginine was about 38% (Castillo 
et al, 1993). Interestingly, the amount of dietary arginine intake did not have an effect on 
NO synthesis, and a similar proportion of arginine flux was used for NO synthesis in both 
fed and fasted situations (Castillo et al, 1996). In contrast, dietary L-arginine 
supplementation stimulated endothelial NO synthesis in adult rats (Kohli et al, 2004). 
Currently, there are no such data available for healthy human neonates. In sick neonates 
recovering from persistent pulmonary hypertension (PPHN), NO synthesis accounted for 
less than 0.5% of plasma arginine flux, which was less than the proportion of arginine 
converted into NO in healthy adults. In the same study of infants with PPHN, Castillo et al 
(1995) reported that the rate of plasma arginine conversion to NO synthesis was higher 
(45.6 versus 10.3 µmol. d-1) when dietary arginine intake was 36 compared to 16 µmol.kg-
1.h-1. Urschel et al (2007) studied the synthesis of NO from dietary arginine in healthy 
neonatal piglets. In contrast to sick human neonates (0.5%), Urschel et al (2007) 
demonstrated that NO synthesis accounted for 13% of whole-body arginine flux in enterally 
fed neonatal piglets, irrespective of the amount of arginine in the diet. In the Urschel study, 
the isotope tracers were infused into a gastric catheter, and as such included small intestinal 
NO synthesis, as opposed to Castillo’s study which used IV infusion. The difference 
between the two studies in the amount of arginine flux directed to NO synthesis is quite 
large, which may be due to the route of infusion, or the model used. Urschel et al (2007) 
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fed either generous (1.8 g.kg-1.d-1) or deficient (0.2 g.kg-1.d-1) arginine diets intragastrically 
to piglets and found significantly higher whole-body arginine conversion into NO with the 
higher intake of arginine. Accordingly, piglets fed the generous arginine diet had 
significantly higher NO synthesis compared to piglets fed the deficient arginine diet, but 
the proportion of whole-body arginine converted into NO was not different. Thus, greater 
arginine intake led to greater NO production in both sick human neonates and neonatal 
piglets; however, arginine deficient piglets could not up-regulate NO synthesis.  
 
1.2.5 Importance of arginine in creatine synthesis in neonatal piglets 
 
Despite the importance of arginine and creatine in neonates, there have been no reports of 
the impact of dietary arginine availability on GAA and creatine concentrations in an in-
vivo neonatal model. A piglet study from our lab produced preliminary data on the tissue 
and plasma GAA and creatine concentrations when piglets were provided with very low to 
very high concentrations of dietary arginine in an intravenous diet for a duration of less 
than 20 hours. We found that the liver and plasma GAA and creatine concentrations 
reflected the short-term manipulation of dietary arginine in PN, suggesting the importance 
of adequate arginine intake to maintain creatine concentrations in neonatal piglets. 
Understanding the relationship between dietary arginine intake and creatine status in 
neonates is also important as the concentrations of arginine and creatine in the commercial 
infant formulas are quite variable, and at the present time all commercial parenteral 
products are devoid of creatine.   
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1.3 Methionine  
 
Methionine is a sulfur amino acid that is involved in multiple important metabolic 
pathways. Methionine, similar to most other amino acids, is primarily involved as a 
substrate for protein synthesis. Methionine is also a key precursor for the synthesis of non-
protein metabolites such as cysteine, taurine, glutathione, and as the major methyl donor, 
it is involved in the synthesis of number of methylated products including creatine, 
phosphatidylcholine (PC) and DNA.   
 
1.3.1 Methionine cycle  
 
In the methionine cycle, methionine is adenylated to form S-adenosylmethionine (SAM) 
via methionine adenosyltransferase (MAT). SAM is a universal methyl donor for many 
transmethylation reactions. SAM transfers terminal methyl groups (labile methyl groups) 
to various substrates for the synthesis of transmethylated products and S-
adenosylhomocysteine (SAH) via various methyltransferases. Creatine and PC are 
quantitatively the major methylated products, but SAM is involved in numerous other 
methylation reactions including DNA methylation, and it is also involved in polyamines 
synthesis.  SAH conversion into homocysteine is a reversible reaction. Homocysteine has 
two pathways and can transfer its sulfur atom irreversibly to cysteine through a 
"transsulfuration" reaction. Alternatively, homocysteine may be remethylated to 
methionine by methyl donors through one of two distinct pathways. In one reaction, 
methionine synthase (MSyn) transfers the labile methyl group from 5-
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methyltretrahydrofolate (folate) to homocysteine. Cyanocobalamin (B12) act as a cofactor 
for this reaction. A second route involves betaine: homocysteine methyltransferase 
(BHMT) which transfers a methyl group from betaine, a nutrient derived from choline, to 
homocysteine (Robinson et al, 2016a).   
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                      Used permission from the Oxford University Press (Robinson et al, 2016a) 
 
FIGURE 1.3 Schematic diagram of methionine cycle   
Circled numbers indicate the enzymes: 1) glycine N-methyltransferase (GNMT, (EC 2.1.1.20); 2) 
guanidinoacetate methyltransferase (GAMT, EC 2.1.1.2); 3) phosphatidylethanolamine 
methyltransferase (PEMT EC 2.1.1.17); 4) DNA methyltransferase (DNMT, EC 2.1.1.204/37); 5) 
various phospholipases (mostly phospholipase D; EC 3.1.4.4); 6) both choline dehydrogenase (EC 
1.2.1.8) and betaine aldehyde dehydrogenase (EC 1.1.3.17); 7) betaine:homocysteine 
methyltransferase (BHMT, EC 2.1.1.5); 8) serine hydroxymethyltransferase (SHMT, EC 2.1.2.1); 
9) methylenetetrahydrofolate reductase (MTHFR, EC 1.5.1.15); and 10) methionine synthase 
(MSyn, EC 2.1.1.13). DMG, dimethylglycine; GAA, guanidinoacetic acid; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; THF, tetrahydrofolate. 
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1.3.2 Methionine synthesis  
 
Methionine is an indispensable amino acid, but its metabolism is partially cyclic; when 
methionine participates in transmethylation reactions, it can be reformed (remethylated) 
from methyl donors such as folate (MSyn pathway) or betaine/choline (BHMT pathways). 
According to current knowledge on methionine metabolism, methionine becomes available 
to the body in three ways, dietary methionine intake, remethylation of homocysteine by 
dietary methyl donors such as folate and choline (via betaine) and methionine release via 
body protein break down. In a study by Robinson et al (2016b), piglets were fed either a 
methyl donor deficient diet or a methyl donor sufficient diet. These piglets were fed 
methionine at the requirement concentration for 5 days. On day six, dietary methionine was 
reduced to 80% of the requirement in both groups. Transmethylation and remethylation 
were affected by deficient methionine, however, neither transsulfuration or protein 
synthesis were affected. This suggests the deficiency of methionine sustained protein 
synthesis by sacrificing transmethylation and remethylation reactions (Robinson et al, 
2016b). According to Robinson et al (2016b) and Riedijk et al (2007), the remethylation 
accounts for only 7 - 10% of the whole-body methionine flux, however, a major portion of 
the rate of appearance of methionine was directed towards protein synthesis and 
transmethylation reactions. Transmethylation reactions are critical during neonatal 
development and because they are sacrificed during methionine deficiency, the methionine 
requirement must include the demands for all the fates of methionine, including protein 
synthesis, transsulfuration, and transmethylation.   
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1.3.3 Methionine requirement  
 
The methionine requirement of piglets was determined using the indicator oxidation 
technique (Shoveller et al, 2003a). This method measures the methionine intake necessary 
to optimize whole-body protein synthesis. Piglets supported on parenteral nutrition have a 
lower methionine requirement (0.26 g.kg-1.d-1) compared to those fed enterally (0.44 g.kg-
1.d-1), suggesting that first pass splanchnic metabolism consumes approximately 30% of the 
dietary methionine in healthy, enterally-fed piglets. This requirement was determined using 
a cysteine-free diet. Parenteral and enteral methionine requirements were lower (0.18 g.kg-
1.d-1 and 0.25 g.kg-1.d-1, respectively) when excess cysteine was included in the diet, 
indicating that ~40% of the methionine requirement was spared by adequate dietary 
cysteine in growing piglets (Shoveller et al, 2003b). 
 
1.4 The metabolic burden of creatine synthesis on precursor amino acids  
 
Creatine biosynthesis requires three amino acids: glycine, arginine and methionine. Piglets 
can synthesize glycine from serine, choline or threonine. Glycine is also available from 
endogenous protein breakdown. Other than de novo synthesis and protein breakdown, sow 
milk also provides a source of dietary glycine during the neonatal period (Davis et al, 1994). 
The estimated amount of glycine necessary for creatine synthesis in neonatal piglets is 10% 
of the amount provided in sow milk. However, the glycine deposited as body proteins in 
the neonatal period is greater than four times the intake of glycine from sow milk (Brosnan 
et al, 2009). Accordingly, glycine appears to be a dispensable amino acid for healthy 
29 
 
neonatal piglets. In contrast, a study was conducted with preterm infants fed human donor 
breast milk in which 15N glycine was infused as a tracer. None of the tracer appeared in 
urea, and the authors speculated that the glycine provided in the milk was insufficient to 
meet the demand for growth, and that glycine might be a conditionally indispensable amino 
acid for sick neonates (Jackson et al, 1981). However, further experiments are warranted 
to estimate the capacity for glycine synthesis in healthy neonates. 
 
Arginine is available to neonates via endogenous synthesis and both arginine and 
methionine are available through the release from protein breakdown and intake from sow 
milk. The absolute amount of arginine needed for creatine biosynthesis is equivalent to 
20% of arginine available from sow milk (Brosnan et al, 2009). The net arginine deposition 
during neonatal growth was estimated as 6.7% of total body proteins (Wu et al, 2004). 
Based on this calculation, the arginine deposition into proteins was equivalent to twice the 
amount of arginine provided by sow milk. Therefore, the arginine requirement for protein 
synthesis without considering the arginine requirement for urea, NO, creatine and other 
non-protein metabolite synthesis, exceeds the arginine intake from sow milk. This 
demonstrates that substantial endogenous arginine synthesis must occur in growing piglets. 
 
Similar to the calculation for arginine, Brosnan et al (2009) also estimated the net 
methionine deposition in neonates (Brosnan et al, 2009). Subsequently, Robinson et al 
(2016b) reported an estimate of methionine accretion that was similar Brosnan et al (2009), 
despite the fact that Robinson et al (2016b) restricted the methionine intake to 80% of 
requirement. In the Robinson et al (2016b) study, piglets were fed either a methyl deficient 
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(methionine at 80% of the requirement) or methyl sufficient (restricted methionine with 
added folate, choline or betaine) diet. The methionine deposition in proteins was not 
different between treatments, and an equivalent amount of methionine was directed towards 
transsulfuration; however, the remethylation and transmethylation reactions were affected 
by the availability of the methyl donors (Robinson et al, 2016b). A methyl deficit would 
likely place a metabolic burden on the availability of methionine for the methylation 
reactions. This should be addressed during the formulation of neonatal diets as methylation 
reactions such as creatine and phosphatidylcholine synthesis are of paramount importance.    
 
1.5 Parenteral Nutrition (PN)  
 
Parenteral nutrition (PN) refers to the provision of a nutritionally complete, elemental 
formula via an intravenous route; the provision of nutrients into the gastrointestinal tract is 
known as enteral nutrition (EN). PN is frequently necessary for the nutritional management 
of preterm or premature neonates who cannot tolerate complete enteral feeding. It is 
common for newborn preterm infants to require short term PN for nutritional support, often 
due to severe respiratory distress syndrome that precludes oral feeding (Hay, 2008). Long 
term PN support is sometimes required by infants born with congenital gastrointestinal (GI) 
malformations, or those who develop necrotizing enterocolitis (NEC) which can lead to 
short bowl syndrome (Quiros-Tejeira et al, 2004). In neonatal intensive care units, 
providing small amounts of enteral feeding, known as partial enteral nutrition, in parallel 
with PN feeding is a common practice to avoid complications that are known to develop 
with prolonged PN feeding.  
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1.5.1 PN and amino acids  
 
One of the main aims of PN support is to provide adequate but not excessive amounts of 
indispensable amino acids to fulfill the requirement for whole-body protein synthesis and 
growth. Excess amounts of indispensable amino acids or their by-products could stress 
immature metabolic systems in neonates, and lead to the accumulation of toxic end 
products such as ammonia. For human neonates, the amino acid profiles of the various 
commercial parenteral products currently available were devised based on the amino acid 
profiles in human milk, infant plasma or cord blood (Brunton et al, 2000).  
 
Ideally, the specific enteral or parenteral requirement for each indispensable amino 
acid should be determined in neonates; currently, they are not well defined. What is 
currently known about the requirements for the indispensable amino acids has been 
determined by a number of different methods in adults and to a lesser extent in children. In 
the past, nitrogen balance was used to determine individual amino acid requirements of 
adult humans (Zello et al, 1995). However, more precise metabolic approaches such as 
plasma amino acid concentrations, amino acid oxidation (AAO) and the indicator amino 
acid oxidation (IAAO) techniques were subsequently introduced to estimate amino acid 
requirements (Zello et al, 1995). The AAO technique is based on the concept that amino 
acids in excess of the amounts needed for protein synthesis are preferentially oxidized. An 
important methodological issue with AAO is that all of the excess amino acids are not 
always oxidized completely but catabolized to other metabolic products (Zello et al, 1995). 
The IAAO technique was developed to address such issues. The IAAO technique is based 
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on the partitioning of a single indispensable amino acid between oxidation and protein 
synthesis, and the balance is sensitive to the most limiting indispensable amino acids in the 
diet. The provision of excess amounts of the previously limiting amino acid will reduce the 
oxidation of the indicator amino acid to a low and constant level. Lately, this method has 
been adapted to be minimally invasive and has been employed to measure the requirement 
for some amino acids in parenterally fed neonates (Bertolo et al, 1998; House et al, 1998). 
 
The amino acid requirements of infants are not the same for parenteral versus 
enteral feeding for many amino acids. Wykes et al (1992) demonstrated that plasma amino 
acid concentrations were very different in human neonates fed the same elemental formula 
via the two different routes, suggesting that a significant role is played by the splanchnic 
organs in amino acid metabolism. A series of studies in neonatal piglets demonstrated that 
the requirements for lysine, threonine, branched-chain amino acids and methionine are 
substantially lower during PN feeding compared to enteral feeding (House et al, 1998; 
Bertolo et al, 1998; Elango et al, 2002; Shoveller et al, 2003ab). The methionine, threonine 
and lysine requirements for post-surgical intravenously fed human neonates estimated by 
IAAO technique were also lower than the amounts provided in commercially available 
pediatric PN products (Courtney-Martin et al, 2008, Chapman et al, 2009; Chapman et al, 
2010). These studies have demonstrated the importance of considering the concentration of 
individual amino acids in the diet when the route of feeding by-passes the splanchnic 
tissues.  
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1.6 Arginine metabolism in pathological situations 
1.6.1 Arginine de novo synthesis in human neonates during pathological situation 
 
PN feeding reduces plasma arginine in human neonates: Arginine is considered to be a 
conditionally indispensable amino acid for human neonates. It is unlikely, based on current 
evidence, that the healthy neonate can synthesize adequate arginine in the small intestinal 
mucosa from abundantly available precursors, suggesting that arginine is semi-
indispensable. Early in the history of PN use for neonates, it was clear that there was a 
requirement for arginine in PN solutions. Hypoargininemia in parallel with 
hyperammonemia was observed in three infants receiving total parenteral nutrition with a 
synthetic amino acid mixture (Heird et al, 1972). Interestingly, the hypoargininemia and 
accompanying hyperammonemia resolved with the administration of arginine 
intravenously, clearly demonstrating the inadequacy of arginine in neonatal PN. However, 
the absolute requirement for arginine was not known; nor was it known that bypassing 
small intestinal metabolism would impair de novo synthesis of arginine. Later studies by 
Batshaw et al (1984) reported that premature neonates had elevated plasma ammonia and 
significantly lower plasma arginine and ornithine concentrations within the first two 
months of life, compared to normal birth weight neonates. Again, elevated plasma ammonia 
was corrected by the provision of additional arginine in PN. These findings suggest that the 
concentration of arginine in the intravenous diets used for premature human neonates was 
not sufficient to maintain ammonia detoxification, even with full PN feeding.  
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1.6.2 Arginine metabolism and PN feeding in neonatal piglets 
 
The recommended intake of arginine has not been established during PN feeding for 
neonatal piglets. Therefore, commercial pediatric PN formulas vary greatly in arginine 
content. Brunton et al (2000) reported the amino acid compositions of different brands of 
pediatric PN solutions, and the arginine levels in those brands varied from 0.7 g.kg-1d-1 to 
1.8 g.kg-1d-1. According to the NRC (1998), the dietary requirement of arginine for healthy 
neonatal piglets is 0.38 g.kg-1d-1. However, hypoargininemia and hyperammonemia 
occurred during a PN feeding trial in piglets provided arginine at the NRC requirement 
(Brunton et al, 2003). Even with slightly more than double the amount of arginine than the 
NRC recommendation, low plasma arginine and high ammonia concentrations were 
observed. This amount of arginine (1.0 g arginine.kg-1d-1) is mid-range among the 
concentrations delivered by the various commercial pediatric products. In the neonatal 
piglet, it is apparent that the concentration is not adequate to meet the metabolic demands 
for arginine during PN feeding. Brunton et al (2003) demonstrated that 1.0 g.kg-1d-1 of 
arginine in PN did not maximise muscle protein synthesis in PN-fed neonatal piglets, which 
implies that although ureagenesis might be maintained, the demand for arginine for creatine 
biosynthesis, NO synthesis and growth may not be fulfilled. In the same study, plasma 
arginine concentration increased with increasing dietary arginine, and reached a plateau at 
a concentration similar to sow-fed reference piglets only when the piglets received greater 
than 1.2 g.kg-1d-1 of arginine. The plasma ammonia concentration was low and stable at 
this arginine intake, although it was unclear whether muscle protein synthesis was 
maximised. Therefore, they suggested that metabolic arginine requirement for PN-fed, 
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neonatal piglets must be 1.2 g.kg-1d-1 or higher. Arginine de novo synthesis becomes 
compromised during PN feeding, and as such, the whole-body arginine requirement must 
be met by the dietary (IV) intake. In infant studies that provided arginine in PN at 
concentrations similar to human milk, hypoargininemia and hyperammonemia were 
reported among premature neonates (Batshaw et al, 1984). Therefore, de novo arginine 
synthesis in the neonatal intestine seems to be impaired in both humans and piglets during 
PN feeding. 
 
1.7 PN, arginine, creatine and protein synthesis 
 
The growing fetus relies at least partially on the maternal supply of creatine via the placenta, 
but after birth the newborn must rely on endogenous synthesis (Ireland et al, 2009, Lamarre 
et al, 2010). It remains to be determined whether the prematurely born infant has the 
capacity to synthesize creatine efficiently, particularly if a dietary creatine source is not 
supplied. Following preterm birth, PN is often required as a means of nutritional support 
for infants who are medically unstable, or with gastrointestinal disorders or prolonged 
intolerance of enteral feeding. However, creatine is not a component of paediatric 
parenteral nutrition products. In this situation, the entire creatine requirement must be met 
by de novo synthesis. This must necessitate considerable demand for the amino acid 
precursors, particularly arginine and methionine. Parenteral nutrition interferes with normal 
arginine synthesis, but whether this affects optimal creatine accretion in the growing 
neonate has not yet been investigated. The neonatal period is characterized by rapid growth 
and with very high rates of protein synthesis to support the growth. Compromised de novo 
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arginine synthesis during PN feeding, as well as an increased demand for arginine to 
support creatine synthesis may limit the arginine available for protein synthesis. 
Alternatively, the sparing of arginine through the provision of pre-formed creatine in PN 
may lead to enhanced protein synthesis in growing neonates.  
 
1.8 PN feeding and associated liver damage 
 
The use of parenteral nutrition (PN) alone or in combination with enteral nutrition in 
neonates is effective in providing sufficient nutrients to maintain growth in the ill newborn 
infant. However, PN can result in hepatic dysfunction, complicated by fat infiltration in the 
liver. Abnormal lipid deposition in the liver is exacerbated by prematurity and in piglets, 
can be detected within few days of PN initiation (Hyde et al, 2008). In many cases, a mild 
fat infiltration progresses to chronic lipid accumulation and then to fibrotic changes and 
cirrhosis. Cholestasis is also a common complication of PN which presents in one-fifth of 
neonates receiving PN for more than two weeks’ duration (Jolin-Dahel et al, 2013). The 
exact etiology of PN liver disease is unknown and likely multifactorial; suggested 
contributing factors include low birth weight, prematurity, duration of PN, sepsis, absence 
of enteral feeding, quality or quantity of amino acid intake and trace mineral toxicity (Wang 
et al, 2006). Liver transplantation is used to treat the most severe condition. However, the 
morbidity and mortality associated with this procedure is high. Therefore, the prevention 
of PN-induced liver damage has become an important part of managing infants requiring 
intravenous nutrition support.  
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1.8.1 Creatine and lipid deposition in the liver  
 
 Lipid accumulation in the liver has been associated with impaired methionine metabolism 
(Deminice et al, 2011). Both phosphatidylcholine (PC) and creatine synthesis require 
methylation reactions to occur in the liver and rely on an adequate methionine pool to serve 
as a methyl donor. Approximately 70% of PC synthesis occurs via the cytidine-
diphosphate-choline pathway, also known as the Kennedy pathway, which is not SAM 
dependent. The remaining 30% of PC is synthesized via the PEMT pathway (Reo et al., 
2002) which is SAM dependent. SAM provides three methyl groups to 
phosphatidylethanolamine to produce PC via the PEMT pathway, which demonstrates the 
quantitative importance of methyl consumption for PC synthesis. In contrast, creatine 
synthesis only consumes one methyl group (Stead et al., 2006). PC is important for the 
secretion of very low-density lipoproteins (VLDL) from the liver. Recently, it was 
demonstrated that creatine could protect the liver from non-alcoholic fatty liver disease 
(NAFLD) in a rodent model (Deminice et al, 2011). In that study, rats were fed a very high 
fat diet, with or without creatine supplementation. Creatine supplementation prevented 
lipid accumulation in the liver and maintained a more normal histology (Deminice et al, 
2011). It is tempting to speculate that creatine may have a role in ameliorating PN-induced 
liver damage, but clear evidence is lacking. A dietary source of creatine may spare methyl 
groups for the synthesis of PC, allowing for more efficient transport of cholesterol and 
triglycerides out of the liver as PC-rich lipoproteins. In a situation of a creatine-free diet, 
the necessity for creatine synthesis may place a burden on other metabolic pathways that 
involve arginine or methionine. However, no studies have been done to assess the impact 
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of creatine added to PN, including the amelioration of liver damage in neonates. Whether 
the addition of creatine to PN could support total body creatine accretion in neonates and 
concomitantly be useful in ameliorating PN-induced liver damage should be investigated 
in rapidly growing neonates.  
 
1.9 Porcine neonatal model  
 
The piglet is an appropriate animal model to investigate questions related to nutritional 
metabolism in human neonates because of similar gastrointestinal tract morphology, 
physiology and metabolic changes during development (Pond et al, 1978). The gross body 
composition of the newborn piglet is more similar to the preterm infant than the term-born 
infant which has greater fat accretion at birth (Shulman et al, 1993). Piglets are also 
developmentally immature compared to term-born infants (Shulman et al, 1993). 
Therefore, the neonatal piglet is a clinically relevant model to study the complications 
associated with PN feeding in prematurely born infants. Furthermore, larger species such 
as piglets, in contrast other animal models such as rats, are suitable for investigating 
metabolic kinetics as when multiple blood samples have to be taken over time. 
 
The neonatal miniature piglet has not been widely used for studies of nutrient 
metabolism compared to the domestic piglet.  Shulman et al (1988) reported that the small 
intestinal mucosal enzyme activities of 6-wk-old miniature piglets were similar to those 
found in human infants. The mean growth rate of sow-fed Yucatan miniature piglets is less 
rapid during first month of life compared to domestic piglets, growing at a rate of ~45 g.kg-
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1d-1 (Myrie et al, 2012) compared 79 g.kg-1d-1 (Wykes et al, 1993). In contrast, low birth 
weight premature infants grew at ~20.5 g.kg-1d-1 during first month of their life when fed 
fortified human milk (Kashyap et al, 1990). Thus, studies using a piglet model may quickly 
identify nutrient deficiencies or metabolic changes because of the accelerated growth rate; 
however, the miniature pig model may represent a better model for nutrient metabolism in 
infants, growing at a rate that is half the growth rate of domestic piglet and more similar to 
infants.  
 
For the study of amino acid metabolism and requirements, there are data to 
demonstrate that the piglet is an ideal model for the human infant. There have been some 
studies in piglets which determined specific amino acid requirements in both enteral (EN) 
and parenteral nutrition (PN) (House et al (1997a; 1997b), and subsequent studies in human 
infants (Roberts et al, 2001) that confirmed the piglet findings. The absolute amino acid 
requirement values for human infants were also predicted from the piglet data by dividing 
the piglet value by five, to accommodate the differing growth rates. Using this correction, 
the similarity between the predicted (from piglets) and measured requirements in humans 
have now been established for threonine (Bertolo et al, 1998; Chapman et al, 2009), 
methionine (Shoveller et al, 2003a,b; Courtney-Martin et al, 2008), and tyrosine (House et 
al, 1997a; Roberts et al, 2001). It is now clear that estimates of amino acid requirements 
derived from piglet data are transferable to human infants (Chapman et al, 2010). 
Unfortunately, the requirement for arginine, a metabolically important amino acid for the 
neonate, has not yet been determined for the human infant. An attempt was made to 
determine the arginine requirement for PN-fed neonatal piglets using the IAAO technique. 
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However, the researchers were not successful in determining a breakpoint estimate of 
requirement, likely because the capacity for de novo arginine synthesis changes with 
development, resulting in highly variable data.   
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CHAPTER TWO 
2.0 Problem of investigation 
2.1 Rationale, objectives and hypotheses 
 
2.1.1 Rationale 
 
Creatine is an important neuromodulator which is critical for neonatal brain development. 
Neonates receive creatine from their mother's milk; however, up to 77% of the daily 
creatine requirement must be synthesized in the neonatal body (Brosnan et al, 2009). De 
novo creatine synthesis is an inter-organ mechanism which requires three amino acids, 
arginine, glycine and methionine, and two simple step reactions. The first step involves the 
conversion of arginine to guanidinoacetic acid (GAA) via the enzyme L-arginine: glycine 
amidinotransferase (AGAT) predominantly in the kidney. The, subsequent step, the 
conversion of GAA to creatine, requires methionine and the enzyme guanidinoacetate N-
methyltransferase (GAMT) (Walker et al, 1979, Wyss et al, 2000).  In adult humans and 
rodents, creatine synthesis appeared to be regulated at the AGAT level. However, the effect 
of creatine supplementation on in-vitro enzyme activities of creatine synthesis has not been 
studied in a neonatal model. 
 
Arginine is synthesized in the small intestinal enterocytes in healthy neonates, 
which is bypassed during PN feeding. Therefore, PN feeding interferes with normal 
arginine synthesis. However, whether the PN-induced gut atrophy in neonates affects 
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arginine supply and optimal creatine accretion in the growing neonate has yet to be 
investigated.  
 
Unpublished data from our lab demonstrated that tissue and plasma creatine 
concentrations were proportionate to the parenteral arginine delivery which suggests that 
arginine availability limits de novo creatine synthesis. The lower in-vitro AGAT enzyme 
activity demonstrated by adult humans or rats may be a consequence of limited substrate 
availability rather than limited enzyme capacity. This has never been studied. 
 
Methionine is also an essential amino acid for neonates which is involved in nearly 
50 transmethylation reactions in the body, and both arginine and methionine are important 
for incorporation into body proteins. Therefore, guanidine and methyl group incorporation 
into creatine or proteins will depend on the amount of arginine and methionine available. 
Hepatic synthesis of creatine utilizes a significant proportion of methyl groups which 
originate from methionine. In an acute study with neonatal piglets, the intraportal infusion 
of GAA led to high creatine synthesis (McBreairty et al, 2013), and this limited the 
methionine available for liver protein synthesis. Brosnan et al (2009) conducted a factorial 
approximation to quantify the amount of arginine, glycine and methionine incorporated into 
newly synthesized proteins and creatine in neonatal piglets. However, direct measures of 
arginine and methionine incorporation into creatine and proteins have not been studied in-
vivo, particularly when differing amounts of precursors are available or when GAA or 
creatine have been supplemented in the diet of piglets.   
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Tissue GAA and creatine concentrations and in-vitro enzyme activities involved in 
the creatine synthesis pathway are used to describe the inter-organ system of creatine 
synthesis in rats, adult humans and in piglets (Walker et al, 1979, Wyss et al, 2000, Brosnan 
et al, 2009). Based on the in-vitro enzyme activities or the tissue GAA and creatine 
concentrations, the kidney has been considered the major organ responsible for GAA 
synthesis and the liver has been considered the major organ responsible for creatine 
synthesis, using data from rats and piglets (Brosnan et al, 2009). In spite of the presence of 
both enzymes, the role of the pancreas in creatine synthesis remains unclear in neonatal 
piglets including the quantitative contribution of the pancreas to whole-body GAA supply. 
Furthermore, individual contributions of the kidney or pancreas in situations where 
differing amounts of precursors are available may be of importance. A direct measurement 
of inter-organ fluxes of GAA and creatine in piglets is required to confirm the importance 
of the kidney, pancreas and liver for creatine biosynthesis. 
 
Citrulline is converted to arginine in the kidney, but only three quarters of citrulline 
entering the kidney appeared as arginine in a study of young pigs (Marini et al, 2012). The 
importance of citrulline as a precursor for GAA synthesis in the kidney, pancreas and gut 
also needs to be assessed, and compared to arginine as a precursor for GAA synthesis in 
neonatal piglets. 
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2.1.2 Objectives: 
 
The objectives for the work in the entire thesis are separated by Chapter.   
For the first experimental Chapter (Chapter Three, titled “Creatine supplementation to total 
parenteral nutrition improves creatine status and supports greater liver and kidney protein 
synthesis in neonatal piglets”), the objectives were to: 
 
a) determine whether creatine in PN could normalize the tissue and plasma GAA and 
creatine concentrations; and, 
b) to determine whether creatine supplemented PN fed to piglets with gut atrophy could 
spare arginine (and/or methionine) for protein synthesis. 
 
 
The objectives for the second study (Chapter Four, “Low dietary arginine sacrifices creatine 
biosynthesis while maintaining whole-body protein synthesis in neonatal piglets”) were to: 
a) to determine whether the limited creatine accretion is due to limited enzyme capacity or 
limited substrate availability; and 
b) to determine whether the availability of arginine and/or methionine in a situation of a 
high methyl demand diet, or a methyl sparing diet, will affect protein synthesis.  
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The objectives for the final experiment (Chapter Five, ‘”Kidneys are quantitatively more 
important than pancreas and gut as a source of GAA for hepatic creatine synthesis in sow-
reared Yucatan miniature piglets”) were to: 
 
a) to measure the net flux (release or uptake) of amino acids involved in GAA and creatine 
synthesis across the kidney, pancreas and gut with differing amounts of substrates; and 
b) to describe the inter-organ pathway of creatine synthesis and the capacity of the kidney, 
pancreas and gut for GAA and creatine synthesis in sow-reared piglets using an in-vivo 
model.  
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2.1.3 Hypotheses 
The hypotheses for the work in the entire thesis are separated by Chapter. 
For the first experimental Chapter (Chapter Three, “Creatine supplementation to total 
parenteral nutrition improves creatine status and supports greater liver and kidney protein 
synthesis in neonatal piglets”), the hypotheses were: 
 
a) Piglets fed creatine-supplemented PN will have greater creatine concentrations but lower 
GAA concentrations in tissues and plasma, compared to littermates fed creatine-free PN. 
Tissue and plasma GAA and creatine concentrations in creatine-fed piglets will be closer 
to the reference values of sow-reared piglets.  
b) The provision of creatine in PN will reduce the demand for arginine and/or methionine 
for creatine synthesis and consequently will spare arginine (and/or methionine) to enhance 
the tissue protein synthesis in neonatal piglets compared to littermates provided creatine-
free PN.  
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The hypotheses for second study (Chapter Four, “Low dietary arginine sacrifices creatine 
biosynthesis while maintaining whole-body protein synthesis in neonatal piglets”) were: 
 
a) Limited substrate (arginine and methionine) availability will have a more pronounced 
effect on tissue creatine accretion and the partitioning of precursors of creatine than the 
capacity of enzymes involved in creatine synthesis. 
b) Provision of dietary GAA with excess methionine will result in greater creatine accretion 
compared to littermates fed GAA with limited methionine. 
 
The hypotheses for third study (Chapter Five, “Kidneys are quantitatively more important 
than pancreas and gut as a source of GAA for hepatic creatine synthesis in sow-reared 
Yucatan miniature piglets”) were: 
 
a) The majority of GAA entering the liver will originate from the kidney as opposed to 
pancreas and gut. 
b) Infusion of citrulline will result in greater GAA flux across the kidney compared to the 
infusion of arginine or alanine. 
  
48 
 
2.2 References 
 
Batshaw ML, Wachtel RC, Thomas GH, Starrett A, Brusilow SW. Arginine-responsive 
asymptomatic hyperammonemia in the premature infant. J Pediatr. 1984; 105(1): 86-
91. 
Battini R, Leuzzi V, Carducci C, et al. Creatine depletion in a new case with AGAT 
deficiency: clinical and genetic study in a large pedigree. Mol Genet Metab. 2002; 
7794): 326-31. 
Bertolo RF, Chen CZ, Law G, Pencharz PB, Ball RO. Threonine requirement of neonatal 
piglets receiving total parenteral nutrition is considerably lower than that of piglets 
receiving an identical diet intragastrically. J Nutr. 1998; 128(10): 1752–1759. 
Bertolo RF, Brunton JA, Pencharz PB, Ball RO. Arginine, ornithine, and proline 
interconversion is dependent on small intestinal metabolism in neonatal pigs. Am J 
Physiol Endocrinol Metab. 2003; 284(5): E915–22.  
Bertolo RF & Burrin DG. Comparative aspects of tissue glutamine and proline metabolism. J 
Nutr. 2008; 138(10):2032S-2039S. 
Blachier F, Selamnia M, Robert V, M'Rabet-Touil H, Duée PH. Metabolism of L-arginine 
through polyamine and nitric oxide synthase pathways in proliferative or differentiated 
human colon carcinoma cells. Biochem Biophys Acta. 1995; 1268(3):255-62.  
Braissant O, Henry H, Villard AM, Speer O, Wallimann T, Bachmann C. Creatine synthesis 
and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT 
and CT1. BMC Dev Biol. 2005;5, 9.  
49 
 
Brosnan JT. Interorgan amino acid transport and its regulation. J Nutr. 2003; 133:2068S-
2072S.  
Brosnan JT, Brosnan ME. Creatine: endogenous metabolite, dietary, and therapeutic 
supplement. Annu Rev Nutr. 2007; 27:241-61. 
Brosnan JT, Wijekoon EP, Warford-Woolgar L, Trottier NL, Brosnan ME, Brunton JA, 
Bertolo RF. Creatine synthesis is a major metabolic process in neonatal piglets and has 
important implications for amino acids metabolism and methyl balance. J Nutr. 2009; 
139(7): 1292-7. 
Brunton JA, Bertolo RF, Pencharz PB, Ball RO. Proline ameliorates arginine deficiency 
during enteral but not parenteral feeding in neonatal piglets. Am J Physiol. 1999; 277: 
E223–31. 
Brunton JA, Ball RO, Pencharz PB. Current total parenteral nutrition solutions for the 
neonate are inadequate. Curr Opin Clin Nutr Metab Care. 2000; 3: 299–304.  
Brunton JA, Bertolo RF, Pencharz PB, Ball RO. Neonatal piglets with small intestinal 
atrophy fed arginine at concentration 100 to 300% of NRC were arginine deficient. In: 
9th International Symposium on Digestive Physiology in Pigs. 2, Short 
Communications: 2003; 210–2. 
Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. Dietary arginine uptake 
by the splanchnic region in adult humans. Am J Physiol. 1993; 265: E532-9. 
Castillo L, DeRojas-Walker T, Yu YM, Sanchez M, Chapman TE, Shannon D, 
Tannenbaum S, Burke JF, Young VR. Whole-body arginine metabolism and nitric 
oxide synthesis in newborns with persistent pulmonary hypertension. Pediatr Res. 
1995; 38(1): 17. 
50 
 
Castillo L, Beaumier L, Ajami AM, Young VR. Whole-body nitric oxide synthesis in healthy 
men determined from [15N] arginine-to-[15N] citrulline labelling. Proc Natl Acad Sci U 
S A. 1996; 93(21): 11460-5.  
Chapman KP, Courtney-Martin G, Moore AM, Ball RO, Pencharz PB. Threonine 
requirement of parenterally fed postsurgical human neonates. Am J Clin Nutr. 2009; 
89(1): 134-41.  
Chapman KP, Courtney-Martin G, Moore AM, Langer JC, Tomlinson C, Ball 
RO, Pencharz PB. Lysine requirement in parenterally fed postsurgical human 
neonates. Am J Clin Nutr. 2010; 91: 958–65.  
Cheng ZB, Li DF, Ge CR, Xing JJ. Polyamines in sow colostrum and milk at different 
stages of lactation. J Anim Sci. 2006; 82 (5): 95-99. 
Clark JF, Cecil KM. Diagnostic method and recommendations for cerebral creatine 
deficiency syndromes. Pediatr Res. 2015; 77(3): 398–405. 
Courtney-Martin G, Chapman KP, Moore AM, Kim JH, Ball RO, Pencharz PB. Total sulfur 
amino acid requirement and metabolism in parenterally fed postsurgical human 
neonates. Am J Clin Nutr. 2008; 88: 115–24. 
Cynober LA. Plasma amino acid levels with a note on membrane transport: characteristics, 
regulation, and metabolic significance. Nutrition. 2002; 18(9): 761-6. 
da Silva RP, Nissim I, Brosnan ME, Brosnan JT. Creatine synthesis: hepatic metabolism 
of guanidinoacetate and creatine in the rat in-vitro and in-vivo. Am J Physiol 
Endocrinol Metab. 2009; 296: E256–61.  
da Silva RP, Clow K, Brosnan JT, Brosnan ME. Synthesis of guanidinoacetate and creatine 
from amino acids by rat pancreas. Br J Nutr. 2014; 111: 571-7. 
51 
 
Davis TA, Nguyen HV, Garcia-Bravo R, Fiorotto ML, Jackson EM, Lewis DS, Lee DR, 
Reeds PJ. Amino acid composition of human milk is not unique. J Nutr. 1994; 124: 
1126–32.  
deGrauw TJ, Salomons GS, Cecil KM, Chuck G, Newmeyer A, Schapiro MB, Jakobs C. 
Congenital creatine transporter deficiency. Neuropediatrics. 2002; 33: 232-238. 
Deminice R, da Silva RP, Lamarre SG, Brown C, Furey GN, McCarter SA, Jordao AA< 
Kelly KB, King-Jones K, Jacobs RL, Brosnan ME, Brosnan JT. Creatine 
supplementation prevents the accumulation of fat in the livers of rats fed a high-fat 
diet. J Nutr. 2011; 141: 1799-804. 
Derave W, Marescau B, Eede EV, Eijnde BO, De Deyn PP and Hespel P. Plasma guanidino  
compounds are altered by oral creatine supplementation in healthy humans. J Appl 
Physiol. 2004; 97(3): 852-7. 
Dhanakoti SN, Brosnan JT, Herzberg GR, Brosnan ME. Renal arginine synthesis: studies 
in-vitro and in-vivo. Am J Physiol. 1990; 259: E437-42. 
Edison EE, Brosnan ME, Meyer C and Brosnan JT. Creatine synthesis: production of 
guanidinoacetate by the rat and human kidney in-vivo. Am J Physiol Renal Physiol. 
2007; 293: F1799-F1804. 
Elango R, Pencharz PB, Ball RO. The branched-chain amino acid requirement of 
parenterally fed neonatal piglets is less than the enteral requirement. J Nutr. 2002; 
132:3123–9.  
Fitch CD and Shields RP. Creatine metabolism in skeletal muscle I. Creatine movement 
across muscle membranes. J Biol Chem. 1966; 241(15): 3611-3614.  
Hanna-El-Daher L, Braissant O. Creatine synthesis and exchanges between brain cells: 
52 
 
What can be learned from human creatine deficiencies and various experimental 
models? Amino Acids. 2016; 48(8): 1877-95. 
Hay WW Jr. Strategies for feeding the preterm infants. Neonatology. 2008; 94(4): 245-54. 
Heird WC, Nicholson JF, Driscoll JM Jr, Schullinger JN, Winters RW.  Hyperammonemia 
resulting from intravenous alimentation using a mixture of synthetic l-amino acids: a 
preliminary report. J Pediatr. 1972; 81(1): 162-5. 
Homer K and Wanstall J. Cyclic GMP-independent relaxation of rat pulmonary artery by 
spermine NONOate, a diazeiumdiolate nitric oxide donor. Br J Pharmacol. 2000; 4: 
673.  
House JD, Pencharz PB, Ball RO. Tyrosine kinetics and requirement during total parenteral 
nutrition in the neonatal piglet: the effect of glycyl-L-tyrosine supplementation. Pediatr 
Res. 1997a; 41: 575–583b. 
House JD, Pencharz PB, Ball RO. Phenylalanine requirements determined by using L-[1- 
14C] phenylalanine in neonatal piglets receiving total parenteral nutrition 
supplemented with tyrosine. Am J Clin Nutr. 1997b; 65(4): 984–993a. 
House JD, Pencharz PB, Ball RO. Lysine requirement of neonatal piglets receiving total 
parenteral nutrition as determined by oxidation of the indicator amino acid L-[1-C-14] 
phenylalanine. Am J Clin Nutr. 1998; 67: 67–73. 
Hyde MJ, Amusquivar E, Laws J, Corson AM, Geering RR, Lean IJ, Putet G, Dodds PF, 
Herrera E, Clarke L. Effects of lipid-supplemented total parenteral nutrition on fatty 
liver disease in a premature neonatal piglet model. Neonatology 2008; 93(2): 77-86. 
53 
 
Ireland Z, Russell AP, Wallimann T, Walker DW, Snow R. Developmental changes in the 
expression of creatine synthesizing enzymes and creatine transporter in a precocial 
rodent, the spiny mouse. BMC Dev Biol. 2009; 9: 39. 
Item CB, Stockler-Ipsiroglu S, Stromberger C, Muhl A, Alessandri MG, Bianchi MC, 
Bianchi MC, Tosetti M, Fornai F, Cioni G. Arginine:glycine amidinotransferase 
deficiency: the third inborn error of creatine metabolism in humans. Am J Hum 
Genet. 2001; 69: 1127–33. 
Jackson AA, Shaw JCL, Barber A and Golden MHN. Nitrogen metabolism in preterm infants 
fed human donor breast milk: the possible essentiality of glycine. Pediatr Res. 1981; 15: 
1454–1461. 
Johnson LR. Regulation of gastrointestinal mucosal growth. Physiol Rev. 1988; 68(2): 456-
502. 
Jolin-Dahel K, Ferretti E, Montiveros C, Grenon R, Barrowman N, Jimenez-Rivera C. 
Parenteral nutrition-induced cholestasis in neonates: where does the problem lie? 
Gastroenterol Res Pract. 2013;2013: 163632.  
Jones ME. Conversion of glutamate to ornithine and proline: pyrroline-5-carboxylate, a 
possible modulator of arginine requirements. J Nutr. 1985; 115: 509–15.  
Kashyap S, Schulze KF, Forsyth M, Dell RB, Ramakrishnan R, Heird WC. Growth, 
nutrient retention, and metabolic response of low-birth-weight infants fed 
supplemented and unsupplemented preterm human milk. Am J Clin Nutr. 1990; 52(2): 
254-62.  
Kelly D, King TP, Brown DS, McFadyen M. Polyamine profiles of porcine milk and of 
intestinal tissue of pigs during suckling. Reprod Nutr Dev. 1991; 31: 73-80. 
54 
 
Kim SW & Wu G. Dietary arginine supplementation enhances the growth of milk-fed 
young pigs. J Nutr. 2004; 134(3): 625-30. 
Kohli R, Meininger CJ, Haynes TE, Yan W, Self JT, Wu G. Dietary L-arginine 
supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced 
diabetic rats. J Nutr. 2004; 134(3): 600-8. 
Kohler ES, Sankaranarayanan S, Ginneken CJV, Dijk PV, Vermeulen JLM, Ruijter JM, 
Lamers WH, Bruder E. The human neonatal small intestine has the potential for 
arginine synthesis. Developmental changes in the expression of arginine-synthesizing 
and catabolizing enzymes. BMC Dev Biol. 2008; 8: 107. 
Lamarre SG, Edison EE, Wijekoon EP, Brosnan ME, Brosnan JT. Suckling rat pups 
accumulate creatine primarily via de novo synthesis rather than from dam milk. J Nutr. 
2010; 140: 1570–3. 
Leuzzi V, Bianchi MC, Tosetti M, Carducci C, Cerquiglini CA, Cioni G, Antonozzi I. Brain 
creatine depletion: guanidinoacetate methyltransferase deficiency (improving with 
creatine supplementation). Neurology. 2000; 55: 1407–9. 
Ligthart-Melis GC, van de Poll MC, Dejong CH, Boelens PG, Deutz NE, van Leeuwen PA. 
The route of administration (enteral or parenteral) affects the conversion of isotopically 
labelled L-[2-15N] glutamine into citrulline and arginine in humans. JPEN J Parenter 
Enteral Nutr. 2007; 31(5): 343-48; discussion 349-50. 
Ligthart-Melis GC, van de Poll MC, Boelens PG, Dejong CH, Deutz NE, van Leeuwen PA. 
Glutamine is an important precursor for de novo synthesis of arginine in humans. Am 
J Clin Nutr. 2008; 87(5): 1282-9. 
Magri E, Baldoni G, Grazi E. On the biosynthesis of creatine. Intramitochondrial 
55 
 
localization of transamidinase from rat kidney. FEBS Letters. 1975; 55(1-2): 91-93. 
Marini JC, Didelija IC, Castillo L, Lee B. Plasma arginine and ornithine are the main 
citrulline precursors in mice infused with arginine-free diets. J Nutr. 2010; 140 (8): 
1432–7. 
Marini JC. Arginine and ornithine are the main precursors for citrulline synthesis in mice. 
J Nutr. 2012; 142(3): 572-80.  
McBreairty LE, McGowan RA, Brunton JA and Bertolo RF. Partitioning of [methyl-3H] 
methionine to methylated products and protein is altered during high methyl demand 
conditions in young Yucatan miniature pigs. The J Nutr. 2013; 143: 804-809. 
McGuire DM, Gross MD, Van Pilsum JF, Towle HC. Repression of rat kidney L-
arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. J 
Biol Chem. 1984; 10;259: 12034-8. 
Mercimek-Mahmutoglu S, Salomons GS. Creatine deficiency syndromes. GeneReviews® 
2009; 1993-2016.  
Moughan PJ, Birtles MJ, Cranwell PD, Smith WC, Pedraza M. The piglet as a model 
animal for studying aspects of digestion and absorption in milk-fed human infants. 
World Rev Nutr Diet. 1992; 67: 40–113. 
Murphy R, McConell G, Cameron-Smith D, Watt K, Ackland L, Walzel B, Wallimann T, 
Snow R. Creatine transporter protein content, localization, and gene expression in rat 
skeletal muscle. Am J Physiol Cell Physiol. 2001; 280:C415-22. 
Myrie SB, MacKay DS, Van Vliet BN, Bertolo RF. Early programming of adult blood 
pressure in the low birth weight Yucatan miniature pig is exacerbated by a post–
weaning high-salt-fat-sugar diet. Br J Nutr. 2012; 108(7): 1218-25. 
56 
 
National Research Council. Nutrient requirement of swine. National Academy Press, 
Washington, DC. 1998. 
Pond WG, Houpt KA. The Biology of the Pig. Ithaca, NY: Comstock. 1978; 371. 
Quirós-Tejeira RE, Ament ME, Reyen L, Herzog F, Merjanian M, Olivares-Serrano N, 
Vargas JH. Long-term parenteral nutritional support and intestinal adaptation in 
children with short bowel syndrome: a 25-yearexperience. J Pediatr. 2004; 145(2): 57-  
63. 
Reo NV, Adinehzadeh M and Foy BD. Kinetic analyses of liver phosphatidylcholine and 
phosphatidylethanolamine biosynthesis using 13C NMR spectroscopy. Biochim 
Biophys Acta. 2002; 1580: 171-188. 
Riedijk M, Stoll B, Chacko S, Schierbeek H, Sunehag A, Goudoever H, Burrin D. 
Methionine transmethylation and transsulfuration in the piglet gastrointestinal tract. 
Proc Natl Acad Sci U S A. 2007; 104(9), 3408-3413. 
Roberts SA, Ball RO, Moore AM, Filler RM, Pencharz PB. The effect of graded intake of 
glycyl-L-tyrosine on phenylalanine and tyrosine metabolism in parenterally fed 
neonates with an estimation of tyrosine requirement. Pediatr Res. 2001; 49(1): 111-9. 
Robinson JL, Bertolo RF. The pediatric methionine should incorporate potential and 
transmethylation demands. Adv Nutr. 2016a; 7(3): 523-34.  
Robinson JL, McBreairty LE, Randell EW, Brunton JA, Bertolo RF. Restriction of dietary 
methyl donors limits methionine availability and affects the partitioning of dietary 
methionine for creatine and phosphatidylcholine synthesis in the neonatal piglet. J Nutr 
Biochem. 2016b; 35: 81-6. 
57 
 
Royes LF, Fighera MR, Furian AF, Oliveira MS, Myskiw JC, Fiorenza NG, Petry JC, 
Coelho RC, Mello CF. Effectiveness of creatine monohydrate on seizures and 
oxidative damage induced by methylmalonate. Pharmacol Biochem Behav. 2006; 83: 
136-44.  
Shoveller AK, Brunton JA, House JD, Pencharz PB, Ball RO. Dietary cysteine reduces the 
methionine requirement by an equal proportion in both parenterally and enterally fed 
piglets. The J Nutr. 2003a; 133: 4215-4224. 
Shoveller AK, Brunton JA, Pencharz PB, Ball RO. The methionine requirement is lower in 
neonatal piglets fed parenterally than in those fed enterally. The J Nutr. 2003b; 133: 
1390-1397. 
Shulman RJ, Henning SJ, Nichols BL. The miniature pig as an animal model for the study 
of intestinal enzyme development. Pediatr Res .1988; 23(3): 311-5. 
Shulman RJ. The piglet can be used to study the effects of parenteral and enteral nutrition 
on body composition. J Nutr. 1993; 123: 395-8. 
Sipila I. Inhibition of arginine-glycine amidinotransferase by ornithine. A possible 
mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the 
choroid and retina with hyperonithinemia. Biochim Biophys Acta. 1980; 613(1) : 79-
84. 
Sorenson RL, Stout LE, Brelje TC, et al. Evidence for the role of pancreatic acinar cells in 
the production of ornithine and guanidinoacetic acid by L-arginine:glycine 
amidinotransferase. Pancreas. 1995; 10: 389 – 394.  
Stead LM, Brosnan JT, Brosnan ME, Vance DE, Jacobs RL. Is it time to reevaluate methyl 
balance in humans? Am J Clin Nutr. 2006; 83: 5-10. 
58 
 
Stockler-Ipsiroglu S, van Karnebeek C, Longo N, Korenke GC, Mercimek-Mahmutoglu S, 
Marquart I, Barshop B, Grolik C, Schlune A, Angle B, Araújo HC, Coskun T, Diogo 
L, Geraghty M, Haliloglu G, Konstantopoulou V, Leuzzi V, Levtova A, Mackenzie 
J, Maranda B, Mhanni AA, Mitchell G, Morris A, Newlove T, Renaud D, Scaglia F, 
Valayannopoulos V, van Spronsen FJ, Verbruggen KT, Yuskiv N. Nyhan, Schulze 
A. Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 
individuals and recommendations for diagnosis, treatment and monitoring. Mol 
Genet Metab. 1996; 111: 16–25.  
Stockler-Ipsiroglu S, Apatean D, Battini R, DeBrosse S, Dessoffy K, Edvardson S, Eichler 
F, Johnston K, Koeller DM, Nouioua S, Tazir M, Verma A, Dowling MD, Wierenga 
KJ, Wierenga AM, Zhang V, Wong LJ. Arginine:glycine amidinotransferase 
(AGAT) deficiency: Clinical features and long term outcomes in 16 patients 
diagnosed worldwide. Mol Genet Metab. 2015; 116(4): 252-9.  
Takeda M, Kiyatake I, Koide H, Jung KY, Endou H. Biosynthesis of guanidinoacetic acid 
in isolated renal tubules. Eur J Clin Chem Clin Biochem. 1992; 30: 325–331. 
Tomlinson C, Rafii M, Ball RO, Pencharz PB. Arginine can be synthesized from enteral 
proline in healthy adult humans. J Nutr. 2011a; 141(8): 1432-6.  
Tomlinson C, Rafii M, Ball RO, Pencharz PB. Arginine synthesis from enteral glutamine 
in healthy adults in the fed state. Am J Physiol Endocrinol Metab. 2011b; 301(2): 
E267-73.  
Urschel KL, Shoveller AK, Pencharz PB, Ball RO. Arginine synthesis does not occur 
during first-pass hepatic metabolism in the neonatal piglet. Am J Physiol Endocrinol 
Metab. 2005; 288: E1244–E1251. 
59 
 
Urschel KL, Evans AR, Wilkinson CW, Pencharz PB, Ball RO. Parenterally fed neonatal 
piglets have a low rate of endogenous arginine synthesis from circulating proline. J 
Nutr. 2007; 137: 601–6.  
Walker JB. Creatine: biosynthesis, regulation and function. Adv Enzymol Relat Areas Mol 
Biol. 1979; 50: 177–242.  
Wang H, Khaoustov VI, Krishnan B, Cai W, Stoll B, Burrin DG, Yoffe B. Total parenteral 
nutrition induces liver steatosis and apoptosis in neonatal piglets. J Nutr. 2006; 
136(10): 2547-52. 
Widdowson EM, Southgate DAT, Hey EN. Body composition of the fetus and infant. Nutr 
Metab Fetus and Infant. 1979; 169-177.  
Wilkinson DL, Bertolo RF, Brunton JA, Shoveller AK, Pencharz PB, Ball RO. Arginine 
synthesis is regulated by dietary arginine intake in the enterally fed neonatal piglet. 
Am J Physiol Endocrinol Metab. 2004; 287: E454–E62.  
Williams HH, Curtin LV, Abraham J, Loosli JK, Maynard LA. Estimation of growth 
requirements for amino acids by assay of the carcass. J Biol Chem. 1954; 208(1): 277-
86.  
Wu G, Borbolla AG, Knabe DA. The uptake of glutamine and release of arginine, citrulline 
and proline by the small intestine of developing pigs. J Nutr. 1994; 124: 2437–44. 
Wu G. Amino acid metabolism in the small intestine. Trends Comp Biochem Physiol. 1998; 
4: 39–74. 
Wu G, Knabe DA, Kim SW. Arginine nutrition in neonatal pigs. J Nutr. 2004; 134: S2783–
90. 
60 
 
Wykes LJ, Ball RO, Menendez CE, Ginther DM, Pencharz PB. Glycine, leucine and 
phenylalanine flux in low-birth-weight infants during parenteral and enteral feeding. 
Am J Clin Nutr 1992; 55: 971. 
Wykes LJ, Ball RO, Pencharz PB. Development and validation of a total parenteral 
nutrition model in the neonatal piglet. J Nutr. 1993; 123(7): 1248-59. 
Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000; 80: 
1107–213.  
Zello GA, Wykes LJ, Ball RO, Pencharz PB. Recent advances in methods of assessing 
dietary amino acid requirements for adult humans. J Nutr. 1995; 125(12): 2907-15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
CHAPTER THREE 
 
 
Creatine supplementation to total parenteral nutrition improves 
creatine status and supports greater liver and kidney protein 
synthesis in neonatal piglets 
 
Pediatr Res. 2018 Jan; 83 (1-1):135-141 
(reproduced with permission from Spring Nature publisher) 
 
The work presented in this Chapter was funded in part by Janeway Children’s Hospital 
Foundation Research Grant. It represents work that was presented at Canadian Nutrition 
Society Annual Conference 2012 and the abstract was published in the journal Applied 
Physiology, Nutrition and Metabolism (Appl Physiol Nutr and Metab 2011, 36(3): 446). 
Portions of the work were also presented at Experimental Biology 2014 in San Diego, 
CA, and the abstract was published in FASEB (Vol 28, Issue 1_supplement, April 2014). 
The manuscript from this study is published in Pediatric Research (Pediatr Res. 2018 Jan; 
83 (1-1):135-141). Therefore, the layout of this Chapter follows the format required by 
that journal, and the version presented in this thesis represents the final version submitted 
for publication. 
 
 
62 
 
3.0 Creatine supplementation to total parenteral nutrition 
improves creatine status and supports greater liver and kidney 
protein synthesis in neonatal piglets 
 
Running title: Creatine-supplemented PN for neonates 
  
1O. Chandani Dinesh, 1Robert F. Bertolo, 1Janet A. Brunton 
 
1Department of Biochemistry, Memorial University of Newfoundland, St John's, NL, 
Canada, A1B 3X9 
*To whom correspondence should be addressed, e-mail: jbrunton@mun.ca, Department of 
Biochemistry, Memorial University of Newfoundland, St John's, NL, Canada, A1B 3X9, 
Phone:1-709-864-8533; Fax: 1-709-864-2422. 
 
1Supported by the Janeway Children’s Hospital Foundation Research Grant. 
 
2Disclosures: O. Chandani Dinesh, Robert F Bertolo, Janet A Brunton have no conflicts of 
interest. 
 
Category: Basic research 
  
63 
 
3.1 ABSTRACT 
 
Background: Creatine is not included in commercial pediatric parenteral products; the 
entire creatine requirement must be met by de novo synthesis from arginine during 
parenteral nutrition (PN). Poor arginine status is common during PN in neonates which 
may compromise creatine accretion. We hypothesized that creatine supplementation will 
improve creatine status and spare arginine in PN-fed piglets. Methods: Piglets (3-5 d old) 
were provided PN with or without creatine for 14 d. Tissue concentrations of creatine 
metabolites and activities of creatine synthesizing enzymes were measured as well as tissue 
protein synthesis rates and liver lipid parameters. Results: Creatine provision lowered 
kidney and pancreas L-arginine: glycine amidinotransferase (AGAT, EC number 2.1.4.1) 
activities and plasma guanidinoacetic acid (GAA) concentration, suggesting down-
regulation of de novo creatine synthesis. Creatine increased plasma creatine concentrations 
to sow-fed reference levels and increased the creatine concentrations in most tissues, but 
not brain. PN creatine resulted in greater protein synthesis in the liver and in the kidney, 
but not in the pancreas, skeletal muscle or gut. Creatine supplementation also reduced liver 
cholesterol concentrations, but not triglyceride or total fat. Conclusions: The addition of 
creatine to PN may optimize the accretion of creatine and reduce the metabolic burden of 
creatine synthesis in rapidly growing neonates.  
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3.2 INTRODUCTION 
 
Creatine and creatine phosphate are amino acid-derived compounds that are necessary to 
meet short-term energy requirements in tissues that have high and variable rates of energy 
demand. Severe creatine deficiency because of inborn errors of creatine synthesis or 
transport results in profound neurological defects, demonstrating its importance in brain 
development [1-4]. Creatine can be acquired from the diet or synthesized endogenously as 
a multi-organ process. In terms of loss, creatine is subjected to continuous degradation and 
in adults, is excreted as creatinine at a rate of approximately 1.7 g.d-1 [5], which represents 
the maintenance cost of creatine. In addition, rapidly growing neonates must accrue 
creatine as lean tissues expand. Factorial assessment in piglets suggests that the absolute 
creatine needs in growing neonates is greater than that supplied by porcine milk (~12.7 
versus 2.8 mmol.wk-1, respectively); as such, neonates rely on de novo creatine synthesis 
[6]. Creatine synthesis requires three amino acids (arginine, glycine and methionine) and 
two enzymes [7]. The first enzyme, L-arginine: glycine amidinotransferase (AGAT; EC 
number 2.1.4.1), is expressed in the kidney and pancreas, and transfers the amidino 
compound from arginine to glycine in order to synthesize ornithine and guanidinoacetic 
acid (GAA). The second enzyme, guanidinoacetate N-methyltransferase (GAMT; EC 
2.1.1.2), methylates GAA to synthesize creatine, primarily in the liver [6]. Methionine 
donates a methyl group via S-adenosylmethionine (SAM). 
 
The growing fetus relies at least partially on the maternal supply of creatine via the 
placenta, but after birth the newborn must rely on endogenous synthesis [6, 8, 9]. It remains 
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to be determined whether the prematurely born infant has the capacity to synthesize creatine 
effectively, particularly if a dietary creatine source is not supplied. Following preterm birth, 
total parenteral nutrition (PN) is often required as a means of nutritional support for infants 
with gastrointestinal disorders or prolonged intolerance of enteral feeding. However, 
creatine is not a component of paediatric PN products. In this situation, the entire creatine 
requirement must be met by de novo synthesis which must create considerable demand for 
the amino acid precursors, arginine and methionine. Arginine is a conditionally essential 
amino acid for neonates, although de novo arginine synthesis does occur in the small 
intestinal mucosa during first-pass metabolism, predominantly from dietary proline [10, 11, 
12]. PN feeding by passes the gut metabolism and thus causes gut atrophy, therefore the 
PN feeding interferes with normal arginine synthesis; whether this affects optimal creatine 
accretion in the growing neonate has not yet been investigated. 
 
The neonatal period is characterized by rapid growth and very high rates of protein 
synthesis to support the growth. Compromised de novo arginine synthesis during PN 
feeding, as well as an increased demand for arginine to support creatine synthesis, may 
limit arginine availability for protein synthesis. Alternatively, the sparing of arginine 
through the provision of pre-formed creatine in PN may lead to enhanced protein synthesis 
in growing neonates. We hypothesized that the addition of creatine to PN would reduce the 
need for de novo creatine synthesis and spare arginine for protein synthesis in a PN-fed 
piglet model.  
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3.3 METHODS 
 
Animals, surgical procedure and daily care: All procedures were approved by the 
Institutional Animal Care Committee of Memorial University of Newfoundland (St. John’s, 
Canada) and conformed to the guidelines of the Canadian Council on Animal Care. 
Fourteen Yucatan miniature piglets (3 – 5 days old) were obtained from the breeding herd 
(Animal Care Services, Memorial University of Newfoundland) as littermate pairs. 
Animals immediately underwent surgical implantation of two silastic venous catheters 
(jugular and femoral) under general anaesthesia. Detailed descriptions of surgical 
procedure and post-surgical care were published elsewhere [13]. Immediately following 
surgery, piglets were housed individually in metabolic cages with a single-port swivel and 
tether system (Lomir Biomedical, Notre-Dame-de-l'Île-Perrot, Canada) that facilitates 
continuous PN feeding while allowing piglets to move freely. Piglets were weighed each 
morning and diet infusion rates were adjusted daily according to the piglet body weight. 
Five additional piglets were identified in the herd but were left with the sow until the study 
end. These piglets were of the similar age to the catheterized piglets but were not 
littermates. 
 
Diet Regimen: Piglets were randomized to either creatine-supplemented PN (Creatine) or 
creatine-free PN (Control). Intravenous diets were provided as continuous infusions; PN 
was initiated immediately following surgery at 50% of target rate, then increased to 75% 
on the following morning and to 100% of target rate (13.5 mL.kg-1.d-1) on the evening of 
day 1. Both diets provided similar amounts of total amino acids (Sigma Aldrich, Oakville, 
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Canada) (SUPPLEMENTAL TABLE 3.1 (online). Vitamins, iron dextran, minerals and 
trace elements were added to each diet just prior to feeding (SUPPLEMENTAL TABLE 
3.2 (online)), along with Intralipid 20% (52 mL.kg-1.d-1) as previously described [13]. 
Creatine-supplemented piglets received 0.12 g.kg-1.d-1 (0.79 mmol.kg-1.d-1) creatine as 
creatine monohydrate (Sigma Aldrich). This concentration satisfied the piglets’ total 
whole-body creatine accretion and maintenance based on previous work in sow-fed 
neonatal piglets from 4 to 11 days old [6]. The diets provided 0.94 g arginine.kg-1.d-1, which 
is considered a moderate arginine intake [14]. Piglets were maintained on the same PN for 
14 days. 
 
Necropsy procedure: After 14 days, a flooding dose of L-phenylalanine (1.5 mmol.kg of 
body weight-1) (Sigma Aldrich) containing 0.15 mmol.kg of body weight-1 L-[ring-2H5] 
phenylalanine (Cambridge Isotopes Inc., Tewksbury, MA) was administrated into the 
jugular vein to measure tissue-specific fractional rates of protein synthesis. The 
phenylalanine (labeled and unlabeled) was dissolved in pyrogen-free water (11 mL.kg of 
body weight-1) and warmed before administering. Thirty min after dosing, piglets were 
anaesthetized with halothane and delivered with oxygen by mask. Tissues including the 
whole right kidney and the pancreas were frozen in liquid nitrogen and stored at -80°C for 
later analyses of AGAT activity, creatine, and GAA concentrations. Samples of brain, 
skeletal muscle and liver were also removed and frozen for the analysis of creatine and 
GAA concentrations. Small intestinal mucosa, liver and skeletal muscle samples were taken 
to analyze rates of protein synthesis. The five sow-fed (SF) piglets underwent the same 
necropsy protocol for establishing SF reference data.  
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GAA and creatine analyses: Tissue (kidney, pancreas, brain, and liver) and plasma GAA 
and creatine concentrations were assayed using an HPLC method modified from 
Buchberger and Ferdig [15] using a C18 reverse phase column (Hypersil ODS 5 U 150x4.6 
mm column) with ninhydrin (Sigma Aldrich) derivatization and fluorescence detection 
(Ex/EM 390/470). 
 
Skeletal muscle creatine concentrations: Creatine concentration of gastrocnemius muscle 
was determined using the simplified method of Lamarre et al [9]. Tissues were 
homogenized in a 50 mmol.L-1 Tris buffer (pH 7.4) and kept for 30 min at room temperature 
to convert phosphocreatine into free creatine. The homogenates were then deproteinized 
with trifluoroacetic acid (TFA) in methanol and micro-centrifuged at 13,500 x g for 10 min. 
Creatine was eluted with an isocratic mobile phase of 0.1% TFA and 3% methanol in an 
N/RP-HPLC Hypercarb 100 x 4.6 mm column with UV detection at 210 nm. Total creatine 
concentrations were determined by reference to a standard curve which was run with 
samples.  
 
AGAT assay: AGAT activity was assayed using a modified method of Van et al [16]. The 
assay measured the amount of ornithine converted from arginine due to AGAT activity 
(transamidinase). Whole kidney was pulverized, and a representative sample was used to 
measure transamidinase activity. Supernatants prepared from homogenized frozen kidney 
or pancreas samples were incubated at 37oC in a shaking water bath with different substrate 
buffers containing either arginine or glycine or arginine and glycine or phosphate buffer 
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with no substrates. The resulting supernatants were incubated in a 92oC water bath with 
ninhydrin colour reagent dissolved in 1-propanol anhydrous (Sigma Aldrich). The 
absorbance of the final incubations was read at 505 nm in a spectrophotometer. The protein 
content of homogenates was assayed using the PierceTM BCA protein assay kit (Thermo 
Fisher Scientific, Mississauga, Canada). The ornithine produced by AGAT was presented 
as nmol of ornithine per mg of protein per min.  
 
GAMT assay: GAMT activity was assayed as described previously by da Silva et al [17] 
which was modified from Ogawa et al [18]. Reactions, stop reactions and blanks were 
prepared from fresh liver samples immediately following necropsy and frozen at -80oC for 
later analysis. Creatine synthesized by GAMT activity was measured via HPLC and 
ninhydrin derivatization [15] and activity was expressed per mg of protein per min. 
 
Tissue-specific protein synthesis: A 100 mg sample of frozen tissue was homogenized and 
prepared for extraction of phenylalanine as per the method of Lamarre et al [19]. Both the 
tissue free and hydrolyzed protein fractions were applied to a hydrophobic solid phase 
extraction cartridge (Bond Elute C18, 100 mg 1 mL; Agilent Technologies, Santa Clara, 
CA). The eluent was dried overnight and re-suspended in 80 µL of HPLC water for the 
derivatization. The isotopic enrichment of L-[ring-2H5] phenylalanine in tissue free and 
protein bound fractions was determined by GC-MS, pentafluorobenzyl bromide (PFBBr) 
derivative (Sigma Aldrich) with a model 6890 GC linked to a 5976N quadrupole MS 
(Agilent Technologies) operating in the electron ionization mode [19]. A mixed sample of 
L-[ring-2H5] phenylalanine and unlabeled phenylalanine was run in scan mode, in which 
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91 and 96 ions or 300 and 305 were identified as potential ions. A standard curve was run 
before analyzing samples to identify the linear ranges. Ions with mass-to-charge ratio of 91 
and 96 ions were monitored via selected ion monitoring for liver, small intestinal mucosa 
and muscle tissues; for kidney and pancreas samples, 300 and 305 ions were monitored.  
Percent molar enrichment (mol%) was determined, and fractional synthesis rate (FSR, %/d) 
of protein was calculated as follows: 
 
FSR = IE bound / IE free 1440/t  100 
 
Where IE bound and IE free are the isotopic enrichments (mol%) of L-[ring-
2H5] phenylalanine 
of the PCA-insoluble (protein bound) and PCA-soluble (tissue free) phenylalanine pool; t 
is time of labeling in min and 1440 is the number of minutes per day.  
 
Plasma and tissue free amino acids: Tissues were homogenized as previously described 
[20]. Plasma and tissue free amino acid concentrations were measured by reverse-phase 
HPLC (C18 column) following derivatization with phenylisothiocyanate (PITC) (Waters, 
Woburn, MA) as per the method of Bidlingmeyer et al [21].  
 
Liver lipids and plasma cholesterol and triglyceride (TG) analyses: Lipid was extracted 
using the method of Folch et al [22]. Extracted lipid from triplicate liver samples was dried 
under nitrogen gas and weighed to quantify the lipid content. Extracted lipid was also used 
to analyze hepatic cholesterol and triglyceride (TG) concentrations via spectrophotometer 
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assays (505 nm and 520 nm respectively) using commercially available kits (Genzyme DC-
CAL, Triglyceride-SL and Cholesterol-SL) from Sekisui Diagnostic (Charlottetown, 
Canada). Plasma samples were also analyzed via spectrophotometer assays (505 nm and 
520 nm respectively) using a commercially available glycerol standard (Sigma Aldrich) 
and cholesterol standard (Pointe Scientific, Canton, MI), and the same commercial kits as 
used for liver samples (Triglyceride-SL and Cholesterol-SL, Sekisui Diagnostic, 
Charlottetown, Canada). 
 
Statistical analysis: Data were analyzed using two tailed paired t-tests (GraphPad 5, Graph 
Pad Software Inc., La Jolla, CA), and were considered significantly different if P < 0.05. 
Data are expressed as mean ± SD. Data collected from the sow-fed (SF) reference group 
were used for reference only and were not included in the statistical analyses, as this group 
was not treated identically to the treatment groups (i.e., no surgical or flooding dose 
procedures). SF reference group means  SD are presented for comparison purposes. 
 
3.4 RESULTS 
 
Growth rates of the piglets in the two treatment groups were not significantly different. 
Enzyme activities: Creatine supplementation to PN down-regulated the kidney AGAT 
activity by 52% (P = 0.05) and pancreas AGAT activity by 39% (P = 0.002) compared to 
the Control group (FIGURE 3.1). Mean kidney AGAT activity in the Creatine animals fell 
within the mean ± SD measured in the age-matched SF piglets, while the mean for the 
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Control piglets was ~139% above the SF mean. Similarly, pancreatic AGAT activity in the 
Creatine group was within the SF reference mean ± SD, whereas the Control group 
pancreatic AGAT activity was 40% higher than the SF reference mean (FIGURE 3.1). 
Creatine supplementation did not affect liver GAMT activity and both mean PN values 
were approximately 55% below the SF reference mean. The liver GAMT activity in the SF 
piglets was quite variable (FIGURE 3.2).  
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FIGURE 3.1 AGAT enzyme activity in a) kidney and b) pancreas. Open bars: Control 
group, n = 7; gray bars: Creatine group, n = 7. Values are expressed as means ± SD. **P < 
0.01 and *P < 0.05 by paired t-test. The broken line and box represent the mean  SD 
derived from a group of sow-fed reference piglets (n = 5) that were not littermates to the 
treatment groups.  
 
 
 
 
 
74 
 
 
 
 
C o n tro l C re a tin e
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
L
iv
e
r 
G
A
M
T
(n
m
o
l/
m
in
/m
g
 o
f 
p
ro
te
in
)
 
 
 
 
FIGURE 3.2 GAMT enzyme activity in liver. Open bars: Control group, n = 7; gray bars: 
Creatine group, n = 7. Values are expressed as means ± SD. The broken line and box 
represent the mean  SD, derived from a group of sow-fed reference piglets (n = 5) that 
were not littermates to the treatment groups.  
 
 
 
 
75 
 
Tissue GAA and creatine concentrations: GAA concentrations in the kidney, pancreas, 
liver and brain did not differ between treatment groups (TABLE 3.1). The kidney and 
pancreas GAA concentrations were highly variable in both treatment groups (TABLE 3.1). 
GAA concentrations were comparable to SF reference piglets for most tissues, except liver 
where the mean concentration in SF group was approximately twice that of the 
experimental piglets (TABLE 3.1). Creatine supplementation resulted in significantly 
higher creatine concentrations in kidney, pancreas and liver compared to the Control group 
(TABLE 3.2). Total creatine content (i.e., creatine and phosphocreatine) in the skeletal 
muscle was significantly higher in the Creatine compared to the Control group. SF pigs 
tended to have creatine concentrations between those of the treatment groups for most 
tissues. Lack of creatine in Control piglets did not alter GAA (TABLE 3.1) or creatine 
(TABLE 3.2) concentrations in the brain. Furthermore, the mean brain GAA and creatine 
concentrations measured in both Creatine and Control groups were within the SF reference 
range (TABLE 3.1 & 3.2). 
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TABLE 3.1 Tissue and plasma guanidinoacetic acid (GAA) concentrations in piglets given 
Control versus Creatine PNa  
 
 
 
 
 
 
 
 
 
aValues are mean ± SD; n = 7 per group for PN treatments except for plasma, n = 6. 
 bSF (n = 5) data were derived from a group of sow-fed piglets that were not littermates to 
the PN groups; SF data were not included in the statistical analyses.  
Asterisk indicates different from Control, **P = 0.01 by paired t-test. 
PN, parenteral nutrition; SF, sow-fed. 
 
 
 
 
 
 
 Control Creatine SFb 
nmol.g-1 
Kidney  435 ± 234 376 ± 206 480 ± 123 
Pancreas  240 ± 185 271 ± 170 268 ± 107 
Liver  60 ± 10 68 ± 29 97 ± 50 
Brain  64 ± 14 62 ± 15 79 ± 33 
Plasma (µmol.L-1) 15.2 ± 5.0 8.3 ± 2.2** 6.0 ± 1.2 
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TABLE 3.2 Tissue and plasma creatine concentrations in piglets given Control versus 
Creatine PNa  
 
 
 
 
 
 
 
 
 
 
 
aValues are mean ± SD; n = 7 per group for PN treatments except for plasma, n = 6. 
 bSF (n = 5) data were derived from a group of sow-fed piglets that were not littermates to 
the PN groups; SF data were not included in the statistical analyses. 
 cTotal creatine.  
Asterisks indicate different from Control, **P ≤ 0.01 and *P < 0.05 by paired t-test. 
 PN, parenteral nutrition; SF, sow-fed. 
 Control Creatine SFb 
µmol.g-1 
Kidney  1.2 ± 0.6 2.5 ± 0.7** 1.8 ± 0.5 
Pancreas  1.0 ± 0.4 2.3 ± 0.8** 1.4 ± 0.4 
Liver  1.1 ± 0.7 2.2 ± 1.5* 1.1 ± 0.2 
Skeletal Musclec 22 ± 3.0 26 ± 2.6* 25 ± 5.0 
Brain 9.8 ± 3.1 10.1 ± 1.5 8.2 ± 2.1 
Plasma (µmol.L-1) 54 ± 21 232 ± 46** 249 ± 40 
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Plasma GAA, creatine and amino acid concentrations: Creatine supplementation resulted 
in significantly lower plasma GAA concentration (TABLE 3.1), but higher creatine 
concentration (TABLE 3.2) compared to Control pigs. Creatine supplementation to PN 
resulted in plasma GAA and creatine concentrations that were like SF reference pigs, 
whereas omission of creatine for Control pigs increased plasma GAA by 60% and reduced 
plasma creatine by 80% compared to the mean reference values in SF pigs. Amino acid 
concentrations were similar between Creatine and Control groups, except for proline, which 
tended to be higher in the Control pigs (P = 0.06) (SUPPLEMENTAL TABLE 3.3 
(online)). 
 
Tissue specific fractional protein synthesis rates: Liver and kidney fractional protein 
synthesis rates were significantly higher in Creatine piglets compared to the Control group 
(FIGURE 3.3). There were no differences in protein synthesis rates in pancreas, small 
intestinal mucosa or skeletal muscle between experimental groups (FIGURE 3.3).  
 
 
 
 
 
 
 
 
 
79 
 
 
 
 
 
C o n tro l C re a tin e
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
*
L
iv
e
r 
(K
s
%
/d
)
C o n tro l C re a tin e  
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
S
I 
m
u
c
o
s
a
 (
K
s
%
/d
)
C o n tro l C re a tin e
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
S
k
e
le
ta
l 
m
u
s
c
le
 (
K
s
%
/d
)
C o n tro l C re a tin e
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
P
a
n
c
re
a
s
 (
K
s
%
/d
)
C o n tro l C re a tin e
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
**
K
id
n
e
y
 (
K
s
%
/d
)
a b c
d e
 
 
 
 
FIGURE 3.3 Tissue specific rate of protein synthesis in a) liver, b) kidney, c) pancreas d) 
small intestinal mucosa and e) skeletal muscle. Open bars: Control group; gray bars: 
Creatine group, n = 7 per group except for kidney, n = 6 and pancreas, n = 5. Values are 
expressed as means ± SD. **P = 0.01 and *P < 0.05 by paired t-test. SI, small intestine. 
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Tissue free amino acid concentrations: No differences in free amino acid concentrations 
between treatments were found in liver or kidney tissues (SUPPLEMENTAL TABLE 3.4 
and 3.5 (online)).  
 
Liver weight, liver lipid, triglyceride and cholesterol: Liver cholesterol in the Creatine 
piglets was significantly lower than in the Control group (TABLE 3.3). However, the 
triglyceride concentration, total lipid or liver weights were not different between groups. 
Regardless of the treatment, both PN-fed groups had liver weights, liver lipid 
concentrations and liver triglyceride concentrations that were 1.7 to 2.5 times higher than 
the SF reference ranges. Plasma cholesterol and TG were not different between treatment 
groups. However, the mean cholesterol SF value was approximately two times higher than 
that of the PN-treated piglets. The mean plasma triglyceride concentrations measured in the 
two PN-treated groups were within the range of values measured in the SF piglets (TABLE 
3.3). 
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TABLE 3.3 Body and liver weights, liver and plasma lipid concentrations at necropsy in 
piglets given Control versus Creatine PNa  
 
 
 
aValues are mean ± SD; n = 7 for PN treatments. 
 bSF (n = 5) data were derived from a group of sow-fed piglets that were not littermates to 
the PN groups; SF data were not included in the statistical analyses. 
Asterisk indicates different from Control, **P < 0.01 by paired t-test.  
PN, parenteral nutrition; SF, sow-fed. 
 Control Creatine SFb 
Body weight (BW) (kg) 3.6 ± 0.4 3.6 ± 0.6 3.7 ± 0.2 
Liver weight (g.kg-1 BW) 52 ± 6.4 55 ± 8.4 32 ± 2.3 
Whole liver:  
  Lipid (g.kg-1 BW) 
 
2.0 ± 0.4 
 
2.3 ± 0.6 
 
1.0 ± 0.1 
  Triglyceride (µmol.kg-1 BW) 407 ± 259 351 ± 164 166 ± 81 
  Cholesterol (µmol.kg-1 BW) 
Plasma: 
  Triglyceride (µmol.mL-1) 
  Cholesterol (µmol.mL-1) 
372 ± 151 
 
0.31 ± 0.01 
2.3 ± 0.7 
151 ± 73** 
 
0.29 ± 0.10 
2.2 ± 0.7 
146 ± 56 
 
0.43 ± 0.13 
4.4 ± 1.9 
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3.5 DISCUSSION 
 
Previously, we demonstrated that suckling neonatal piglets cannot meet creatine 
requirements from milk alone and that 75% of creatine needs must come from endogenous 
synthesis from arginine and methionine [6]. Although methionine is required for creatine 
synthesis, it was provided in the PN at 20% over requirement, so likely was not limiting. 
In PN-fed piglets, arginine synthesis is diminished with gut atrophy [10] and we 
demonstrated that tissue creatine concentrations were proportionate to the i.v. arginine 
delivery (unpublished data), suggesting that arginine availability limited de novo creatine 
synthesis. In this study, we hypothesized that the addition of creatine to PN would spare 
arginine for protein synthesis. Indeed, an important finding is that liver and kidney protein 
synthesis were higher with creatine supplementation. However, there was no difference in 
muscle protein synthesis.  
 
The concentration of arginine supplied in the PN diet was designed to be lower than 
that necessary to maximize protein synthesis in the muscle [14] to allow spared arginine to 
affect muscle protein synthesis; however, the amount of arginine spared by creatine was 
not conveyed to muscle. In the liver, the enhanced protein synthesis may be due to greater 
arginine availability, but this was not demonstrated by liver free arginine concentrations, 
which were not different between treatment groups. A similar situation occurred in kidney, 
with greater protein synthesis but no difference in free arginine concentrations. However, 
free concentrations are not necessarily reflective of arginine availability; it may be that 
arginine turnover was more rapid in the Creatine group, directing more arginine toward 
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protein synthesis without changing free concentrations. This possibility could be clarified 
with a tracer study to quantify arginine flux rates. Alternatively, creatine may increase 
tissue protein synthesis via mechanisms unrelated to arginine. In-vitro and in-vivo studies 
have identified several mechanisms by which creatine stimulates protein synthesis in 
muscle. Myogenic cells in culture exposed to oxidative stress have diminished proliferation 
and differentiation, and creatine attenuated these effects [23]. Creatine also upregulates the 
expression of a number of trophic factors in muscle, including IGF-1, which can stimulate 
protein synthesis through activation of mTOR pathway intermediates [24]. To our 
knowledge, none of these mechanisms related to creatine have been studied in liver or 
kidney. The lack of response to creatine in muscle may have been due to limited amino 
acid substrate in that tissue, or due to the relatively low dose of creatine used in this study 
compared to human supplementation trials.  
 
Skeletal muscle contains over 95% of total body creatine, with one third as the free 
form and the rest as phosphorylated creatine [25]. Creatine kinase (CK) activity is found in 
the cytoplasm of several tissues including skeletal muscle, cardiac muscle and brain. We 
hypothesized that two weeks of creatine supplementation to PN would increase skeletal 
muscle and brain creatine concentrations. Interestingly, skeletal muscle total creatine 
concentration was higher in our creatine-fed piglets, but we found no difference in the brain 
creatine concentrations, and both groups were like SF reference piglets. The brain creatine 
pool is relatively minor compared to the creatine stored in muscle, representing less than 
5% of the entire body pool. However, adequate brain creatine must be of physiological 
importance, as profound negative neuro-developmental effects have been reported 
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secondary to inborn errors of creatine synthesis or transport [26]; thus, creatine is critical 
to normal neurological developmental processes in neonates. Previously, we reported that 
brain AGAT activity was not detected and GAMT activity was very low in neonatal piglets 
[6]. In this study, there was a low ratio of GAA to creatine in brain tissues compared to 
major GAA and creatine synthesizing organs, which suggests that the brain's capacity to 
synthesize its own GAA seems unlikely, and accretion likely depends on peripheral de novo 
synthesis [27]. The mean plasma creatine concentration was 80% lower in piglets given the 
creatine-free PN compared to the Creatine and SF reference piglets; as such, perhaps the 
brain has priority for circulating creatine, even in the situation of low plasma creatine 
during PN. Alternatively, it may be that the brain creatine pool was not measurably affected 
during the short-term use of creatine-free PN. SF neonatal piglets studied at 4 and 11 days 
of age had 50% greater body weight at the older age, but no change in the brain weight or 
brain creatine concentration [6]; so unlike muscle, brain does not have the same need for 
rapid creatine accretion and might be less sensitive to dietary supply. The rate of creatine 
degradation in the neonatal brain is also unknown but is likely very slow. In infants with 
AGAT deficiency, neurological symptoms do not become apparent until the second year 
of life [26]. Thus, brain creatine likely degrades too slowly to create a deficit after only 14 
days of creatine-free PN. 
 
With the addition of dietary creatine, down-regulation of creatine synthesis was 
evident by lower AGAT activity in kidney and pancreas as well as by lower GAA 
concentrations in plasma. AGAT has been demonstrated as the rate limiting step in creatine 
bio-synthesis in humans [28] and in rodents [7, 17, 29, 30] as creatine feeding induced 
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lower AGAT activity with no change in liver GAMT activity. Similarly, in our piglets the 
AGAT activity was affected with a dietary supply of creatine, and liver GAMT activity did 
not change. Therefore, it appears that creatine synthesis is regulated at the level of AGAT 
in neonatal piglets as well. 
 
The kidney has been identified as the major organ responsible for GAA synthesis 
in rodents [5]. Interestingly, in piglets, we measured pancreatic AGAT specific activity that 
was 53 to 159% higher (per gram of protein) than measured in the kidney. However, 
considering piglet kidneys are ~4 times the mass of the pancreas [6], the kidneys are likely 
still the organ responsible for the most of endogenous GAA synthesis in neonatal piglets. 
Although the pancreas has higher AGAT specific activity than kidney, its GAMT specific 
activity is relatively low (i.e., only ~25% that of the liver) [6], suggesting the pancreas has 
a net release of GAA with minimal net release of creatine into portal blood. Therefore, the 
high pancreatic AGAT specific activity may contribute some GAA directly to the liver for 
creatine synthesis, although this requires confirmation.   
 
Because prolonged PN can lead to hepatic fat accumulation and PN-associated liver 
disease [31], we also measured lipid parameters in the liver as a secondary objective.  As 
expected, the PN-fed groups had higher liver lipid content and heavier livers compared to 
SF piglets of the same age. Lipid accumulation in the liver has been associated with 
impaired methionine metabolism [32]. Both PC and creatine synthesis require hepatic 
methylation reactions, which rely on an adequate methionine pool to serve as a methyl 
donor. Moreover, adequate PC synthesis is required for VLDL assembly and secretion of 
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lipids from the liver. It is possible that creatine supplementation might spare methionine 
for transmethylation to PC, thereby reducing liver lipids in this PN-fed model. We found 
that creatine supplementation lowered the total liver cholesterol concentration, but no 
differences in liver weight or triglyceride concentration were detected. While creatine 
supplementation may have enhanced PC synthesis allowing for more efficient transport of 
cholesterol out of the liver, it is unclear why total lipids or triglycerides were also not 
measurably reduced. In rodents fed a high fat diet, creatine supplementation led to a 
profound reduction in lipid accumulation in the liver [33], but creatine was provided in the 
diet at almost 30 times the concentration delivered in our PN. It is tempting to speculate 
that creatine has a role in ameliorating PN-induced liver steatosis, but more research is 
needed on lipid metabolism outcomes. 
 
To our knowledge, this is the first time that creatine has been studied as a 
supplement to PN for use in neonates. Our data suggest that the requirement for creatine 
synthesis might be a burden on other arginine metabolic pathways. The addition of creatine 
to PN appears necessary to support optimal creatine accretion and liver and kidney protein 
synthesis in rapidly growing neonates.  
 
STATEMENT OF FINANCIAL SUPPORT 
This research was funded by a Janeway Children's Hospital Foundation Research Award. 
 
DISCLOSURE 
The authors declare no conflict of interest.  
87 
 
3.6 REFERENCES 
 
1. Leuzzi V, Bianchi MC, Tosetti M, et al. Brain creatine depletion: guanidinoacetate 
methyltransferase deficiency (improving with creatine supplementation). Neurology 
2000; 55:1407–9. 
2. Battini R, Leuzzi V, Carducci C, et al. Creatine depletion in a new case with AGAT 
deficiency: clinical and genetic study in a large pedigree. Mol Genet Metab 
2002;77:326-331. 
3. deGrauw TJ, Salomons GS, Cecil KM, et al. Congenital creatine transporter deficiency. 
Neuropediatrics 2002;33:232-238. 
4. Royes LF, Fighera MR, Furian AF, et al  Effectiveness of creatine monohydrate on 
seizures and oxidative damage induced by methylmalonate. Pharmacol Biochem Behav 
2006; 83:136-44.  
5. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 
2000;80:1107–213. 
6. Brosnan JT, Wijekoon EP, Warford-Woolgar L, et al. Creatine synthesis is a major 
metabolic process in neonatal piglets and has important implications for amino 
acids metabolism and methyl balance. J Nutr 2009;139:1292-7. 
7. Walker JB. Creatine: biosynthesis, regulation and function. Adv Enzymol Relat Areas 
Mol Biol 1979;50:177–242. 
8. Ireland Z, Russell AP, Wallimann T, Walker DW, Snow R. Developmental changes in 
the expression of creatine synthesizing enzymes and creatine transporter in a precocial 
rodent, the spiny mouse. BMC Dev Biol 2009;9:39.  
88 
 
9. Lamarre SG, Edison EE, Wijekoon EP, Brosnan ME, Brosnan JT. Suckling rat pups 
accumulate creatine primarily via de novo synthesis rather than from dam milk. J Nutr 
2010; 140:1570–3.  
10. Brunton JA, Bertolo RF, Pencharz PB, Ball RO. Proline ameliorates arginine deficiency 
during enteral but not parenteral feeding in neonatal piglets. Am J Physiol 1999;277: 
E223–31. 
11. Bertolo RF, Brunton JA, Pencharz PB, Ball RO. Arginine, ornithine, and proline 
interconversion is dependent on small intestinal metabolism in neonatal pigs. Am J 
Physiol Endocrinol Metab 2003;284: E915–22. 
12. Wilkinson DL, Bertolo RF, Brunton JA, Shoveller AK, Pencharz PB, Ball RO. 
Arginine synthesis is regulated by dietary arginine intake in the enterally fed neonatal 
piglet. Am J Physiol Endocrinol Metab 2004;287: E454–E62. 
13. Brunton JA, Baldwin MP, Hanna RA, Bertolo RF. Proline supplementation to 
parenteral nutrition results in greater rates of protein synthesis in the muscle, skin, and 
small intestine in neonatal Yucatan miniature piglets. J Nutr 2012;142:1004-8.  
14. Brunton JA, Bertolo RF, Pencharz PB, Ball RO. Neonatal piglets with small intestinal 
atrophy fed arginine at concentration 100 to 300% of NRC were arginine deficient. In: 
9th International Symposium on Digestive Physiology in Pigs. 2, Short 
Communications 2003;210–2. 
15. Buchberger W, Ferdig M. Improved high-performance liquid chromatographic 
determination of guanidino compounds by pre-column derivatization with ninhydrin 
and fluorescence detection. J Sep Sci 2004;27:1309–12. 
89 
 
16. Van Pilsum JF, Taylor D, Zakis B, McCormick P. Simplified assay for transamidinase 
activities of rat kidney homogenates. Anal Biochem 1970;35:277–86. 
17. da Silva RP, Nissim I, Brosnan ME, Brosnan JT. Creatine synthesis: hepatic 
metabolism of guanidinoacetate and creatine in the rat in-vitro and in-vivo. Am J 
Physiol Endocrinol Metab 2009;296: E256–61. 
18. Ogawa H, Ishiguro Y, Fujioka M. Guanidinoacetate methytransferase from rat liver: 
purification, properties, and evidence for the involvement of sulfhydryl groups for 
activity. Arch Biochem Biophys 1983;226:265–75. 
19. Lamarre SG, Saulnier RJ, Blier PU, Driedzic WR. A rapid and convenient method for 
measuring the fractional rate of protein synthesis in ectothermic animal tissues using a 
stable isotope tracer. Comp Biochem physiol B Biochem Mol Biol 2015;182:1–5. 
20. Nichols NL, Bertolo RF. Luminal threonine concentration acutely affects intestinal 
mucosal protein and mucin synthesis in piglets. J Nutr. 2008;138:1298-303. 
21. Bidlingmeyer BA, Cohen SA, Tarvin TL. Rapid analysis of amino acids using pre-
column derivatization. J Chromatogr 1984;336:93–104. 
22. Folch J, Lees M, Sloane Stanley GH.  A simple method for the isolation and purification 
of total lipids from animal tissues. J Biol Chem 1957;226:497-509.  
23. Sestili P, Barbieri E, Martinelli C, et al. Creatine supplementation prevents the 
inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts. 
Mol Nutr Food Res 2009; 53: 1187-1204. 
24. Sestili P, Ambrogini P, Barbieri E, et al. New insights into the trophic and 
cytoprotective effects of creatine in in-vitro and in-vivo models of cell maturation. 
Amino Acids 2016;48(8):1897-911.  
90 
 
25. Balsom PD, Soderlund K, Ekblom B. Creatine in humans with special reference to 
creatine supplementation. Sports Med 1974;18:268-80. 
26. Mercimek-Mahmutoglu S, Salomons GS. Creatine deficiency syndromes. 
GeneReviews®.2009;1993-2016.   
27. Hanna-El-Daher L, Braissant O. Creatine synthesis and exchanges between brain cells: 
What can be learned from human creatine deficiencies and various experimental 
models? Amino Acids 2016;48:1877-95. 
28. Derave W, Marescau B, Vanden Eede E, Eijnde BO, De Deyn PP, Hespel P. Plasma 
guanidino compounds are altered by oral creatine supplementation in healthy humans. 
J Appl Physiol 2004;7(3):852-7.  
29. McGuire DM, Gross MD, Van Pilsum JF, Towle HC. Repression of rat kidney L-
arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. J 
Biol Chem 1984;10;259:12034-8. 
30. da Silva RP, Clow K, Brosnan JT, Brosnan ME. Synthesis of guanidinoacetate and 
creatine from amino acids by rat pancreas. Br J Nutr 2014; 111:571-7.  
31. Burrin DG, Ng K, Stoll B, Saenz De Pipaon M. Impact of new-generation lipid 
emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. Adv 
Nutr 2014;1;5:82-91.  
32. Corrales F, Alvarez L, Pajares MA, Ortiz P, Mato JM. Impairment of Methionine 
Metabolism in Liver Disease. Drug Investigation 1992;4:8-13.  
33. Deminice R, da Silva RP, Lamarre SG, et al. Creatine supplementation prevents the 
accumulation of fat in the livers of rats fed a high-fat diet. J Nutr 2011;141:1799-804. 
 
91 
 
3.7 ACKNOWLEDGEMENTS 
 
We thank ME Dodge for her assistance in the surgeries. O.C.D, J.A.B. and R.F.B. designed 
the research; O.C.D., J.A.B. and R.F.B conducted the research; O.C.D. analyzed the data; 
O.C.D. drafted the paper. J.A.B. and R.F.B. reviewed and revised the paper. O.C.D, J.A.B. 
and R.F.B had primary responsibility for final content. All authors read and approved the 
final manuscript. 
 
  
92 
 
3.8 ONLINE SUPPLEMENTARY MATERIAL 
 
SUPPLEMENTAL TABLE 3.1 Amino acid profile of Control and Creatine PNa,b  
 
Amino acid g·L-1 g·kg-1·d-1 Amino acid g·L-1 g·kg-1·d-1 
Amino acids related to arginine metabolism Indispensable amino Acids 
 Arginine 3.47 0.94 Histidine 1.76 0.48 
Aspartate 3.47 0.94 Isoleucine 2.64 0.72 
Glutamate 5.99 1.63 Leucine 5.94 1.62 
Proline 4.73 1.29 Lysine 4.73 1.29 
Dispensable Amino Acids Methionine 1.10 0.30 
Alaninec 5.34 (6.12) 1.45 (1.66) Phenylalanine 3.03 0.82 
Cysteine 0.83 0.22 Threonine 3.03 0.82 
Glycine 1.76 0.48 Tryptophan 1.21 0.33 
Serine 3.19 0.87 Valine 3.03 0.82 
Taurine 
 
 
0.28 0.08 
 
   
Tyrosine 0.43 0.12    
       
aPN, parenteral nutrition. bThe creatine-supplemented PN contained 0.44 g·L-1 creatine 
monohydrate and 5.34 g·L-1 alanine while the Control PN (within the brackets in the table) 
contained 6.12 g·L-1 alanine and no creatine monohydrate. cAlanine was manipulated to 
make the diets isonitrogenous. With the exception of alanine, the amino acid composition 
of the diets was similar. 
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SUPPLEMENTAL TABLE 3.2 Composition of the Control and Creatine PNa,b  
 
Composition of Elemental Diets 
L-Amino acids  
D-Glucose 
Trihydrate K2HPO4 
Monobasic KH2PO4 
Potassium acetate 
NaCl 
MgSO4 
ZnSO4 
Calcium gluconate 
g/L 
56.0 
90.3 
1.57 
1.09 
1.47 
2.17 
0.78 
0.09 
6.41 
Multivitamin solution  
Ascorbic acid, mg 
Vitamin A, µg 
Vitamin D, µg  
Thiamine (as hydrochloride), mg 
Riboflavin (as phosphate), mg 
Pyridoxine hydrochloride, mg 
Niacinamide, mg 
d-Panthenol, mg 
Vitamin E (dl-alpha tocopheryl acetate), mg IU)  
Vitamin K1, mg 
Biotin, µg 
Folic Acid, µg 
            Vitamin B12, µg 
 
17.4 
150 
2.2 
0.26 
0.30 
0.22 
3.70 
1.1 
 
1.4 
0.04 
4.35 
30.5 
0.22 
Trace Element Mixd  
Zinc (as ZnSO4.7H2O), mg  
Copper (as CuSO4.5H2O), mg 
Manganese (as MnSO4.H2O), mg 
Chromium (as CrCl3.6H2O), mg 
Selenium (as SeO2), mg 
Iodide (as NaI), mg 
     Iron Dextrane 
Iron (as ferric hydroxide), mg 
 
10.07 
0.86 
0.66 
0.01 
0.05 
0.02 
 
3.0 
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aCreatine-supplemented and Control treatments were identical, with the exception of the 
amino acid composition (SUPPLEMENTAL TABLE 3.1). The diets were comprised of 
amino acids, glucose and minerals mixture, which was infused at a rate of 272 mLkg-1 
BWday-1.   
 
bIntralipid® 20% (Baxter, Canada) was infused with the parenteral diets at a rate of 52 
mLkg-1 BWday-1 (10.4 g.kg-1 BW.day-1). 
 
cMulti-12/K1 Pediatric
® multivitamin solution for parenteral nutrition (Baxter, Canada). 
 
dThe the trace element mix (components from Sigma-Aldrich, Canada) was prepared in the 
laboratory, and added to the PN just prior to use. 
 
eIron dextran (Bimeda-MTC Animal Health, Canada). 
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SUPPLEMENTAL TABLE 3.3 Plasma amino acid concentrations in Control versus 
Creatine PNa. 
 
aValues are mean ± SD by paired t-test; n = 7 (for PN treatments). bSF data were derived 
from a group of sow-fed piglets (n = 5) that were not littermates to the PN groups; SF data 
were not included in the statistical analyses. PN, total parenteral nutrition. SF, sow-fed. 
 
 
Control Creatine SFb 
(µmol.L-1) 
 
 
Amino acids related to arginine metabolism 
Amino acids related to arginine metabolism 
Arginine     55  15   68  17 135 ± 54 
Aspartate     20  13   20  9   86 ± 90 
Citrulline     91  32   68  25 100 ± 51 
Glutamine   218  44 194  39 242 ± 46 
Glutamate   182  41 186  80   87 ± 38 
Ornithine     51  21   50  18   89 ± 35 
Proline   481  130 329  88 469 ± 202 
Indispensable amino acids 
Histidine     30  9   24  10   46 ± 14 
Isoleucine   120  53 125  46 139 ± 56 
Leucine   204  49 183  92 220 ± 88 
Lysine   250  82 242  81 306 ± 82 
Methionine     30  9   22  7   20 ± 5 
Phenylalanine 1237  462 991  554 111 ± 47 
Threonine   201  49 209  98 153 ± 47 
Tryptophan   130  29 112  33   80 ± 31 
Valine   284  50 249  90 310 ± 137 
Dispensable amino acids 
Alanine   419  105 332  108 408 ± 139 
Glycine   841  373 740  208 558 ± 146 
Hydroxyproline     47  15   46  30   94 ± 38 
Serine   474  169 357  111 223 ± 74 
Taurine   249  68 233  68 167 ± 68 
Tyrosine   144  96 118  50 135 ± 68 
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SUPPLEMENTAL TABLE 3.4 Liver free amino acid concentrations in piglets fed 
Control versus Creatine PNa. 
 
aValues are mean ± SD by paired t-test; n = 7 (for PN treatments). bSF data were derived from a 
group of sow-fed (n = 5) piglets that were not littermates to the PN groups; SF data were not 
included in the statistical analyses. PN, total parenteral nutrition. SF, sow-fed. 
 
 
Control Creatine SFb 
(µmol.g-1) 
 
 
Amino acids related to arginine metabolism 
Amino acids related to arginine metabolism 
Arginine  0.21  0.13  0.29  0.19 0.22  0.16 
1.05  0.32 
0.35  0.15 
1.92  0.26 
2.01  0.58 
0.47  0.12 
0.90  0.14 
 
Aspartate  1.95  1.37  2.29  1.70 
1 0 32
0 35 15
1 92 26
2 01 58
47 2
0.90  0.14 
 
Citrulline  1.45  0.64  1.62  0.54 
0 32
0 35 15
1 92 26
2 01 58
47 2
0.90  0.14 
 
Glutamine  0.54  0.20  0.36  0.22 
32
35 5
1 2 26
2 01 58
47 2
0.90  0.14 
 
Glutamate  0.33  0.21  0.50  0.21 
3
35 5
1 2 26
2 01 58
47 2
0.90  0.14 
 
Ornithine  0.91  0.51  0.83  0.49 
3
35 5
1 2 26
2 01 58
47 2
0.90  0.14 
 
Proline  3.65  1.14  2.61  1.53 
3
35 5
1 2 26
2 01 58
47 2
0.90  0.14 
 
Indispensable amino acids 
Histidine  0.66  0.25  1.17  1.03 
Isoleucine  0.66  0.17  0.76  0.46 36
Leucine  1.09  0.52  0.88  0.25 55 9
Lysine  1.63  0.98  1.08  0.48 03 0
Methionine  0.48  0.37  0.91  0.46 25 8
Phenylalanine  3.32  0.51  3.31  0.48 1.56  0.25 
Threonine  0.67  0.31  0.63  0.27 0.37  0.10 
Tryptophan  0.07  0.03  0.07  0.03 0.07  0.03 
Valine  0.92  0.35  0.93  0.40 1.00  0.60 
Dispensable amino acids 
Alanine   6.72  1.96   6.25  2.86 1.63  0.64 
Glycine 10.11  2.18 11.04  2.56 3.64  0.78 
Hydroxyproline   0.26  0.09  0.28  0.21 0.22  0.05 
Serine   5.02  2.33  4.66  1.84 1.73  0.32 
Taurine   9.14  3.03  9.78  4.31 8.20  1.25 
Tyrosine   0.94  0.42   0.92  0.47   0.50  0.20 
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SUPPLEMENTAL TABLE 3.5 Kidney free amino acid concentrations in piglets fed 
Control versus Creatine PNa. 
 
aValues are mean ± SD by paired t-test; n = 7. PN, total parenteral nutrition. bSF data were derived 
from a group of sow-fed piglets (n = 5) that were not littermates to the PN groups; SF data were not 
included in the statistical analyses. PN, total parenteral nutrition. SF, sow-fed. 
 
 
Control Creatine SFb 
(µmol.g-1) 
 
 
Amino acids related to arginine metabolism 
Amino acids related to arginine metabolism 
Arginine 0.09  0.05 0.14  0.01 0.14  0.13 
Aspartate 1.43  0.63 1.40  0.87 1.33  0.38 
Citrulline 0.49  0.13 0.49  0.07 0.35  0.10 
Glutamine 0.10  0.05 0.10  0.04 0.73  0.15 
Glutamate 0.34  0.15 0.30  0.12 2.70  0.30 
Ornithine 0.36  0.12 0.36  0.25 0.33  0.16 
Proline 0.94  0.30 0.83  0.19 0.90  0.30 
Indispensable amino acids 
Histidine 1.27  0.37 1.82  0.68 0.24  0.08 
Isoleucine 0.56  0.14 0.46  0.16 0.43  0.08 
Leucine 0.61  0.16 0.57  0.15 0.48  0.12 
Lysine 0.52  0.19 0.71  0.26 0.40  0.20 
Methionine 0.18  0.02 0.22  0.07 0.23  0.06 
Phenylalanine 2.58  0.37 2.38  0.65 1.85  0.20 
Threonine 0.43  0.09 0.46 0.21 0.35  0.01 
Tryptophan 0.18  0.04 0.14  0.07 0.07  0.01 
Valine 0.61  0.21 0.51  0.10 0.63  0.09 
Dispensable amino acids 
Alanine 3.69  0.77 4.48  2.57 1.80  0.40 
Glycine 4.26  0.84 5.29  3.66 4.75  0.20 
Hydroxyproline 0.22  0.08 0.22  0.12 0.09  0.01 
Serine 1.05  0.25 1.57  1.65 0.68  0.16 
Taurine 6.83  1.38 8.23  3.03 4.50  0.90 
Tyrosine 0.27  0.13 0.35  0.18 0.34  0.10 
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CHAPTER FOUR 
 
Low dietary arginine sacrifices creatine biosynthesis while 
maintaining whole-body protein synthesis in neonatal piglets 
 
The work presented in this Chapter was funded by a grant from the NSERC Collaborative 
Research and Development program, with Evonik Industries (Hanau, Germany) as the 
industry partner. It represents work that was presented at Canadian Nutrition Society 
Annual Conference (2015) and the conference abstract was published in the journal 
Applied Physiology Nutrition and Metabolism (Appl. Physiol. Nutr. Metab. Vol. 40, 2015). 
Part of this work was also presented at Experimental Biology 2016 in San Diego, CA, and 
the abstract was published in FASEB (Vol.30, Issue 1_supplement, April 2016). Included 
in this thesis are data from the same experimental piglets on liver GAMT activity and 
plasma cysteine and homocysteine; these data were generated and generously shared by 
Kankayaliyan Thillayampalam (in TABLE 4.1 GAMT activity and TABLE 4.2: Cysteine 
and homocysteine). Dr. M. Rademacher is a scientist with the industry partner (Evonik). 
Dr. C. Tomlinson collaborated on this project because of his expertise in mass spec analysis 
of creatine-related metabolites. O. Chandani Dinesh performed all of the other laboratory 
and statistical analyses and data interpretation in this Chapter. The manuscript is formatted 
to follow the guidelines of the Journal of Nutrition, the journal of choice for this work. 
 
99 
 
4.0 Low dietary arginine sacrifices creatine biosynthesis while 
maintaining whole-body protein synthesis in neonatal piglets 
 
4.1 ABSTRACT 
 
Background: We previously demonstrated low tissue accretion of creatine in piglets fed 
creatine-free diets. However, it is unknown whether insufficient endogenous synthesis of 
creatine is due to limited enzyme capacity or inadequate substrate availability. Arginine 
(Arg) and methionine (Met) are indispensable amino acids for neonates as well as 
precursors for creatine biosynthesis. Hypothesis: The limited availability of dietary Arg 
and Met limits guanidinoacetic acid (GAA) and creatine syntheses, to conserve whole-body 
protein synthesis. Methods: Piglets (9 - 11 d old, n = 35) were fed one of five elemental 
diets for 5 days: 1) low Arg and low Met (Base), 2) Base plus GAA (+GAA), 3) Base plus 
GAA plus excess Met (+GAA/Met) 4) Base plus creatine (+Cre) 5) excess Arg and excess 
Met (+Arg/Met). Isotope tracers were infused to determine whole-body GAA, creatine and 
protein synthesis. Results: Piglets fed the Base diet had lower Arg conversion to GAA and 
creatine compared to the +Arg/Met group (P < 0.0001), demonstrating that creatine 
biosynthesis was limited by low dietary Arg and Met. Renal L-arginine:glycine 
amidinotransferase activity in piglets on the Base diet was higher than that in piglets fed 
+Arg/Met (P < 0.0001), suggesting that the lower Arg to GAA conversion was due to 
inadequate substrate availability, rather than lack of enzyme activity. One week 
manipulation of the dietary arginine, methionine, GAA or creatine did not affect the brain 
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creatine levels or whole-body protein synthesis. Conclusions: The substrate availability 
rather than the presence of creatine in the diet/tissues or in vitro enzyme capacities 
determined the rate of arginine conversion to GAA and creatine in our piglets. Whole-body 
protein synthesis is conserved even when the diet is low in arginine, by diverting less 
arginine to GAA and creatine synthesis. Supplemental GAA can be used to sustain required 
levels of creatine, but only if provided with excess methionine. Accommodation of all 
metabolic fates of Arg and Met need to be considered when determining dietary 
requirements for neonates.  
 
Abbreviations: AGAT, L-Arginine:glycine amidinotransferase; APE, atom percent excess; 
arg, arginine; BCA, bicinchoninic acid; cre, creatine; GAA, guanidinoacetic acid; GAMT, 
guanidinoacetate N-methyltransferase; met, methionine; NO,  nitric oxide; NRC, National 
Research Council. 
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4.2 INTRODUCTION 
 
Creatine accretion in early life occurs at a rapid rate, to accommodate the expanding tissue 
pools during this period of swift growth (Brosnan et al, 2009); furthermore, creatine is 
critical for brain function and neurological development in neonates (Beard & Braissant, 
2010). Neonates receive some creatine in mother's milk; however, up to 77% of the daily 
creatine requirement must be synthesized in the neonatal body (Brosnan et al, 2009), likely 
resulting in a high demand for the precursor amino acids. Arginine is a conditionally 
essential amino acid precursor of creatine, that is also involved in protein synthesis. Along 
with arginine, creatine biosynthesis utilizes glycine and methionine. L-Arginine:glycine 
amidinotransferase (AGAT) catalyzes the first step by the formation of guanidinoacetic 
acid (GAA), which is the intermediate metabolite in creatine biosynthesis. A second 
enzyme, guanidinoacetate N-methyltransferase (GAMT) methylates GAA to synthesize 
creatine in the liver. Methionine donates a methyl group for the final reaction to form 
creatine (Walker et al, 1979).  As an essential amino acid, a dietary source of methionine 
is necessary for protein synthesis as well as to fulfill methyl donor functions for several 
important reactions including creatine synthesis. It may follow that the rate of creatine 
accretion depends on the amount of preformed creatine, or arginine and methionine that is 
available to the neonate; however, this has not been quantified. Nutritional management 
strategies used for term and preterm infants vary in the quantities of creatine and amino 
acids, and some are nearly devoid in creatine, including parenteral nutrition, and soy or 
lactose free formulas (Edison et al, 2013). Thus, it is of critical importance to understand 
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how the lack of dietary creatine or limiting precursor amino acids might affect overall 
creatine accretion, protein synthesis and growth. Similarly, an important question is 
whether the provision of preformed creatine or its precursor GAA could spare amino acids 
to be used for growth.  Neither of these questions has been adequately addressed in neonates 
to date. 
 
The use of GAA as a low-cost feed additive to enhance creatine accretion and spare 
amino acids has captured the interest of the agricultural industry. GAA supplementation to 
growing pigs enhanced muscle creatine accretion, but at the expense of liver protein 
synthesis (McBreairty et al, 2015). The effects on whole-body protein synthesis or the 
potential benefits of sparing arginine were not assessed in neonates but should be 
quantified. A further question is whether additional methionine supplemented with GAA 
would ameliorate the depletion of methionine and lead to better growth outcomes. 
 
In our previous study, neonatal piglets that were fed creatine-free diets had lower 
plasma and tissue creatine concentrations compared to those fed a creatine-supplemented 
diet (Dinesh et al, 2018). However, AGAT activity was high in piglets fed the creatine-free 
diet. Whether low creatine accretion was due to limited enzyme capacity or limited 
substrate availability is not known. However, tissue and plasma creatine concentrations 
were proportionate to the concentration of arginine delivered to piglets as a parenteral diet 
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(Gagnon et al, 2010), suggesting that limited arginine availability will impact de novo 
creatine synthesis. 
 
The addition of creatine to the diet has the potential to spare both arginine and methyl 
groups, through negative feedback regulation of AGAT activity (Dinesh et al, 2018). 
Therefore, in this study, we measured tissue creatine accretion and whole-body protein 
synthesis in piglets fed diets that were supplemented with creatine or GAA in combination 
with arginine and methionine intakes just slightly below requirements. This would facilitate 
detection of a change in protein synthesis when amino acids are spared. A diet with arginine 
and methionine concentrations slightly below requirement served as the negative control. 
As a positive control, we included a group with excess arginine and methionine, to meet 
the requirements for all synthesized products including protein as well as GAA/creatine. 
Lastly, because GAA has been shown to be proportionately converted to creatine with no 
regulatory feedback, we included a group that was fed GAA with low arginine plus excess 
methionine to ensure sufficient methionine was available for creatine synthesis.  
 
In-vitro enzyme activities measure the maximum capacity of enzymes present in 
tissues without accounting for in-vivo substrate availability. In contrast, a multi-tracer 
approach allows for the measurement of whole-body in-vivo conversions of precursors to 
products and is a more sophisticated method to measure metabolic flux through the 
enzymes involved in creatine synthesis. Therefore, the present study used a multiple stable 
isotope tracer protocol to address how whole-body arginine and methionine were 
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quantitatively partitioned into GAA, creatine or protein synthesis when differing amounts 
of arginine and methionine were available or when pre-made GAA or creatine was 
supplied. Finally, the in-vivo flux through creatine biosynthesis enzymes was compared to 
in-vitro activities. 
 
4.3 METHODS 
 
Chemicals: All the amino acids, dipeptide, GAA, creatine and stable isotopes were 
pharmaceutical grade and were purchased from either Sigma, Evonik, Ajinomoto or CDN 
Isotopes. The other chemicals were analytical grade and purchased from either Sigma or 
Fisher Scientific.  
 
Animal and surgical procedure: All procedures were approved by Institutional Animal 
Care Committee at Memorial University of Newfoundland (St. John’s, Canada) and 
conformed to the guidelines of the Canadian Council on Animal Care. Thirty-five Yucatan 
miniature piglets (9 – 11 d old) were taken from the breeding herd at Memorial University 
of Newfoundland as littermate groups (sex-matched). The animals immediately underwent 
surgical implantation of two silastic central venous catheters and a gastric catheter under 
general anesthesia. Detailed descriptions of pre-anesthesia, surgical procedures, post-
surgical care, and the diet feeding during recovery (until d 2) have been previously 
published (Dodge et al, 2012). On the morning of d 2, the piglets were randomized to 
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receive one of 5 experimental diets (n = 7 per group) for 5 days via the gastric catheter 
continuously (24 h) using pressure sensitive peristaltic pumps.   
 
Experimental diets: Arginine and methionine were manipulated to provide excess arginine 
and methionine or low arginine and methionine with or without GAA and creatine in five 
different experimental diets: 1) Base diet was designed to marginally limit creatine and/or 
protein synthesis. Arginine was fed at 0.3 g.kg-1.d-1, which represents 80% of the arginine 
requirement (0.38 g.kg-1.d-1) according to NRC (1994). Methionine was added to provide 
0.2 g.kg-1.d-1, which represents 80% of the methionine requirement for piglets at this age 
(Shoveller et al, 2003, NRC, 1994). These marginal levels of arginine and methionine 
allowed us to detect both decreases and increases in amino acid utilization due to 
treatments. 2) +GAA diet was designed to determine whether GAA can spare arginine; 
GAA was supplemented at a rate of 0.093 g.kg-1.d-1 which is the molar equivalent of the 
total creatine accretion rate in piglets (Brosnan et al, 2009). 3) +GAA/Met diet was 
designed to determine if methionine availability can limit creatine synthesis from 
supplemented GAA, so the Base-GAA diet was supplemented with excess methionine (0.5 
g.kg-1.d-1).  4) +Cre diet was supplemented with creatine (as creatine monohydrate) at a rate 
equal to the total creatine accretion rate of piglets (0.12 g.kg-1.d-1) (Brosnan et al, 2009) to 
determine if creatine can spare arginine and/or methionine. 5) +Arg/Met diet was the 
positive control and included excess dietary arginine (1.8 g.kg-1.d-1) and methionine (0.5 
g.kg-1.d-1) to enable protein and de novo creatine synthesis. For arginine, because we have 
some preliminary data that muscle protein synthesis is still increasing at 0.9 g.kg-1.d-1, we 
added arginine at twice that estimate. This level of arginine resulted in only one SD above 
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the upper limit of the sow fed plasma reference value in Wilkinson study (2004). 
Methionine was fed at twice the requirement.  
 
The rest of the amino acid pattern of the diets was adapted from a commercially 
available paediatric parenteral nutrition solution (Vaminolact-Fresenius Kabi, Germany) 
with nitrogen provided as free amino acids with or without GAA or creatine. Glycine and 
tyrosine were provided as both the free form and as the soluble dipeptide glycine-L-tyrosine 
to ensure feeding adequate dietary tyrosine. All diets were designed to provide identical 
amounts of metabolizable energy and total amino acids. Alanine and aspartate 
concentrations were manipulated to accommodate the nitrogen provided by GAA, creatine, 
or higher arginine and/or methionine in the diets (SUPPLEMENTAL TABLE 4.1). 
Minerals, iron dextran, trace elements (SUPPLEMENTAL TABLE 4.2) and Intralipid 
20% (52 mL.kg-1.d-1) were added to the diet bags as previously published (Creatine paper), 
with the exception that the vitamin mix was prepared in our lab for this study 
(SUPPLEMENTAL TABLE 4.2). 
 
Tracer infusion and blood sampling: A continuous infusion of L-arg-13C6-HCl (28 
µmol.kg-1.h-1; prime 16.8 µmol.kg-1), guanidineacetic-2,2-D2 acid (8.6 µmol.kg
-1.h-1; prime 
5.16 µmol.kg-1), creatine-D3-H2O (methyl-D3) (9.9 µmol.kg
-1.h-1; prime 9.9 µmol.kg-1), L-
[ring-2H5]-phenylalanine (20 µmol.kg
-1.h-1; prime 6.39 µmol.kg-1)  and  L-[ring-3,5-D2]-
tyrosine (9 µmol.kg-1.h-1; prime 2.74 µmol.kg-1) and  was conducted for 6 hours. Only a 
bolus dose of L-[ring-D4]-tyrosine (2.74 µmol.kg
-1) was given to prime the product pool. 
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Arginine, GAA and creatine tracers were used to measure the whole-body conversions of 
arginine to GAA and creatine whereas phenylalanine and tyrosine tracers were used to 
measure whole-body protein kinetics. The isotope infusion doses (both prime and constant) 
were based on a target atom percent excess (APE) of 5% for most tracers, and 7% for 
arginine, and considering pool size and the whole-body rate of appearance (Bruins et al, 
2002). On d 6, the infusion was initiated as priming dose (1 mL.kg-1), and the constant 
isotope infusion during the 6 h experiment was carried out as repeated half-hourly bolus 
doses of one eleventh of the total constant infusion volume (0.5 mL.kg-1.h-1) via the gastric 
catheter. An interim analysis using plasma from 10 piglets was conducted to ensure 
achieving a steady state of all the isotopes before recruiting the rest of the piglets. The 
prime and constant doses for creatine were changed from 1.16 mg.kg-1 and 1.86 mg.kg-1.h-
1 to 1.5 mg.kg-1 and 1.5 mg.kg-1.h-1 after completing the analysis from the first 10 animals. 
Amino acid compositions of the experimental diets were adjusted to accommodate the 
arginine isotope molar contribution.  
 
Blood was collected from the femoral vein every 30 min into a 4 mL vacutainer (K2 
EDTA 7.2 mg, BD, USA), and the plasma was separated by centrifugation and stored at -
80oC for later analyses of isotopic enrichments. Before each infusion experiment, three 
baseline blood samples were collected to determine the background enrichment of each 
compound of interest. At the end of the tracer infusion, the piglets were maintained on the 
experimental diets until necropsy the next day, when piglets were placed under general 
anesthesia (halothane/oxygen). The whole right kidney, pancreas and whole brain were 
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harvested and stored at -80°C for later analyses of AGAT activity, GAA and creatine 
concentrations.  
 
Tissue enzyme activities: Renal and pancreatic AGAT activities were assayed using a 
modified method of Van et al (1970) as we described previously (Dinesh et al, 2018). 
Analysis of liver GAMT activity was conducted as per the method of Ogawa et al (1983) 
as modified by da Silva et al (2009) using fresh samples. The protein contents of both 
AGAT and GAMT homogenates were assayed using the PierceTM BCA protein assay kit 
(ThermoFisher Scientific). The final values were expressed as per mg of protein.  
 
Tissue and plasma measurements: Tissue (kidney, liver and brain (cerebellum) and 
plasma GAA and creatine concentrations were assayed using an HPLC method modified 
from Buchberger and Ferdig (2004) using a C18 reverse phase column (Hypersil ODS 5 U 
150 x 4.6 mm column) with ninhydrin (Sigma Aldrich) derivatization and fluorescence 
detection (Ex/EM 390/470). Plasma amino acid concentrations were measured via HPLC 
following derivatization with phenylisothiocyanate (Bidlingmeyer et al, 1984). Plasma 
homocysteine and cysteine concentrations were determined as per the method of Vester & 
Rasmussen (1991). 
 
Mass spectrometric analysis: 25 µL of plasma were deproteinized with 200 µL of 100% 
methanol. The mixture was vortexed for 30 seconds and centrifuged at 18,000 x g for 10 
minutes. Supernatants were frozen at -80oC for 20 minutes and subsequently freeze-dried 
for one hour. Dried samples were reconstituted with mobile phase and analyzed for tracer 
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to tracee ratio of each isotope via LC-MS/MS as per the method of Tomlinson et al (2011) 
in the Analytical Facility for Bioactive Molecules at the Hospital for Sick Children, 
Toronto, Canada. Isotopic enrichments of L-arg-13C6-HCl, guanidineacetic-2,2-D2, 
creatine-D3-H2O (Methyl-D3), L-[ring-
2H5] phenylalanine, L-[ring D4]-tyrosine, L-[ring-
3,5-D2]-tyrosine and their products were determined by monitoring daughter ions (m/z) at 
70 (M+0) and 76 (M+6) for arginine, 76 (M+0), 77 (M+1) and 78 (M+2) for GAA, 90 
(M+0), 91 (M+1), 92 (M+2) and 93 (M+3) for creatine, 120 (M+0) and 125 (M+5) for 
phenylalanine and 136 (M+0), 138 (M+2) and 140 (M+4) for tyrosine.  
 
Calculations: Isotope enrichment of precursor tracers and their products and flux 
(turnover) and precursor conversions into products (arginine to GAA and creatine, 
phenylalanine to tyrosine) were calculated as described by Tomlinson et al (2011). The 
equations are summarized in SUPPLEMENTAL TABLE 4.3. The whole-body 
phenylalanine kinetics were determined as described by Thivierge et al (2005) and were 
then used as a measure of whole-body protein kinetics. The detailed formulas can be found 
in SUPPLEMENTAL TABLE 4.3.  
 
Statistical analyses: Isotopic steady state was demonstrated by a visual inspection of the 
data and the absence of a significant slope as determined by regression analysis. For all 
isotopes infused, steady state was achieved by ~3.5 h of constant infusion. Data were 
analyzed using one-way ANOVA and groups were compared by Newman-Keuls post hoc 
test (GraphPad5, Graph Pad Software Inc. CA, USA). All data were expressed as mean ± 
SD. When the group variances were significantly different (not normally distributed), 
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ANOVA testing was conducted using log-transformed variables, although values presented 
are mean ± SD of non-transformed data.  
 
4.3 RESULTS 
The dietary treatments did not significantly affect body weight gain of the piglets during 
the study.  
Enzyme activities: Kidney AGAT activity in piglets fed the Base diet was higher than that 
in piglets fed +GAA/Met, +Cre and +Arg/Met diets, while piglets fed +GAA was higher 
only to +Cre diet (P = 0.0005) (TABLE 4.1). In the pancreas, the +Cre diet also had lower 
AGAT activity compared to the Base and +Arg/Met groups (TABLE 4.1). No other 
differences in AGAT were determined among groups in both kidney and pancreas. Liver 
GAMT activity was highest in piglets fed +GAA/Met diet compared to all other treatment 
groups (P = 0.01) (TABLE 4.1). 
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TABLE 4.1 Activities of enzymes of creatine synthesis and tissue GAA and creatine 
concentrations in piglets fed either Base, +GAA, +GAA/Met, +Cre or +Arg/Met diets1  
 
 Base +GAA +GAA/Met + Cre +Arg/Met 
AGAT activity (nmol.min-1.mg protein-1) 
Kidney  
Pancreas  
9.70 ± 3.10a 
19.9 ± 4.70a 
7.40 ± 2.90ab 
16.9 ± 3.40ab 
5.00 ± 1.80bc 
17.8 ± 3.10ab 
4.00 ± 1.20c 
13.7 ± 4.20b 
6.50 ± 1.80bc 
21.4 ± 2.10a 
GAMT activity (nmol.min-1.mg protein-1) 
Liver   0.60 ± 0.2a      0.67 ± 0.30 a    1.12 ± 0.50b                0.54 ± 0.20a  0.79 ± 0.20a     
GAA concentration (µmol.g tissue-1) 
Kidney 
Liver 
Brain 
1.28 ± 0.45a 
0.07 ± 0.01a 
0.04 ± 0.01 
1.41 ± 0.78a 
0.06 ± 0.03a 
0.05 ± 0.02 
1.25 ± 0.25a 
0.10 ± 0.02b 
0.06 ± 0.04 
0.89 ± 0.31a 
0.06 ± 0.02a 
0.06 ± 0.03 
2.58 ± 1.31b 
0.11 ± 0.03b 
0.06 ± 0.03 
Creatine concentration (µmol.g tissue-1) 
Kidney 
Liver 
Brain 
1.50 ± 0.03a 
1.70 ± 0.60a 
14 ± 5 
1.80 ± 1.20a 
1.40 ± 0.80a 
17 ± 7 
4.50 ± 1.80b 
10.50 ± 3.80c 
18 ± 5 
4.00 ± 1.70b 
4.40 ± 1.50b 
17 ± 6 
3.80 ± 1.80b 
9.40 ± 5.40bc 
16 ± 7 
 
1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 7. Means with differing superscripts are significantly 
different within rows (≤ 0.01) (produced by one-way ANOVA) and were compared by 
Newman-Keuls multiple comparisons test. AGAT, L-arginine-glycine amidinotransferase; 
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Arg, arginine; Cre, creatine; GAA, guanidinoacetic acid; GAMT, Guanidinoacetate 
methyltransferase; Met, methionine. Base, low Arg and low Met; +GAA, Base plus GAA; 
+GAA/Met, Base plus GAA plus excess Met; +Cre, Base plus creatine; +Arg/Met, excess 
Arg and excess Met. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
 
Tissue GAA and creatine concentrations: The groups fed the excess methionine 
concentration (+Arg/Met and +GAA/Met) had significantly higher liver GAA 
concentrations compared to the other three treatments. However, in the kidney, the GAA 
concentration was higher in the +Arg/Met group compared to the +GAA/Met treatment 
(TABLE 4.1). Significantly higher kidney and liver creatine concentrations were measured 
in +GAA/Met, +Cre and +Arg/Met groups compared to the Base and +GAA groups 
(TABLE 4.1), while +GAA/Met diet resulted in significantly higher creatine 
concentrations in the liver tissues than the +Cre diet. Regardless of the amount of arginine 
and methionine in the diet, or the provision of dietary GAA or creatine, the brain GAA and 
creatine concentrations were unaffected by treatments (TABLE 4.1). 
 
Plasma metabolite concentrations: In spite of the moderately low arginine concentration 
in most of our treatments, plasma ammonia and urea concentrations were not significantly 
different among the treatment groups (TABLE 4.2). 
 
Provision of dietary GAA did not affect plasma GAA concentrations, in 
that the +GAA and +GAA/Met treated piglets were similar to all other treatments. The only 
difference in plasma GAA was between +Arg/Met and Base groups (TABLE 4.2). 
However, plasma GAA concentrations in both groups were not different from the other diet 
groups that were given low arginine (TABLE 4.2). Similar to the patterns of creatine 
concentrations in liver and kidney, plasma creatine concentration was significantly higher 
in +GAA/Met, +Cre and +Arg/Met compared to Base and +GAA groups (TABLE 4.2). 
The excess dietary arginine and methionine provided in +Arg/Met piglets led to 
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significantly higher plasma arginine and methionine concentrations (TABLE 4.2). Plasma 
glycine concentration was significantly lower in +Arg/Met group compared to +GAA/Met 
and +Cre diet groups (TABLE 4.2) suggesting greater glycine utilization for GAA 
synthesis in +Arg/Met piglets. Excess methionine diets also led to higher plasma taurine 
concentrations, although there was no difference in plasma cysteine concentrations across 
diet treatments. Plasma homocysteine concentrations in Base diet-fed piglets was higher 
compared to +Cre and +Arg/Met treatments, with +GAA piglets also significantly higher 
than +Arg/Met piglets (P = 0.002) (TABLE 4.2). 
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TABLE 4.2 Selected plasma amino acid and other plasma metabolite concentrations in 
piglets fed either Base, +GAA, +GAA/Met, +Cre or +Arg/Met diets1 
Amino acid Base +GAA +GAA/Met + Cre +Arg/Met 
P5C amino acid (µmol.L-1) 
Alanine 
Arginine 
Asparagine 
Glutamine 
Glutamate 
Glycine 
Citrulline 
Methionine 
Ornithine  
Taurine 
1400 ± 403a 
52 ± 19a 
48 ± 7ab 
357 ± 62a 
101 ± 27a 
1493 ± 138ab 
154 ± 43 
54 ± 15a 
115 ± 19a 
146 ± 17a 
1013 ± 289ab 
67 ± 17a 
50 ± 7ab 
273 ± 105a 
96 ± 21ab 
1475 ± 207ab 
135 ± 33 
47 ± 9a 
112 ± 16a 
153 ± 18a 
1132 ± 520a 
66 ± 28a 
55 ± 6b 
292 ± 64a 
106 ± 23a 
1655 ± 315a 
153 ± 27 
90 ± 27b 
97 ± 18a 
229 ± 43b 
1004 ± 301ab 
77 ± 20a 
54 ± 19b 
358 ± 138a 
92 ± 27ab 
1613 ± 280a 
133 ± 40 
57 ± 12a 
100 ± 31a 
139 ± 23a 
573 ± 133b 
436 ± 89b 
38 ± 4a 
122 ± 11b 
67 ± 8b 
1204 ± 208b 
107 ± 27 
99 ± 27b 
334 ± 66b 
209 ± 210b 
Other plasma metabolites (µmol.L-1) 
Cysteine  
GAA 
Creatine 
Homocysteine 
Ammonia 
Urea (mmol/L) 
168 ± 20 
5.9 ± 1.8a 
58 ± 17a 
20 ± 8a 
84 ± 70 
6.9 ± 3.6 
178 ± 45 
6.1 ± 2.1ab 
55 ± 28a 
18 ±7ab 
53 ± 25 
7.6 ± 3.4 
158 ± 32 
6.0 ± 1.8ab 
292 ± 117b 
14 ± 4ac 
109 ± 115 
5.8 ± 1.1 
154 ± 24 
8.0 ± 4.6ab 
259 ± 112b 
11 ± 2bc 
159 ± 116 
6.3 ± 2.2 
130 ± 37 
12.0 ± 4.0b 
201 ± 100b 
10 ± 3c 
65 ± 49 
7.8 ± 1.7 
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1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 7 per group, except for the ammonia concentration ( n 
= 4 per group).  Means with differing superscripts are significantly different within the row 
(P ≤ 0.05) (produced by one-way ANOVA) and were compared by Newman-Keuls 
multiple comparison test. Arg, arginine; Cre, creatine; GAA, guanidinoacetic acid; Met, 
methionine; P5C, Pyrroline-5-carboxylic. Base, low Arg and low Met; +GAA, Base plus 
GAA; +GAA/Met, Base plus GAA plus excess Met; +Cre, Base plus creatine; +Arg/Met, 
excess Arg and excess Met. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 117 
 
Arginine, GAA and creatine kinetics: There was significantly lower plasma enrichment of 
the arginine (M+6) and GAA (M+2) tracers in the +Arg/Met compared to the Base group, 
which is likely due to dilution in the larger plasma pools due to the provision of high dietary 
arginine and high endogenous GAA synthesis, respectively (TABLE 4.3). In 
correspondence to this, significantly higher arginine and GAA fluxes were observed with 
the +Arg/Met treatment. The enrichment of the creatine (M+3) tracer that was infused was 
unaffected by the diet treatments, as was the whole-body creatine flux.  
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TABLE 4.3 Plasma isotopic enrichments of arginine, GAA, creatine and their derived 
products, flux of arginine, GAA and creatine and fractional conversion of arginine into 
GAA and creatine during steady-state on study d 6 in piglets fed either Base, +GAA, 
+GAA/Met, +Cre or +Arg/Met diets1 
 Base +GAA +GAA/Met + Cre +Arg/Met 
Enrichment (APE) 
L-Arginine -13C6-HCL (M+6) 
Guanidinoacetic acid 13C1 (M+1) 
Creatine 13C1 (M+1) 
Guanidinoacetic-2,2-d2 acid (M+2) 
Creatine-(methyl d2) monohydrate (M+2) 
Creatine-(methyl d3) monohydrate (M+3) 
6.7 ± 1.1a 
3.7 ± 0.6a 
1.8 ± 0.3a 
6.9 ± 1.3ab 
10.7 ± 1.3a 
9.9 ± 3.9 
8.3 ± 1.9a 
2.8 ± 0.8ab 
1.3 ± 0.4a 
9.7 ± 2.9a 
8.6 ± 2.2ab 
10.0 ± 4.1 
7.4 ± 1.8a 
2.7 ± 0.5b 
0.5 ± 0.1b 
8.3 ± 2.1a 
5.5 ± 1.2c 
6.7 ± 1.4 
6.3 ± 1.0a 
3.1 ± 0.7ab 
0.7 ± 0.1b 
9.5 ± 4.5a 
6.1 ± 1.7bc 
6.6 ± 1.7 
4.5 ± 0 .9b 
3.6 ± 0.2ab 
1.5 ± 0.7a 
4.9 ± 1.0b 
7.2 ± 2.9bc 
8.6 ± 1.6 
Flux (µmol.kg-1.h-1) 
Arginine  
GAA  
Creatine 
398 ± 76a 
119 ± 24a 
111 ± 47 
 329 ± 98a 
 84 ± 20a 
 111 ± 50 
368 ± 94a 
101 ± 35a 
152 ± 31 
425 ± 79a 
101 ± 55a 
157 ± 43 
610 ± 133b 
173 ± 50b 
116 ± 29 
Fractional conversion 
Arginine to GAA 
Arginine to creatine 
GAA to creatine (M+1) 
 0.57 ± 0.12a 
 0.28 ± 0.08a 
 0.48 ± 0.06a 
0.34 ± 0.06a 
0.16 ± 0.04b 
0.47 ± 0.07a 
0.38 ± 0.14a 
0.08 ± 0.03c 
0.20 ± 0.07b 
0.50 ± 0.17a 
0.10 ± 0.02c 
0.23 ± 0.05b 
0.79 ± 0.14b 
0.30 ± 0.17a 
0.42 ± 0.20a 
 
1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 6. Means with differing superscripts are significantly 
different within the row (P ≤ 0.05) (produced by one-way ANOVA) and were compared 
by Newman-Keuls multiple comparisons test. APE, Atom percent excess; Arg, arginine; 
Cre, creatine; GAA, guanidinoacetic acid; Met, methionine. Base, low Arg and low Met; 
+GAA, Base plus GAA; +GAA/Met, Base plus GAA plus excess Met; +Cre, Base plus 
creatine; +Arg/Met, excess Arg and excess Met. 
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Whole-body arginine conversion to GAA and creatine: The rate of whole-body arginine 
conversion to GAA was significantly lower in all the diets with low arginine concentrations 
compared to the diet with additional arginine (+Arg/Met) (TABLE 4.4). Furthermore, in 
the +GAA group, the rate of GAA production from arginine was significantly lower than 
in piglets fed the Base diet (TABLE 4.4). Rate of arginine conversion to creatine followed 
a similar pattern as GAA production, with the highest rate of conversion in the +Arg/Met 
group (TABLE 4.4). The conversion rate of endogenously synthesized GAA (M+1) to 
creatine was not different among all groups (TABLE 4.4). Because mixed body proteins 
of neonates contain 3.60%, 6.70% and 1.96% phenylalanine, arginine and methionine, 
respectively (Wu et al, 1999), phenylalanine incorporation into whole-body proteins was 
used to estimate the arginine and methionine incorporation into whole-body proteins in our 
piglets. Irrespective of the amount of arginine or methionine in the diets, the incorporation 
of arginine and methionine into proteins was unaffected in our piglets (TABLE 4.4). 
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TABLE 4.4 Whole-body arginine, methionine, GAA and creatine kinetics at steady-state 
on study d 6 in piglets fed either Base, +GAA, +GAA/Met, +Cre or +Arg/Met diets1 
 
 Base +GAA +GAA/Met + Cre +Arg/Met 
Fractional conversion rate (µmol.kg-1.h-1) 
Arginine into GAA 
Arginine into creatine 
Arginine to proteins 
GAA to creatine (M+1) 
Methionine to proteins 
Glycine to proteins 
66 ± 15a 
29 ± 12a 
241 ± 48 
52 ± 22 
82 ± 16 
945 ± 186 
29 ± 9b 
18 ± 9b 
251 ± 7 
42 ± 16 
85 ± 6 
982 ± 66 
41 ± 25ab 
12 ± 5ab 
262 ± 28 
30 ± 6 
72 ± 8 
1026 ± 108 
46 ± 15ab 
17 ± 3ab 
244 ± 25 
37 ± 17 
83 ± 9 
954 ± 98 
143 ± 47c 
38 ± 19c 
249 ± 16 
46 ± 16 
85 ± 5 
975 ± 63 
 
1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 6. Means with differing superscripts are significantly 
different within the row (P ≤ 0.05) (produced by one-way ANOVA) and were compared 
by Newman-Keuls multiple comparisons test. Arg, arginine; Cre, creatine; GAA, 
guanidinoacetic acid; Met, methionine. Base, low Arg and low Met; +GAA, Base plus 
GAA; +GAA/Met, Base plus GAA plus excess Met; +Cre, Base plus creatine; +Arg/Met, 
excess Arg and excess Met. 
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Partitioning of arginine between GAA and protein synthesis: A higher proportion of 
arginine flux was directed towards GAA synthesis in our +Arg/Met diet compared to the 
diets with low arginine (P < 0.0001) (TABLE 4.5). Among the four low arginine diet 
treatments, the proportion of arginine flux directed towards GAA was highest in Base diet 
(17%) compared to piglets fed +GAA (9%), +Cre (11%) or +GAA/Met (11%). The 
proportion of arginine flux directed towards whole-body protein synthesis was 51 - 90% (P 
< 0.01) and was different between piglets fed +GAA or +GAA and +Arg/Met. Only the 
+Arg/Met piglets showed no difference to other diet groups (P = 0.01) (TABLE 4.5).  
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TABLE 4.5 Whole-body arginine flux directed to the product as a % of precursor amino acid flux 
during steady-state on study d 6 in piglets fed either Base, +GAA, +GAA/Met, +Cre or 
+Arg/Met diets1 
 
 Base +GAA +GAA/Met + Cre +Arg/Met 
% 
Arginine to GAA 
Arginine to protein 
17 ± 3a 
63 ± 21ab 
9 ± 4b 
81 ± 21a 
11 ± 4b 
76 ± 23a 
11 ± 3b 
59 ± 14ab 
23 ± 6c 
44 ± 9b 
 
 
1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 6. Means with differing superscripts are significantly 
different within the row (P ≤ 0.01) (produced by one-way ANOVA) and were compared 
by Newman-Keuls multiple comparisons test. Arg, arginine; Cre, creatine; GAA, 
guanidinoacetic acid; Met, methionine. Base, low Arg and low Met; +GAA, Base plus 
GAA; +GAA/Met, Base plus GAA plus excess Met; +Cre, Base plus creatine; +Arg/Met, 
excess Arg and excess Met. 
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Utilization of dietary arginine, glycine and methionine for GAA, creatine and protein 
synthesis: The fraction of dietary arginine utilized to synthesize both GAA and creatine 
was significantly higher in the Base diet group (91%) compared to all other treatments (32 
- 63%) (TABLE 4.6). The proportion of dietary glycine used for the synthesis of GAA was 
significantly higher in +Arg/Met piglets compared to the piglets fed diets with low arginine 
(TABLE 4.6). The fraction of dietary methionine utilized to synthesize creatine was 
significantly lower only in the +Arg/Met group compared to all other diets (TABLE 4.6). 
The fractions of dietary arginine and methionine partitioned to whole-body proteins was 
only affected by the amount of arginine in the diets (P < 0.0001) (TABLE 4.6).  
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TABLE 4.6 Percentage of dietary amino acid utilization (arginine, glycine or methionine) to 
synthesize GAA & creatine (%) determined at steady-state on study d 6 in piglets fed either 
Base, +GAA, +GAA/Met, +Cre or +Arg/Met diets1 
 Base +GAA +GAA/Met + Cre +Arg/Met 
% 
Arginine to GAA 
Arginine to creatine 
Arginine to proteins 
 
(GAA M+1 to Cre M+1) 
Methionine to proteins 
 
Glycine to GAA 
Glycine to creatine 
Glycine to proteins 
91 ± 21a 
40 ± 16a 
335 ± 66a 
 
94 ± 40a 
146 ± 29a 
 
33 ± 8a 
14 ± 5ab 
476 ± 94 
40 ± 12bc 
24 ± 13b 
348 ± 23a 
 
97 ± 58a 
152 ± 11a 
 
15 ± 4b 
 9 ± 5ac 
495 ± 33 
44 ± 19bc 
16 ± 7b 
364 ± 39a 
 
53 ± 11a 
129 ± 14a 
 
21 ± 13b 
6 ± 3c 
518 ± 54 
63 ± 21b 
23 ± 5b 
338 ± 34a 
 
65 ± 30a 
148 ± 15a 
 
23 ± 8ab 
8 ± 2ac 
481 ± 49 
32 ± 10c 
9 ± 4b 
58 ± 4b 
 
33 ± 11b 
61 ± 4b 
 
72 ± 24c 
19 ± 8b 
492 ± 31 
 
1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 6. Means with differing superscripts are significantly 
different within the row (P ≤ 0.01) (produced by one-way ANOVA) and were compared 
by Newman-Keuls multiple comparisons test. Arg, arginine; Cre, creatine; GAA, 
guanidinoacetic acid; Met, methionine. Base, low Arg and low Met; +GAA, Base plus 
GAA; +GAA/Met, Base plus GAA plus excess Met; +Cre, Base plus creatine; +Arg/Met, 
excess Arg and excess Met.  
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TABLE 4.7 Fate of metabolites in the whole-body pool in piglets fed either Base, +GAA, 
+GAA/Met, +Cre or +Arg/Met diets1 
 
1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 7. Means with differing superscripts are significantly 
different within the row (P ≤ 0.05) (produced by one-way ANOVA) and were compared 
by Newman-Keuls multiple comparisons test. 2Sum of the creatine synthesis and stored 
creatine release from muscles. Arg, arginine; Cre, creatine; GAA, guanidinoacetic acid; 
Met, methionine. Base, low Arg and low Met; +GAA, Base plus GAA; +GAA/Met, Base 
plus GAA plus excess Met; +Cre, Base plus creatine; +Arg/Met, excess Arg and excess 
Met. 
 Base +GAA +GAA/Met + Cre +Arg/Met 
µmol.kg-1.h-1 
Dietary intake 
    Arginine 
    Methionine 
    Creatine 
De novo synthesis 
    Arginine 
 
72 
56 
0 
 
223 ± 72a 
 
72 
56 
0 
 
155 ± 80ab 
 
72 
140 
0 
 
192 ± 96a 
 
72 
56 
33 
 
237 ± 87a 
 
432 
140 
0 
 
56 ± 100b 
116 ± 29 
 
124 ± 22 
42 ± 8 
    Creatine2  
Release from protein break-down 
    Arginine 
    Methionine 
111 ± 47 
 
132 ± 60 
45 ± 21 
111 ± 50 
 
110 ± 64 
38 ± 22 
152 ± 31 
 
133 ± 38 
45 ± 13 
124 ± 43 
 
150 ± 32 
51 ± 11 
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Whole-body phenylalanine, tyrosine kinetics: There was no diet effect on phenylalanine 
incorporated into whole-body proteins, or phenylalanine released from whole-body protein 
breakdown in our piglets (TABLE 4.8). 
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TABLE 4.8 Phenylalanine (Phe) enrichment, flux and rate of incorporation into whole-
body proteins at steady-state on study d 6 in piglets fed either Base, +GAA, +GAA/Met, 
+Cre or +Arg/Met diets1 
 Base +GAA +GAA/Met + Cre +Arg/Met 
Enrichment (APE) 
L-Phenyl-[ring-2H5] alanine (M+5) 8.1 ± 0.5 8.5 ± 1.2 7.8 ± 0.5 7.8 ± 0.7 8.2 ± 0.4 
L-Tyrosine-(phenyl-d4) (M+4) 0.7 ± 0.2 0.7 ± 0.3 0.5 ± 0.1 0.6 ± 0.2 0.6 ± 0.3 
L-[ring 3,5 d2]-tyrosine (M+2) 4.3 ± 0.5 4.4 ± 0.6 4.2 ± 0.4 4.3 ± 0.8 4.1 ± 1.0 
Flux (µmol.kg-1.h-1) 
Phe 254 ± 50 245 ± 63 264 ± 56 264 ± 41 250 ± 42 
Tyr 201 ± 25 199 ± 24 208 ± 20 209 ± 37 199 ± 22 
(µmol.kg-1.h-1) 
Phe into Tyr conversion rate 17 ± 5 14 ± 4 12 ± 5 16 ± 9 16 ± 4 
Phe incorporation into proteins  211 ± 13 205 ± 37 224 ± 16 223 ± 21 211 ± 9 
Phe released from protein break-down  75 ± 34 63 ± 36 75 ± 22 85 ± 18 70 ± 12 
Net phe incorporation into whole-body 
proteins 
 
137 ± 27 
 
142 ± 10 
 
149 ± 16 
 
138 ± 14 
 
141 ± 9 
 
1Values are mean ± SD of non-transformed data; statistics were determined using log values 
when variances were different; n = 6. Means with differing superscripts are significantly 
different within the row (produced by one-way ANOVA) and were compared by Newman-
Keuls multiple comparisons test. Arg, arginine; APE, Atom percent excess; Cre, creatine; 
GAA, guanidinoacetic acid; Met, methionine. Phe, phenylalanine; Tyr, tyrosine. Base, low 
Arg and low Met; +GAA, Base plus GAA; +GAA/Met, Base plus GAA plus excess Met; 
+Cre, Base plus creatine; +Arg/Met, excess Arg and excess Met. 
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4.5 DISCUSSION 
 
This is the first report of the partitioning of arginine into GAA, creatine, and protein in-
vivo, with the corresponding plasma and tissue GAA and creatine concentrations. As GAA 
and creatine synthesis depend on arginine availability (Gagnon et al, 2010), we quantified 
the partitioning of arginine into GAA/creatine and towards protein synthesis when low 
versus excess amounts of arginine and methionine were provided in the diet.  
 
Determinants of GAA and creatine synthesis: substrate, dietary creatine and 
endogenously synthesized creatine availability or enzyme activity An important 
question from our previous study (Dinesh et al, 2018) was whether the low creatine 
accretion in our piglets fed a creatine-free diet was due to limited enzyme capacity or 
limited substrate availability. It is clear from this study, that arginine/methionine 
availability, rather than enzyme activity, affects GAA and creatine biosynthesis. The 
highest GAA/creatine synthesis occurred in piglets fed excess arginine and methionine, but 
tissues from these same piglets exhibited lower in-vitro AGAT activity with no differences 
in GAMT activity. Similarly, AGAT activity was highest in the piglets fed the lowest 
arginine concentration, but these piglets demonstrated lower GAA synthesis, clearly 
demonstrating that substrate availability rather than the enzyme activity was the primary 
determinant of GAA synthesis.  
 
In our previous study (Dinesh et al, 2018) and in the present study, we have 
demonstrated that a dietary supply of creatine results in reduced in-vitro AGAT specific 
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activity in piglets. Creatine supplementation has been reported to down regulate creatine 
synthesis by lowering kidney AGAT activity, AGAT protein and AGAT mRNA levels in 
rats (McGuire et al, 1984, Edison et al, 2007, da Silva et al, 2009, 2014). Based on these 
findings, we predicted a lower rate of conversion of arginine to GAA and creatine in piglets 
fed creatine; however, this did not happen. We observed no difference in the rate of GAA 
or creatine synthesis between creatine supplemented and un-supplemented piglets when 
arginine and methionine were low, despite lower in-vitro AGAT activity with creatine in 
the diet. It should be noted that we provided low arginine in both diets, so again, it may 
have been substrate availability rather than the presence of creatine in the diet that 
determined the rate of arginine conversion to GAA and creatine.  
 
The interpretation of data from the in-vitro enzyme capacity and the in-vivo isotope 
kinetics were inconsistent and perhaps the in-vitro enzyme capacity is misleading. It is clear 
that the information derived from in-vitro enzyme studies (enzyme capacity) does not 
necessarily reflect the in-vivo flux through the enzymes and strongly suggests that enzyme 
activity data should not be used in isolation to interpret metabolite conversions.  
 
Similarly, we expected that providing dietary GAA with excess methionine would 
lower arginine conversion to GAA and creatine, as this condition led to plasma and tissue 
creatine concentrations which were similar to piglets fed creatine; but again, this was not 
the case, suggesting that it may be excess arginine availability, rather than endogenously 
synthesized creatine, that alters the rate of GAA synthesis.  
 
 130 
 
Capacity of piglet to synthesize creatine Low dietary arginine in the present study and 
moderate arginine in our previous study  (Dinesh et al, 2018) both led to deficits in plasma 
GAA and creatine even with high AGAT capacity. In the present study, as expected, excess 
arginine and methionine sustained de novo GAA and creatine synthesis and a concomitant 
increase in the plasma and tissue creatine concentrations similar to piglets fed their entire 
creatine requirement in the diet. Therefore, the amount of arginine and methionine provided 
in the excess arginine and methionine diet appeared to be sufficient to meet the whole-body 
creatine requirement in piglets of this age, at least in the short-term.  
 
We calculated de novo arginine synthesis from the proportion of arginine released 
from protein break down, the dietary arginine intake and whole-body arginine flux. The 
calculated de novo arginine synthesis in piglets fed the low arginine diets was higher than 
in piglets fed excess arginine. However, this higher de novo arginine synthesis did not 
translate into higher peripheral plasma arginine concentrations. None of the low arginine 
treatments, even with de novo arginine synthetic capacity, could overcome arginine 
deficiency and the concomitant reduction in GAA and creatine synthesis. Arginine levels 
in different brands of pediatric PN solutions varied from 0.7 g.kg-1.d-1 to 1.8 g.kg-1.d-1 
(Brunton et al, 2000). We included 0.3 g.kg-1.d-1 arginine in the low arginine treatments, 
while arginine was 1.8 g.kg-1.d-1 in the excess arginine treatment. Therefore, the provision 
of excess amounts of arginine and methionine, is required to meet the neonatal whole-body 
creatine requirement when pre-made creatine is not provided in the diet.   
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GAA, an effective precursor for creatine biosynthesis Because GAA is proportionately 
converted to creatine with no feedback regulation (da Silva et al, 2009, McBreairty et al, 
2015), we hypothesized that supplemental GAA would be maximally converted to creatine 
only if sufficient methionine was available to provide methyl groups for GAMT. This 
strategy produced plasma and tissue creatine concentrations that were similar to those 
resulting from the direct provision of dietary creatine, which demonstrates that under such 
conditions, the piglets had the capacity to synthesize enough creatine. Moreover, liver 
GAMT activity was higher only in piglets fed dietary GAA with excess methionine, 
demonstrating that GAMT was induced to accommodate creatine synthesis, but only when 
methionine was abundant. Therefore, dietary GAA is an effective intermediate precursor 
for creatine biosynthesis, but only when provided with excess methionine.  
 
Low methionine in the GAA diet hampered creatine synthesis, as plasma and tissue 
creatine concentrations were low compared to piglets fed creatine. We predicted, therefore, 
higher plasma and liver GAA concentrations in these same piglets. However, we observed 
no differences in plasma GAA concentrations between piglets fed dietary GAA with low 
methionine and other low arginine groups suggesting that dietary GAA did not appear in 
the peripheral circulation. Liver is considered to be the main organ that takes up GAA to 
synthesize creatine in the body (Brosnan et al, 2009). When dietary GAA was provided 
with excess methionine, it was clearly evident that GAA was absorbed via the small 
intestine, since we observed high plasma and liver creatine concentrations in these piglets, 
similar to piglets fed creatine. Further to this, it was evident that dietary GAA was 
channeled to the liver, as piglets fed excess methionine with dietary GAA exhibited high 
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liver GAA concentrations which were similar to piglets fed excess arginine and methionine. 
When methionine was low in the diet, it is possible that dietary GAA was still absorbed, 
but not channeled into the liver for the transmethylation given low methyl group 
availability. However, the fate of this absorbed, but unmethylated GAA is unclear because 
GAA did not accumulate in the liver or kidney or in the plasma for catabolism and 
excretion. We did not measure urinary GAA, but we would have expected plasma GAA to 
increase concomitant with high renal excretion, so it seems unlikely that urinary excretion 
was the fate of the dietary GAA.  
 
Maintenance of whole-body protein synthesis versus whole-body GAA/creatine 
synthesis In the current study, surprisingly, short-term dietary manipulation of arginine, 
methionine, GAA or creatine and concomitant acute changes in plasma arginine and 
methionine did not affect the whole-body protein synthesis in neonatal piglets.  
 
The proportion of arginine flux directed towards GAA synthesis was only 17% in 
low arginine and methionine treated piglets; however, the proportion of flux was 23% in 
piglets fed excess arginine and methionine, suggesting that GAA and creatine synthesis 
were disproportionately affected by the acute changes in arginine in the diet. This reduction 
in the partitioning towards GAA and creatine synthesis may have allowed the piglets to 
accommodate a lower arginine intake without sacrificing whole-body protein synthesis. A 
more severe arginine deficiency might be necessary to observe a sparing effect of arginine 
for protein synthesis. Alternatively, the measurement of whole-body protein synthesis 
might not capture small increases in organ specific protein synthesis.  
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Short-term diet manipulations on brain GAA/creatine concentrations In our previous 
study we supplemented creatine to parenterally-fed piglets for two weeks and found no 
differences in brain GAA or creatine levels (Dinesh et al 2018). In the current study, we 
wanted to test whether the short-term provision of dietary arginine and methionine or the 
supplementation of GAA or creatine would affect brain GAA and creatine concentrations. 
The brain GAA and creatine levels were unaffected, suggesting that brain creatine accretion 
may be conserved and not readily affected by changes in whole-body creatine metabolism. 
Whether more chronic changes in arginine and methionine intake affect brain creatine 
accretion needs to be examined.  
 
Conclusion The data from this study demonstrated that the short-term changes in arginine, 
methionine, GAA and creatine synthesis did not translate into differences in the brain GAA 
and creatine levels in neonatal piglets. The novel finding in this study was that 
GAA/creatine synthesis have been driven by the arginine and methionine availability rather 
than enzyme capacity or creatine concentration in the tissues. Since in-vitro enzyme 
activities do not reflect in-vivo arginine conversion into GAA/creatine, therefore, they 
cannot solely be utilized to speculate on the regulation of creatine biosynthesis. We 
demonstrated that the piglet is capable of synthesizing its requirement for creatine provided 
sufficient arginine and methionine are fed. The noteworthy finding was that supplemental 
GAA can be used to satisfy whole-body creatine needs, but only if accompanied by 
adequate methionine in the diet, perhaps to facilitate intestinal absorption of the GAA, and 
certainly to transmethylate GAA to creatine in the liver. Overall, we demonstrated that 
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creatine biosynthesis was disproportionately sacrificed to maintain whole-body protein 
synthesis when arginine and methionine were limiting in the diets of neonatal piglets. 
Therefore, adequate amounts of precursors of creatine or pre-made creatine 
supplementation must be considered relevant to the amino acid requirements of the 
neonatal diet to accommodate creatine requirement.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135 
 
4.6 REFERENCES 
Beard E and Braissant O. Synthesis and transport of creatine in the CNS: importance for 
cerebral functions. Neurochem. 2010; 115, 297–313. 
Bidlingmeyer BA, Cohen SA, Tarvin TL. Rapid analysis of amino acids using pre-column 
derivatization. J Chromatogr. 1984; 336: 93–104. 
Brosnan JT, Wijekoon EP, Warford-Woolgar L, Trottier NL, Brosnan ME, Brunton JA, 
Bertolo RF. Creatine synthesis is a major metabolic process in neonatal piglets and has 
important implications for amino acid metabolism and methyl balance. J Nutr. 2009; 
139(7): 1292–7.  
Bruins MJ, Lamers WH, Meijer AJ, Soeters PB, Deutz NEP.  In-vivo measurement of 
nitric oxide production in porcine gut, liver and muscle during hyperdynamic 
endotoxaemia. Br J Pharmacol. 2002; 137(8): 1225–1236. 
Brunton JA, Ball RO, Pencharz PB. Current total parenteral nutrition solutions for the 
neonate are inadequate. Curr Opin Clin Nutr Metab Care. 2000; 3: 299–304.  
Buchberger W, Ferdig M. Improved high-performance liquid chromatographic 
determination of guanidino compounds by pre-column derivatization with ninhydrin 
and fluorescence detection. J Sep Sci. 2004; 27:1309–12. 
Buchma AL. The addition of choline to parenteral nutrition. Gastroenterology 2009; 137: 
5: S119–S128. 
da Silva RP, Nissim I, Brosnan ME, Brosnan JT. Creatine synthesis: hepatic metabolism 
of guanidinoacetate and creatine in the rat in-vitro and in-vivo. Am J Physiol 
Endocrinol Metab. 2009; 296(2): E256-61.  
 136 
 
da Silva RP, Clow K, Brosnan JT, Brosnan ME.  Synthesis of guanidinoacetate and creatine 
from amino acids by rat pancreas. Br J Nutr. 2014; 111(4): 571-7.  
Dinesh OC, Bertolo RF, Brunton JA. Creatine supplementation to total parenteral nutrition 
improves creatine status and supports greater liver and kidney protein synthesis in 
neonatal piglets. Pediatr Res.  2018; 83(1-1): 135-141.  
Dodge ME, Bertolo RF, Brunton JA. Enteral feeding induces early intestinal adaptation in 
a parenterally fed neonatal piglet model of short bowel syndrome. J Parenter Enteral 
Nutr. 2012; 36: 205-12.  
Edison EE, Brosnan ME, Meyer C, Brosnan JT. Creatine synthesis: production of 
guanidinoacetate by the rat and human kidney in-vivo. Am J Physiol Renal Physiol. 
2007; 293(6): F1799-804.  
Edison EE, Brosnan ME, Aziz K, Brosnan JT. Creatine and guanidinoacetate content of 
human milk and infant formulas: implications for creatine deficiency syndromes and 
amino acid metabolism. Br J Nutr. 2013 28; 110(6): 1075-8.  
Gagnon A, Bertolo FA, Brunton JA. The effect of varying levels of dietary arginine on 
plasma, kidney and liver concentration of guanidinoacetate and creatine in 
parenterally fed neonatal piglets. 2009. Bachelor of Science (Honours) thesis, 
Memorial University of Newfoundland, St. John’s, Canada. 
McBreairty LE, Robinson JL, Furlong KR, Brunton JA, Bertolo RF. Guanidinoacetate is 
more effective than creatine at enhancing tissue creatine stores while consequently 
limiting methionine availability in yucatan miniature pigs. PLoS ONE. 2015; 10(6): 
e0131563.  
 137 
 
McGuire DM, Gross MD, Van Pilsum JF, Towle HC. Repression of rat kidney L-
arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. J 
Biol Chem. 1984; 259(19): 12034-8. 
National Research Council (NRC). Nutrient Requirements of Poultry. 1994. National 
Academies Press. 
Ogawa H, Ishiguro Y, Fujioka M. Guanidinoacetate methytransferase from rat liver: 
purification, properties, and evidence for the involvement of sulfhydryl groups for 
activity. Arch Biochem Biophys.1983; 226: 265–75. 
Shoveller AK, Brunton JA, House JD, Pencharz PB, Ball RO. Dietary cysteine reduces the 
methionine requirement by an equal proportion in both parenterally and enterally fed 
piglets. J Nutr. 2003; 133(12): 4215-24. 
Thivierge MC, Bush JA, Suryawan A, Nguyen HV, Orellana RA, Burrin DG, Jahoor F, 
Davis TA. Whole-body and hindlimb protein breakdown are differentially altered by 
feeding in neonatal piglets. J Nutr. 2005; 135(6): 1430-7. 
Tomlinson C, Rafii M, Sgro M, Ball RO, Pencharz PB, Hospital T. Arginine is synthesized 
from proline, not glutamate, in enterally fed human preterm neonates. Pediatr Res. 
2011; 69(1): 46–50. 
Van Pilsum JF, Taylor D, Zakis B, Mc Cormick P. Simplified assay for transamidinase 
activities of rat kidney homogenates. Anal Biochem.1970; 35: 277–86. 
Vester B and Rasmussen K. High performance liquid chromatography method for rapid 
and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem 
Clin Biochem. 1991; 29: 549-554. 
 138 
 
Walker JB. Creatine: biosynthesis, regulation and function. Adv Enzymol Relat Areas Mol 
Biol. 1979; 50: 177–242. 
Wilkinson DL, Bertolo RF, Brunton JA, Shoveller AK, Pencharz PB, Ball RO. Arginine 
synthesis is regulated by dietary arginine intake in the enterally fed neonatal piglet. 
Am J Physiol Endocrinol Metab. 2004; 287(3): E454-62.  
 
 
 
 
4.7 ACKNOWLEDGEMENTS 
 
O.C.D, J.A.B. and R.F.B. designed the research; O.C.D. and K.T. conducted the research; 
C.T. produced the raw data for in-vivo isotope kinetics, O.C.D. conducted the laboratory 
analysis for the rest of the data. O.C.D performed the statistical analysis for all the data. 
O.C.D. wrote the paper. J.A.B. and R.F.B. edited the paper. O.C.D., J.A.B. and R.F.B. had 
primary responsibility for final content. All authors read and approved the final content of 
the manuscript. 
 
 
 
 
 
 
 139 
 
4.8 ONLINE SUPPORTING MATERIAL 
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SUPLEMENTAL TABLE 4.1 Amino acid, GAA and creatine compositions of Base, 
+GAA, +GAA/Met, +Cre or +Arg/Met diets1 
 
 
 
 
Amino acid Base  +GAA +GAA/Met  +Cre  +Arg/Met  
g.L-1 (g.kg-1d-1) 
Alanine 11.16 (3.04) 10.39 (2.82) 9.61(2.61) 10.39 (2.82) 0.00 (0.00) 
Arginine 1.10 (0.30) 1.10 (0.30) 1.10 (0.30) 1.10 (0.30) 6.62 (1.80) 
Aspartate 3.47 (0.94) 3.47 (0.94) 3.47 (0.94) 3.47 (0.94) 2.31 (0.63) 
Cysteine 0.83 (0.22) 0.83 (0.22) 0.83 (0.22) 0.83 (0.22) 0.83 (0.22) 
Glutamate 6.00 (1.63) 6.00 (1.63) 6.00 (1.63) 6.00 (1.63) 6.00 (1.63) 
Glycine 1.31 (0.36) 1.31 (0.36) 1.31 (0.36) 1.31 (0.36) 1.31 (0.36) 
Histidine 1.76 (0.48) 1.76 (0.48) 1.76 (0.48) 1.76 (0.48) 1.76 (0.48) 
Isoleucine 2.64 (0.72) 2.64 (0.72) 2.64 (0.72) 2.64 (0.72) 2.64 (0.72) 
Leucine 5.94 (1.62) 5.94 (1.62) 5.94 (1.62) 5.94 (1.62) 5.94 (1.62) 
Lysine 4.73 (1.29) 4.73 (1.29) 4.73 (1.29) 4.73 (1.29) 4.73 (1.29) 
Methionine 0.74 (0.20) 0.74 (0.20) 1.84 (0.50) 0.74 (0.20) 1.84 (0.50) 
Phenylalanine 2.24 (0.61) 2.24 (0.61) 2.24 (0.61) 2.24 (0.61) 2.24 (0.61) 
Proline 4.73 (1.29) 4.73 (1.29) 4.73 (1.29) 4.73 (1.29) 4.73 (1.29) 
Serine 3.19 (0.87) 3.19 (0.87) 3.19 (0.87) 3.19 (0.87) 3.19 (0.87) 
Taurine 0.28 (0.07) 0.28 (0.07) 0.28 (0.07) 0.28 (0.07) 0.28 (0.07) 
Tryptophan 1.21 (0.33) 1.21 (0.33) 1.21 (0.33) 1.21 (0.33) 1.21(0.33) 
Tyrosine 0.43 (0.12) 0.43 (0.12) 0.43 (0.12) 0.43 (0.12) 0.43 (0.12) 
Valine 3.03 (0.82) 3.03 (0.82) 3.03 (0.82) 3.03 (0.82) 3.03 (0.82) 
Threonine 3.03 (0.82) 3.03 (0.82) 3.03 (0.82) 3.03 (0.82) 3.03 (0.82) 
Creatine monohydrate 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.44 (0.12) 0.00 (0.00) 
GAA 0.00 (0.00) 0.34 (0.09) 0.34 (0.09) 0.00 (0.00) 0.00 (0.00) 
Glycine-L-tyrosine 1.42 (0.39) 1.42 (0.39) 1.42 (0.39) 1.42 (0.39) 1.42 (0.39) 
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1Alanine and aspartate were used to make the diets isonitrogenous. With the exceptions of 
arginine, methionine, alanine and aspartate, the amino acid compositions of the diets were 
similar. Arg, arginine; Cre, creatine; GAA, guanidinoacetic acid; Met, methionine. Base, 
low Arg and low Met; +GAA, Base plus GAA; +GAA/Met, Base plus GAA plus excess 
Met; +Cre, Base plus creatine; +Arg/Met, excess Arg and excess Met. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 142 
 
SUPPLEMETAL TABLE 4.2 Composition of either Base, +GAA, +GAA/Met, +Cre or 
+Arg/Met diets1,2 
 
Composition of Elemental Diets g.L-1 
L-Amino acids 56.0 
D-Glucose 90.3 
Trihydrate K2HPO4 1.57 
Monobasic KH2PO4 1.09 
Potassium acetate  1.47 
NaCl 2.17 
MgSO4  0.78 
ZnSO4 0.09 
Calcium gluconate 6.41 
Composition of Admixtures  
Vitamin solutions3  
       Fat soluble vitamins Dosekg-1BWd-1 
Vitamin A, µg 
 
273 
Vitamin D, µg 2.20 
Vitamin E (dl-alpha tocopheryl acetate), mg 
IU) 
 
1.50 
       Vial 1  
Ascorbic acid, mg 17.4 
 
Thiamine (as hydrochloride), mg 
 
0.26 
Riboflavin (as phosphate), mg 
 
0.30 
Pyridoxine hydrochloride, mg 
 
0.22 
Niacinamide, mg 
 
3.70 
d-Panthenol, mg 
 
1.10 
Vitamin K1, mg 
 
0.04 
       Vial 2  
Biotin, µg 
 
4.35 
Folic Acid, µg 
 
30.46 
Vitamin B12, µg 0.22 
Trace ElementMix4 mgkg-1BWd-1 
Zinc (as ZnSO4.7H2O) 
 
10.07 
0.86 
0.66 
0.01 
0.05 
0.02 
Copper (as CuSO4.5H2O) 
 
0.86 
Manganese (as MnSO4.H2O) 
 
0.66 
Chromium (as CrCl3.6H2O) 
 
0.01 
Selenium (as SeO2) 
 
0.05 
Iodide (as NaI) 02
Iron Dextran5  
Iron (as ferric hydroxide) 3.0 
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1All five experimental diets were identical, with the exception of the amino acid 
composition (SUPPLEMENTAL TABLE 1). The diets were comprised of an amino acid, 
glucose mineral mixture, which was infused at a rate of 272 mLkg-1 BWd-1.   
 
2Intralipid® 20% (Baxter, Canada) infused with the diets at a rate of 52 mLkg-1 BWd-1. 
Choline presents as free form (in the form of lecithin) and as bound to phosphatidylcholine 
in the Intralipid® 20% (Baxter, Canada). The bound form is not converted to choline to any 
significant degree. The free choline in Intralipid® 20% emulsion is 24 nmol/mL (Buchman 
AL, 2009). 
 
3Vitamin solutions (components are from Sigma-Aldrich, Canada or Biochemica BDH or 
Fluka, China) during treatment diets were prepared in the laboratory. The compositions of 
all three solutions were as in the Multi-12/K1 Pediatric
® multivitamin solution for 
parenteral nutrition (Baxter). The PH was adjusted using citric acid and/or sodium citrate. 
Doses from Vial 1 and 2 were added to the amino acid mixture just prior to use. Fat soluble 
vitamins were dissolved in vegetable oil (Crisco) and dosed as 0.5 mLkg-1d-1 directly into 
gastric catheter in every morning. During intravenous feeding, commercial Multi-12/K1 
Pediatric® multivitamin solution was infused into diet bag.  
 
4The the trace element mix (components from Sigma-Aldrich, Canada) was prepared in the 
laboratory, and added to the amino acid mixture just prior to use. 
 
5Iron dextran (Bimeda-MTC Animal Health, Canada). 
Base, low Arg and low Met; +GAA, Base plus GAA; +GAA/Met, Base plus GAA plus 
excess Met; +Cre, Base plus creatine; +Arg/Met, excess Arg and excess Met. 
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SUPPLEMENTAL TABLE 4.3 Equations for in-vivo kinetics analysis 
 
 
 
 
APE, Atom percent excess, Arg, arginine; Cre, creatine; Ei, enrichment in the infusate; Ep, 
enrichment in the plasma; Epre, enrichment of the precursor; Epro, enrichment of the product; 
I, isotope infusion rate; Rs, tracer:tracee in enriched sample; Rb, tracer:trace in natural 
abundance; Phe, Phenylalanine; Tyr, tyrosine. 
 
 
 
 
Variable Equation  
• Enrichment (APE)(E) 
• Whole-body turnover (Flux) (µmol.kg-1.hr-1) (q) 
 
Conversion rates: 
o Whole-body conversion rate of arginine into GAA 
o Whole-body conversion rate of arginine into 
creatine 
o Whole-body conversion rate of GAA into creatine 
o Fractional conversion 
 
Arginine de novo synthesis 
 
Creatine release from muscle (creatine synthesis in 
muscle + creatine release from muscle creatine pool) 
 
Estimation of whole-body protein kinetics: 
o Whole-body protein synthesis (µmol.kg-1.hr-1) 
o Whole-body protein break-down (µmol.kg-1.hr-1) 
o Whole-body net protein synthesis (µmol.kg-1.hr-1) 
 
• Fractional conversion rate as a % of precursor 
amino acid flux 
• Fraction of dietary precursor amino acid (arginine, 
glycine or methionine) used to synthesize 
creatine/proteins (%) 
[(Rs-Rb)/(1+Rs)-Rb]*100  
q = I *[(Ei/Ep)-1] 
 
 
QArg > GAA = (EGAA/EArg)*qGAA 
 
QArg > Cre = (ECre/EArg)*qCre 
QGAA > Cre = (ECre/EGAA)*qCre 
Epdc/Epre 
 
FluxArg - (Dietary Arg intake + Arg released from  
Protein-break down) 
 
Flux Cre - (Dietary Cre intake + Creatine de novo synthesis) 
 
 
Flux - (Phe → Tyr conversion rate)  
Flux - Phe infusion rate                      
Protein synthesis - Protein break-down 
 
 
(Fractional conversion rate/Flux precursor)*100 
 
 
(Conversion rate/Dietary amino acid infusion rate)*100 
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CHAPTER FIVE 
 
Kidneys are quantitatively more important than pancreas and 
gut as a source of GAA for hepatic creatine synthesis in sow-
reared Yucatan miniature piglets  
 
The work presented in this Chapter was funded by a grant from the Natural Sciences and 
Engineering Research Council. This work was presented at Canadian Nutrition Society 
Annual Conference in 2017 and the abstract was published in the journal Applied 
Physiology, Nutrition and Metabolism (Appl. Physiol. Nutr. Metab. Vol. 42, 2017). The 
manuscript will be submitted to the Journal of Nutrition and has been formatted as per their 
guidelines. 
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5.0 Kidneys are quantitatively more important than pancreas 
and gut as a source of GAA for hepatic creatine synthesis in 
sow-reared Yucatan miniature piglets  
 
5.1 ABSTRACT 
 
Background: Arginine:glycine amidinotransferase, necessary for the conversion of 
arginine to guanidinoacetic acid (GAA), is expressed mainly in the kidney and pancreas. 
The subsequent methylation of GAA to creatine primarily occurs in the liver. The 
quantitative importance of the kidney, pancreas and gut as sources of GAA for hepatic 
creatine synthesis has not been studied in neonates. Methods: In sow-fed and fasted 
neonatal piglets, the net balance of GAA and creatine across the kidney, pancreas and 
intestine was measured during a constant intravenous infusion of one of the following: 1) 
arginine + methionine (Arg/Met), 2) creatine + arginine + methionine (+Cre), 3) citrulline 
+ methionine (Cit/Met) or 4) alanine (Ala). Results: The kidneys of sow-fed piglets 
contributed 88% of the measured GAA produced, with the remainder released by the 
pancreas. Infusion of arginine (Arg/Met and +Cre) or citrulline (Cit/Met) produced much 
greater net release of GAA from the kidneys compared to that released from the pancreas 
and intestine. However, renal GAA release was greatest with citrulline infusion, suggesting 
that citrulline is a better precursor than arginine for GAA synthesis in the kidneys. In the 
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intestine, arginine during creatine infusion, but not citrulline, resulted in a net release of 
GAA, suggesting that these organs do not have the capacity to convert citrulline into 
arginine. Creatine infusion resulted in a much higher net GAA release from the intestine 
and pancreas compared to other treatments, perhaps because GAA was not required for 
creatine synthesis in these tissues and was subsequently released. Conclusions: The 
kidneys, not the pancreas or intestine, are the major source of GAA for hepatic creatine 
synthesis in neonatal piglets, but the neonatal intestine has the capacity to synthesize GAA 
and creatine when arginine and methionine are available with creatine.  
 
 
Abbreviations: AGAT, L-Arginine:glycine amidinotransferase; Ala, alanine; Arg, arginine; 
CA, carotid artery; Cit, citrulline; Cre, creatine; GAA, guanidinoacetic acid; GAMT, 
guanidinoacetate N-methyltransferase; Met, methionine; PITC, phenylisothiocyanate; PV, 
portal vein; RV, renal vein; SF, sow fed; SV, splenic vein. 
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5.2 INTRODUCTION   
 
De novo creatine synthesis involves the conversion of arginine to guanidinoacetic acid 
(GAA) via the enzyme L-arginine:glycine amidinotransferase (AGAT), and the subsequent 
conversion of GAA to creatine requires methionine and the enzyme guanidinoacetate N-
methyltransferase (GAMT) (Walker et al, 1979, Wyss et al, 2000). Tissue GAA and 
creatine concentrations and in-vitro activities of AGAT and GAMT have been analyzed to 
describe the inter-organ system of creatine synthesis (Walker et al, 1979, Wyss et al, 2000, 
Brosnan et al, 2009, Dinesh et al, 2018). The kidney has been considered the major organ 
responsible for GAA synthesis, based on arterio-venous balance data determined from rats 
(Edison et al, 2007). However, in two previous studies in neonatal piglets that assessed 
creatine status with varying dietary amino acid availability, we demonstrated that 
pancreatic AGAT specific activity was five-fold higher than kidney AGAT activity when 
expressed per g of tissue. In-vitro data from piglets (Brosnan et al, 2009, Dinesh et al, 
2018), as well as data from humans (Wyss et al, 2000), have suggested that the pancreas 
might be of greater importance than was determined in rodents (da Silva et al, 2014). 
Although there are in-vitro data on creatine synthesis, the quantitative contribution of the 
pancreas to whole-body GAA and creatine supply is not known. Furthermore, the 
contributions of the kidney, pancreas and gut likely depends on availability of precursors 
(i.e., arginine and methionine) or preformed creatine and should be elucidated. 
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Arginine is the direct precursor for GAA synthesis, but citrulline is converted to 
arginine in the kidney. Evidence that citrulline may be important for GAA synthesis 
emerged from a study in piglets that measured citrulline balance across the kidney. Only 
74% of citrulline entering the kidney appeared as arginine (Marini et al, 2012). We suggest 
that some of the citrulline entering the kidney could likely be released as GAA, so this was 
also investigated.  
 
In this study, the primary objective was to measure the net release or uptake of 
arginine, citrulline, GAA and creatine across the kidney, pancreas and gut. An in-situ piglet 
model with multiple catheters and blood flow probes was used to describe the net 
contributions of each of these organs to GAA and creatine synthesis in sow-reared piglets.  
 
5.3 METHODS 
 
Twenty-five Yucatan miniature piglets (17 – 21 d old, supplied by Animal Care Services, 
Memorial University of Newfoundland) were transported to the Animal Care Facilities on 
campus and randomized into one of the four different infusion protocols. Within 2.5 h of 
removal from the sow, piglets were sedated as described previously (Dinesh et al, 2014). 
Atropine was also administered prior to endotracheal intubation, and general anesthesia 
was initiated and maintained with isoflurane (0.8 - 1.5%) delivered with oxygen (1.5 L.min-
1). Body temperature was regulated with the use of a heating pad. Heart rate and blood 
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oxygenation were monitored every 15 min throughout the experiment. A jugular vein 
catheter was advanced to superior vena cava to facilitate infusion of one of four 
experimental intravenous solutions (described below). The infusions were initiated using a 
priming bolus followed by a constant infusion that continued for 45 - 60 min. All piglets 
were fasted for at least 3 h prior to starting the test infusions.  Another group of piglets that 
was not fasted prior to the procedure was designated as sow-fed (SF) (n = 4); these piglets 
underwent the same experimental protocol but did not receive any intravenous infusions. 
This group was used as reference data to characterize the normal feeding situation. The 
entire protocol (described below) was completed within 30 min of the SF piglets’ arrival, 
to minimize effect of fasting. The piglets were weight-matched across the infusion 
treatments. 
 
Laparotomy and isolation of blood vessels: The carotid artery was isolated by blunt 
dissection to allow sampling of arterial blood at the termination of the experiment. A 
laparotomy was then performed to expose the visceral organs and right kidney. To measure 
renal metabolism, the renal vein was isolated and an ultrasonic perivascular blood flow 
probe (2 mm) (Transonic Systems Inc., Dutch Mill Road, USA) was secured around the 
renal vein, or the renal artery if the vein was branched. The splenic vein, which is 
surrounded by the ring structure of the pancreas, was isolated by blunt dissection, taking 
care to minimize damage to the pancreatic tissues. (Ferrer et al, 2008). Sixty percent of 
blood flow from the pancreas drains into the splenic vein, and 40% drains into the superior 
mesenteric vein (SMV), both of which drain into the portal vein. The stomach and the 
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spleen also drain into the splenic vein. There are no reports of AGAT activity in the spleen 
or in the stomach; therefore, we assumed that changes in related metabolites analyzed in 
the blood sampled from the splenic and portal veins should represent metabolism in 
pancreas and gut, respectively. A blood flow probe (2 mm) was placed on the splenic vein 
and a 4 mm flow probe was placed on the portal vein to measure the blood flow in those 
vessels. The exposed visceral organs were kept moistened with warmed saline and covered 
with wet gauze and plastic wrap during the entire procedure to prevent dehydration. 
 
Experimental intravenous nutrient solutions: The precursors and products of creatine 
biosynthesis were measured during acute intravenous infusions of each of the following: 1) 
arginine and methionine (Arg/Met), 2) creatine added to the same concentration of arginine 
and methionine (+Cre), 3) citrulline and methionine (Cit/Met), or 4) alanine (Ala). The 
experimental IV solutions were prepared using sterile saline. The Arg/Met treatment 
included arginine delivered at a rate of 4.8 µmol (0.83 mg) arginine.kg-1.min-1, which was 
based on a parenteral arginine intake that was shown to maximize muscle protein synthesis 
in neonatal piglets (Brunton et al, 2003), and methionine delivered at a rate of 1.4 µmol 
(0.21 mg).kg-1.min-1, which was chosen to maintain plasma methionine concentrations 
similar to that of sow-fed piglets (Dinesh et al, 2018). Creatine was infused at a rate of 0.6 
µmol (0.08 mg).kg-1.min-1 which is the accretion rate of neonatal piglets (Brosnan et al, 
2009, Dinesh et al, 2018). The Cit/Met treatment included citrulline at concentrations 
equimolar to the arginine infusion and methionine at the above infusion rate. Finally, 
alanine was used as the control condition, and was infused at a concentration that was 
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equimolar to the arginine plus methionine infusions (6.2 µmol [0.6 mg] alanine.kg-1.min-
1). In a rat model, Edison et al (2007) reported that an acute intravenous infusion of alanine 
resulted in no response in GAA concentration, and was similar to a saline control, 
demonstrating alanine is an appropriate amino acid control.  
 
All experimental treatments were prepared by dissolving amino acids in sterile 
saline at 55oC under nitrogen gas. Once dissolved, the solutions were sterile filtered via 
0.22 µm filters (PALL Life Science, USA) and stored in a cooler until used. Amino acids 
were purchased from Ajinomoto Inc., Canada or Sigma-Aldrich, Canada; the creatine 
monohydrate was purchased from Evonik Industries, Germany. 
 
Experimental protocol: The experimental solutions were infused for 1.5 hours. A bolus 
priming dose of the experimental treatment was given that was equal to 1.5 x the hourly 
rate. Following the prime, the experimental IV solutions were infused at a rate of 10 mL.kg-
1.h-1 via a syringe pump.  
 
Blood flow measurement and blood sampling: Measurement of the blood flow from the 
renal vein (or renal artery), splenic vein and portal vein was initiated approximately 45 min 
after the initiation of the IV treatments. The mean flow was recorded during a minimum of 
two minutes, when the variability in flow measurements was less than 5%. At the end of 
the infusion, blood was sampled from the carotid artery (representing arterial in-flow to the 
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kidney, pancreas and gut), and from the renal, splenic and portal veins at the end of the 
infusion, using a Surflo winged infusion set (23G x 3/4 or 21G x 3/4) (Solmed Pty Limited, 
Australia) or 24-gauge IV catheter (BD Angiocath, USA). At the end of the experiment, 
the piglets were killed while under anesthesia by an intra-cardiac injection of sodium 
pentobarbital (Euthanyl, Biomeda-MTC, Animal Health Ins, ON, Canada). 
 
GAA and creatine analyses: Plasma creatine and GAA concentrations were assayed using 
an HPLC method modified from Buchberger and Ferdig (2004) using a C18 reverse phase 
column (Hypersil ODS 5 U 150x4.6 mm column) with ninhydrin derivatization and 
fluorescence detection (Ex/EM 390/470). 
 
Amino acids: Plasma amino acid concentrations were measured by reverse-phase HPLC 
(C18 column) following derivatization with phenylisothiocyanate (PITC) (Waters, 
Woburn, Massachusetts, USA) as per the method of Bidlingmeyer et al (1984). 
 
Arterio-venous balance: Net arterio-venous balances across organs were determined by 
multiplying the concentration difference between venous and arterial blood by the blood 
flow and correcting for body weight. The net balances of amino acids, GAA and creatine 
reported for the kidney have been doubled to represent the contribution of two kidneys. A 
positive net balance indicates net output while negative net balance indicates net uptake of 
the nutrient by that organ when mean values were different from zero. 
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Statistical analysis: Data were analyzed using a two-way ANOVA and treatments within organs 
and among organs were compared by Bonferroni’s multiple comparisons test (GraphPad 7.03, 
Graph Pad Software Inc. CA, USA) if the interactions were present. The variables analyzed by two-
way ANOVA were organs, experimental groups and their interaction. For the data that did not have 
significant interactions, a one-way ANOVA was performed, and groups were compared by 
Bonferroni’s multiple comparisons test (GraphPad 7.03). All data were expressed as mean ± SD 
and were considered significantly different if P < 0.05. When the group variances were 
significantly different, ANOVA testing was conducted using log-transformed values, 
although the values are presented as means ± SD of the non-transformed data. In addition, 
means were tested to verify whether they were statistically significantly different from zero by 
analyzing the one-sample t-test (GraphPad 7.03).  
 
5.4 RESULTS 
 
Throughout the in-situ studies under anesthesia, all piglets remained stable, well 
oxygenated and maintained a body temperature of 37.5 ± 1.5˚C. The body weight on the 
day of procedure did not differ among treatment groups (APPENDIX A1). No significant 
differences in blood flow were determined among the treatment groups for renal 
artery/vein, splenic vein or portal vein (APPENDIX A2). The blood flow rates measured 
in SF piglets were also not different than those in the IV treated piglets (APPENDIX A2).  
 
GAA balance Independent of the amino acid compositions of the treatments, all piglets 
had a net release of GAA from the kidneys. Moreover, all treatment groups except Cit/Met 
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released GAA from the pancreas (FIGURE 5.1). The kidneys released three to four times 
more GAA than the pancreas. GAA balance across the gut was not different than zero in 
piglets treated with Arg/Met, Cit/Met or Ala; only piglets treated with creatine (+Cre) 
demonstrated a net release of GAA from the gut. GAA balance across the gut was also not 
different than zero in SF piglets (FIGURE 5.1). 
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FIGURE 5.1 Net fluxes of GAA across kidneys, pancreatic, and intestinal tissues of sow-
fed (SF) non-fasted piglets or fasted piglets that received an infusion of either arginine, 
citrulline or alanine. Lines represent significant differences between organs within an 
experimental group (*P < 0.05 or **P < 0.0001). Differing letters represent significant 
differences within each organ among experimental groups (P < 0.0001). n = 6 per infusion 
group and n = 4 per SF group. Values are means ± SD of non-transformed data; statistics 
were determined using log values when variances were different. Arginine and methionine: 
Arg/Met, creatine in Arg/Met: +Cre, citrulline and methionine: Cit/Met and alanine: Ala. 
P: Not different from zero.  
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There were differences among treatments for the GAA released from the kidneys, 
pancreas and gut, with a significant interaction between organs and treatments. In the 
kidneys, piglets infused with Cit/Met had the highest net GAA release, while piglets infused 
with Ala had the lowest; piglets treated with Arg/Met and +Cre were at intermediate levels; 
the GAA released from the kidneys in SF piglets was as high as the GAA released by the 
piglets infused with Cit/Met but did not differ from the piglets infused with Arg/Met, +Cre 
or Cit/Met. (FIGURE 5.1). In contrast to the kidneys, the release of GAA from the pancreas 
and gut demonstrated similar patterns and were only affected by the +Cre treatment, in that 
+Cre piglets had higher GAA release than Arg/Met, Cit/Met and Ala piglets but was similar 
to SF (FIGURE 5.1).  
 
When comparing the net GAA balances among the three organs, the kidneys 
released the highest amount of GAA compared to gut or pancreas in the Arg/Met, Cit/Met 
and SF piglets. Interestingly, with the +Cre treatment, the gut released significantly more 
GAA than the pancreas with kidneys intermediate. GAA release was not different among 
the three organs for the Ala treatment (FIGURE 5.1). 
 
Creatine balance The creatine balance across the kidney was not different from zero for 
any of the treatments (Arg/Met, +Cre, Cit/Met and Ala), unlike the SF piglets which 
demonstrated a significant net release of creatine. Creatine balance across the pancreas was 
similar to zero for all of the treatments that we investigated; however, the net balance of 
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creatine across renal and pancreatic tissues was highly variable. For Arg/Met, +Cre and Ala 
treatments, there was a net creatine release from the gut. For the SF piglets and Cit/Met 
treated piglets, the net release of creatine from gut was highly variable and resulted in a 
mean value not different than zero (FIGURE 5.2). Notably, when comparing creatine 
balance among organs, the creatine release was highest across the gut compared to renal 
and pancreatic tissues with the Arg/Met and +Cre treatments. However, in Cit/Met and Ala 
piglets, the creatine release from the intestinal, pancreatic and renal tissues did not differ 
among organs (FIGURE 5.2). 
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FIGURE 5.2 Net fluxes of creatine across kidneys, pancreatic, and intestinal tissues of 
sow-fed (SF) non-fasted piglets or fasted piglets that received an infusion of either arginine, 
citrulline or alanine. Data were analyzed via two-way ANOVA with Bonferroni’s multiple 
comparisons test for post hoc analysis. Lines represent significant differences between 
organs within an experimental group (**P < 0.0001). Differing letters represent significant 
differences within each organ among experimental groups (P < 0.0001). n = 6 per infusion 
group and n = 4 per SF group. Values are mean + SD. Values are means ± SD of non-
transformed data; statistics were determined using log values when variances were 
different. Arginine and methionine: Arg/Met, creatine in Arg/Met: +Cre, citrulline and 
methionine: Cit/Met and alanine: Ala. p: Not different from zero. 
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Plasma GAA and creatine concentrations There was a significant interaction between 
treatment and vessel for the plasma GAA data (TABLE 5.1). For arterial GAA 
concentration, there was no difference among groups. The Cit/Met and SF groups had the 
highest renal vein GAA concentrations, compared to Ala treatment, with Arg/Met and +Cre 
intermediate. The creatine treatment (+Cre) resulted in higher GAA concentrations in the 
splenic and portal veins compared to the Ala treatment, while Arg/Met, Cit/Met or SF 
piglets were not different from any other treatment group in splenic or portal vein GAA 
concentrations (TABLE 5.1). The renal vein GAA concentration was significantly higher 
than the GAA concentrations in all other blood vessels for all groups except that treated 
with alanine; in Ala group, only the carotid artery GAA was lower than the renal vein 
concentration. In piglets treated with creatine, the lowest GAA concentration was in the 
plasma sampled from the carotid artery (P < 0.05). No other differences were apparent 
among the vessels.  
 
For the plasma creatine concentrations, no significant interactions occurred between 
vessel and treatment (TABLE 5.1). In carotid artery and in portal vein, the +Cre treatment 
resulted in significantly higher creatine concentrations compared to Cit/Met and Ala 
treatments, with SF and +Arg/Met piglets intermediate. In the renal vein, the +Cre and SF 
treatments resulted in the highest creatine concentrations that were different from all other 
treatments, with the Ala demonstrating the lowest creatine concentration (TABLE 5.1). No 
differences in creatine concentrations among groups (including SF) were observed in the 
plasma sampled from splenic vein.   
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TABLE 5.1 Plasma GAA and creatine concentrations measured at the termination of the 
experiments in the carotid artery, renal vein, splenic vein and portal vein of sow-fed (SF) 
non-fasted piglets or fasted piglets that received an infusion of either arginine, citrulline 
or alanine. 
 
The concentrations of GAA and creatine for the portal vein represent GAA and creatine from the 
gut and pancreas. Differing superscript letters within a row represent significant differences among 
groups within each vessel (P < 0.05). * or ! indicates significantly different from the rest of the 
blood vessels while ] denotes significant difference between two vessels (P < 0.0001). Values are 
means ± SD of non-transformed data; statistics were determined using log values when variances 
were different. Sow-fed (SF), arginine and methionine (+Arg/Met), creatine in +Arg/Met infusion 
(+Cre), citrulline and methionine (+Cit/Met), alanine (Ala). Values are mean ± SD, n = 6 -7 for 
each bar for infusion piglets, n = 4 for SF.  
Metabolite Blood vessel SF Arg/Met +Cre Cit/Met Ala 
(µmol.L-1) 
GAA  Carotid Artery 6 ± 2 8 ± 2 5 ± 1* 10 ± 3 2 ± 0.8 
Renal Vein 56 ± 13a! 36 ± 11b! 40 ± 14b! 60 ± 13a! 16 ± 3c 
Splenic Vein 12 ± 3ab 11 ± 2ab 22 ± 10a 12 ± 4.5ab 6 ± 2b 
Portal Vein 7 ± 0.7ab 10 ± 3ab 20 ± 4a 13 ± 4ab 3 ± 0.7b 
Creatine Carotid Artery 179 ± 101ab 170 ± 70ab 265 ± 34a 125 ± 48b 127 ± 16b 
Renal Vein 270 ± 126a 162 ± 62b 306 ± 81a 146 ± 44b 92 ± 25c 
Splenic Vein 235 ± 97 205 ± 66 212 ± 71 147 ± 59 131 ± 25 
Portal Vein 296 ± 162ab 270 ± 74a 362 ± 65a 149 ± 37b 158 ± 34b 
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Amino acid balance A significant interaction between the vessels and treatment was 
observed only in the citrulline data. Independent of the treatment, all groups had a net 
uptake of citrulline by the kidneys, and most of the groups demonstrated a net release of 
citrulline from the gut. One exception was that the net release of citrulline from the gut was 
highly variable for the Cit/Met piglets (TABLE 5.2); as such, the citrulline balance did not 
differ from zero. Citrulline balance across the pancreas was also not different than zero for 
most treatments, except for +Cre piglets which demonstrated a net release of citrulline from 
the pancreas. Across organs, a significantly higher net uptake of citrulline by the kidney 
occurred only in piglets treated with Cit/Met compared to gut and pancreas (TABLE 5.2). 
The Cit/Met infusion resulted in a net release of arginine from the kidneys. Arginine 
balance across the kidney, pancreas and gut did not differ from zero for any other treatment. 
The Arg/Met infusion resulted in a net release of methionine from the gut. Methionine 
balances across organs were highly variable and did not differ from zero for any other 
infusions. Alanine balances across organs were also highly variable and did not differ from 
zero in any groups.  
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TABLE 5.2 Net fluxes of arginine, methionine and citrulline across kidneys, pancreas and 
gut of sow-fed (SF) non-fasted piglets or fasted piglets that received an infusion of either 
arginine, citrulline or alanine. 
 
Data were analyzed via two-way ANOVA with Bonferroni’s multiple comparisons test for 
post hoc analysis. *significantly different from the citrulline balances of pancreas and gut 
(P < 0.01). n = 6 per infusion group and n = 4 per SF group. Values are means ± SD of non-
transformed data; statistics were determined using log values when variances were 
different. Arginine and methionine: Arg/Met, creatine in Arg/Met: +Cre, citrulline and 
methionine: Cit/Met and alanine: Ala. “!” Different from zero. 
  
Amino acid Organ SF Arg/Met +Cre Cit/Met Ala 
( nmol.kg-1min-1) 
Arginine Kidneys 580 ± 490 -1762 ± 2372 111 ± 211 3184 ± 1608!     361 ± 357 
Pancreas 599 ± 1448 -2079 ± 3730 691 ± 1784 849 ± 394 118 ± 443 
Gut 685 ± 1829 -731 ± 4502 -1300 ± 7060 1211 ± 1571 1094 ± 1978 
Methionine Kidneys 48 ± 27 36 ± 65 27 ± 64 11 ± 84 -21 ± 70 
Pancreas 82 ± 122 2 ± 53 41 ± 150 46 ± 120 18 ± 61 
Gut -11 ± 71 212 ± 224! 98 ± 200 -17 ± 129 109 ± 172 
Citrulline Kidneys -1005 ± 179! -546 ± 287! -583 ± 131! -3711 ± 2611*! -543 ± 202! 
Pancreas 227 ± 314 82 ± 265 189 ± 164! 1899 ± 2119 -5 ± 184 
Gut 1273 ± 691! 817 ± 587! 1496 ± 1306! 3116 ± 5381 1999 ± 933! 
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Selected plasma amino acid concentrations As expected, the arginine treatments (as 
Arg/Met and +Cre) resulted in significantly higher arginine in blood sampled from carotid 
artery, compared to all other treatments (TABLE 5.3). Again, arginine treatments had 
significantly higher arginine in blood samples from the renal vein, compared to Ala and SF 
piglets. The Cit/Met piglets appeared to convert citrulline into arginine, as indicated by 
significantly higher arginine in the renal vein, compared to the Ala and SF piglets. The 
renal vein arginine in Cit/Met piglets was not different than the Arg/Met and +Cre piglets. 
Within the Cit/Met treatment group, citrulline was lower in the renal vein compared to all 
other blood vessels (TABLE 5.3).  
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TABLE 5.3 Selected plasma amino acid concentrations in the carotid artery, renal vein, 
splenic vein and portal vein of sow-fed (SF) non-fasted piglets or fasted piglets that 
received an infusion of either arginine, citrulline or alanine. 
The concentrations of amino acids for the portal vein represents output from the gut and 
the pancreas. Differing superscript letters within a row represent significant differences 
Amino acid Vessel SF Arg/Met +Cre Cit/Met Ala 
(µmol.L-1) 
Arginine CA 133 ± 24a 760 ± 239b 652 ± 121b 293 ± 90a 230 ± 180a 
RV 187 ± 37a 620 ± 207b 664 ± 136b 571 ± 154b 242 ± 130a 
SV 178 ± 92a 638 ± 270bc 705 ± 237b 348 ± 50ac 244 ± 199a 
PV 164 ± 44a 715 ± 211b 640 ± 232bc 348 ± 68ac 271 ± 199a 
Methionine CA 25 ± 8 23 ± 6 31 ± 5 24 ± 6 23 ± 5 
RV 30 ± 7ab 26 ± 6ab 34 ± 6a 25 ± 6ab 21 ± 6b 
SV 32 ± 5 24 ± 8 34 ± 15 27 ± 7 24 ± 6 
PV 27 ± 6 30 ±10 34 ± 7 25 ± 6 26 ± 6 
Citrulline CA 142 ± 16a 96 ±18a 100 ± 21a 821 ± 128b 83 ± 20a 
RV 44 ± 8a 53 ± 23a 40 ±18a 557 ± 103b* 36 ± 7a 
SV 160 ± 36a 102 ± 24a 114 ± 29a 949 ± 119b 83 ± 10a 
PV 181 ± 33a 124 ± 31a 135 ± 36a 961 ± 197b 129 ± 29a 
Alanine CA 501 ± 78a 816 ± 233a 859 ± 208a 757 ± 135a 1405 ± 312b 
RV 637 ± 73a 953 ± 288ab 919 ± 222a 669 ± 93a 1358 ± 358b 
SV 672 ± 134a 854 ± 283a 906 ± 247a 801 ± 81a 1424 ± 412b 
PV 648 ± 115a 906 ± 274a 912 ± 231a 842 ± 134a 1456 ± 437b 
Ornithine CA 49 ± 13a 154 ± 43b 164 ± 41b 97 ± 24a 43 ± 9a 
RV 88 ± 21a 181 ± 47b 228 ± 68b 186 ± 28b 52 ± 18a 
SV 48 ± 10a 133 ± 51b 170 ± 61b 105 ± 15ab 40 ± 14a 
PV 51 ± 20a 168 ±51b 164 ± 47b 107 ± 15ab 49 ± 20a 
Glycine CA 1053 ± 292 1015 ± 198 849 ± 97 856 ± 123 893 ± 164 
RV 1221 ± 180 966 ± 203 950 ± 54 960 ± 149 958 ± 227 
SV 1108 ± 188 896 ± 267 880 ± 148 990 ± 127 945 ± 237 
PV 1125 ± 271 975 ± 166 871 ± 146 966 ± 119 981 ± 172 
Proline CA 501 ± 57 407 ± 136 364 ± 91 398 ± 118 358 ± 60 
RV 544 ± 26a 349 ± 106b 370 ± 64b 416 ± 108ab 357 ± 56b 
SV 555 ± 80a 313 ± 96b 367 ± 159ab 442 ± 102ab 370 ± 53ab 
PV 570 ± 43a 375 ± 92b 360 ± 95b 433 ± 119ab 409 ± 50ab 
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among groups within a vessel (P < 0.05). * indicates significantly different from the rest 
of the blood vessels (P < 0.0001). Values are means ± SD of non-transformed data; 
statistics were determined using log values when variances were different. Sow-fed (SF), 
arginine and methionine (+Arg/Met), creatine in +Arg/Met infusion (+Cre), citrulline and 
methionine (+Cit/Met), alanine (Ala). Values are mean ± SD, n = 6 - 7 for each bar for 
infusion piglets, n = 4 for SF. CA; carotid artery, RV; renal vein, SV; splenic vein and 
PV; portal vein.  
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5.5 DISCUSSION 
 
Source of GAA for hepatic creatine synthesis One of the outstanding questions from 
previous studies of GAA and creatine synthesis was whether the high AGAT activity 
measured in-vitro in pancreas tissue translated into a significant source of GAA for hepatic 
creatine biosynthesis (Dinesh et al, 2018). It is clear from this study, that this is not the 
case. The GAA released from the renal tissues accounted for the majority (88%) of the total 
GAA released from the three organs, when measured in suckling piglets. The relative 
contributions of the kidneys and the pancreas to the GAA supply were also assessed when 
the precursor availability was manipulated under experimental conditions. The GAA 
released from the renal tissues accounted for 79 – 94% of the total GAA released from the 
three organs for most of the experimental conditions. An exception was GAA released by 
the renal tissues during the infusion of creatine, which was only 32% of the total GAA 
released from the three organs because other tissues contributed more GAA to the 
circulation. The kidneys consistently released the most GAA, even in the control (alanine) 
condition when no exogenous precursor was supplied. The absolute amount of GAA 
released from the pancreas was more than 75% lower than that from the kidneys but was 
patterned similarly under most experimental conditions; the one exception was during the 
infusion of citrulline (Cit/Met), which did not facilitate a net positive GAA balance. The 
gut also did not demonstrate a net release of GAA under most experimental conditions, 
including in the sow milk fed state. Thus, it appears that in the neonate, the kidneys are the 
major source of GAA for hepatic creatine synthesis.   
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In the Chapter Three (Dinesh et al, 2018), we demonstrated that a dietary supply of 
creatine led to a reduction in in-vitro renal AGAT activity compared to control neonatal 
piglets. Therefore, we predicted that infusing creatine would result in less GAA released 
from the kidneys. However, this was not the case. The kidneys released similar amounts of 
GAA with both the arginine and creatine infusions. The very short timeframe of this study 
may explain this result, in that it likely requires a longer period of exposure to creatine to 
lower the enzyme activity.  
 
The kidney, but not the pancreas or gut, has the capacity to convert citrulline into 
arginine and GAA In a study of arginine metabolism in neonatal piglets, only 74% of 
citrulline entering the kidney appeared as arginine (Marini et al, 2012). We speculated that 
some of the citrulline entering the kidney was ultimately released as GAA. In this study, 
when citrulline was infused, its disappearance across the kidney equaled ~4000 nmol.kg-
1.min-1 while the arginine appearance was ~3000 nmol.kg-1.min-1 and the GAA released 
was ~500 nmol.kg-1.min-1. Thus, similar to previous tracer studies (Marini et al, 2012), it 
appears that ~75% of the citrulline entering the kidneys was utilized to supply arginine to 
the periphery and ~12.5% was converted to arginine and then subsequently GAA; the fate 
of the remaining citrulline entering the kidneys is uncertain, although some of the arginine 
synthesized from citrulline in the kidneys may have been utilized for its own protein 
synthesis. In SF piglets, citrulline disappearance was 1000 nmol.kg-1.min-1 while the 
arginine appearance was 600 nmol.kg-1.min-1 and the GAA release was 500 nmol.kg-1.min-
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1. Therefore, SF piglets appeared to utilize all of the citrulline that disappeared across 
kidneys to synthesize arginine and GAA. An interesting finding is that the GAA released 
from the kidney with the citrulline infusion was approximately 1.5-fold greater than the 
GAA released during an equimolar infusion of arginine. According to recent findings, 
neonatal piglets express argininosuccinate synthase (ASS) and argininosuccinate lyase 
(ASL) in the kidneys to convert citrulline into arginine (Marini et al, 2017). We speculate 
that ASL, ASS and AGAT may be expressed in a manner in the kidney to preferentially 
channel citrulline to GAA (via arginine). 
 
It is not known whether the pancreas expresses enzymes that convert citrulline into 
arginine and then GAA, but our results suggest that this does not occur. Piglets infused with 
citrulline had no net citrulline, arginine or GAA fluxes across the pancreas, suggesting that 
the pancreas does not have the capacity to use citrulline. Similarly, the gut also does not 
appear to have the capacity to convert citrulline into GAA. The gut had zero GAA and 
creatine fluxes when provided with a systemic source of citrulline. Furthermore, the gut 
had no net release of arginine with the citrulline infusion, suggesting that gut cannot utilize 
systemically available citrulline to make arginine. Piglets infused with citrulline also had 
no net release of creatine from pancreatic or gut tissues, which suggests that neither the gut 
nor the pancreas is capable of utilizing citrulline as a precursor of GAA or creatine. 
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GAA synthesis in the gut A particularly novel finding of this study was quantifying a net 
release of GAA from the gut. That the gut has the capacity to synthesize GAA was a 
surprising outcome, because a previous study of in-vitro enzyme activity in small intestinal 
mucosal tissue from piglets reported that AGAT activity was negligible (Brosnan et al, 
2009). Further to this, it was also interesting that a significant release of GAA only occurred 
when creatine was infused, suggesting that perhaps the gut releases GAA when there is no 
need to synthesize creatine. That the gut released the GAA when creatine was plentiful 
suggests that the GAA synthesized by the gut may be utilized for creatine biosynthesis 
within the gut when creatine is limited in supply.  
 
Creatine synthesis in the gut In sow-reared piglets, small intestinal mucosa has a very 
low GAMT specific activity, reported as half of that present in the kidneys (Brosnan et al, 
2009). Therefore, we expected no net release of creatine across the gut in our piglets. 
However, piglets infused with arginine had a significant net release of creatine 
demonstrating the capacity of the gut to synthesize GAA and then creatine, when adequate 
arginine and methionine are available. It does not appear that the gut could utilize 
systemically available GAA as the precursor for the creatine that was released, based on a 
zero net GAA flux across the gut for most of the treatments. The ability of gut to take up 
creatine from the systemic circulation is not certain. Feeding creatine increased plasma and 
tissue creatine concentrations in neonatal piglets (Chapter Four), suggesting that small 
intestine absorbs creatine from the small intestinal lumen and releases that creatine into the 
portal blood. However, it is not certain whether systemic creatine crosses the basolateral 
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membrane of the small intestine. The net release of GAA from the gut when creatine was 
infused suggests that the gut was responding to systemic creatine. However, there was no 
measurable uptake of creatine by the gut when piglets were infused with creatine; rather 
there was a net release. Even in the circumstance where the gut was not exposed to GAA 
precursors, it did not appear to take up creatine from the systemic circulation. Based on the 
results from this experiment, it is not possible to determine whether the neonatal gut has 
the ability to take creatine from systemic circulation. Further investigations using isotopic 
tracers would help to resolve this question.  
 
Pancreatic GAA and creatine synthesis In Chapter Four, we showed that a dietary supply 
of creatine lowered the in-vitro AGAT activity in pancreas. Therefore, a lower GAA release 
from the pancreas was expected with the creatine infusion. However, that was not the case. 
A four-fold higher GAA release was induced when exogenous creatine was supplied, 
suggesting that perhaps the pancreas releases GAA when there is no need to synthesize 
creatine, similar to the small intestine. The creatine treatment induced a higher net release 
of GAA from the pancreas than most other treatments, which leads us to speculate that 
under low creatine conditions, the GAA synthesized in the pancreas may be utilized within 
the organ to synthesize creatine. Support for this concept is the high GAMT activity in 
pancreas of piglets, which was reported to be three times higher than in the kidney (Brosnan 
et al, 2009). Despite this capacity for creatine synthesis, it did not lead to a net release of 
creatine from the pancreas in any of our treatment groups. A creatine and phosphocreatine 
shuttle have been reported in the pancreas (Wyss et al, 2000). Therefore, the pancreas may 
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synthesize and use creatine to support its own secretory functions, ultimately releasing it as 
creatinine. When comparing the pancreatic capacity to synthesize GAA and creatine, 
pancreatic GAMT activity per gram of tissue was only 4 percent of the pancreatic AGAT 
activity in sow reared neonatal piglets (Brosnan et al, 2009). It follows that the net release 
of creatine must be very low compared to the net release of GAA. Therefore, such low 
creatine release may not be detectable in this model. Alternatively, the high systemic 
creatine could have downregulated GAMT in gut and pancreas leading to a higher net 
release of unconverted GAA from these tissues.  
 
In summary, the results from this study demonstrated that the kidney has the 
greatest capacity to supply GAA compared to the pancreas and the gut. We also 
demonstrated that citrulline is a better precursor than arginine for GAA synthesis in the 
kidneys, but not in the pancreas or gut. We also determined that there is no significant 
release of GAA or creatine from the pancreas. In conclusion, the neonatal piglet can convert 
citrulline into arginine and then some of that arginine into GAA in the kidneys. The 
noteworthy novel finding was that the neonatal gut has the capacity to release GAA and 
creatine when arginine and methionine are available. Interestingly, an intravenous creatine 
infusion altered the small intestinal GAA and creatine metabolism in neonatal piglets. 
Because of the complex regulation of inter-organ synthesis of creatine, the dietary levels of 
various precursor amino acids need to be considered when designing neonatal diets, 
especially if organ health is compromised.   
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CHAPTER SIX 
 
6.0 GENERAL DISCUSSION 
 
The overall goal of my PhD program was to understand and quantify the demand for 
arginine to support creatine biosynthesis and protein synthesis in neonates. The research 
presented in this thesis focused on the availability of arginine for creatine and protein 
synthesis during development under two contrasting conditions: when premade creatine is 
available and when premade creatine is not available.  
 
The three research experiments in this thesis focused on clinical problems and 
metabolic questions. The clinical question addressed in the first study was whether PN 
without creatine affects the plasma and tissue creatine levels of neonates. We approached 
this question using the neonatal piglet as a relevant translational model. The second and the 
third studies addressed metabolic questions. The first metabolic question was: how does 
the availability of arginine impact the whole-body arginine partitioning into GAA/creatine 
and proteins in piglets fed diets with differing amounts of precursors of creatine? The 
second metabolic question addressed in my third study was: in a neonatal piglet model, 
how are different organs involved in GAA/creatine synthesis? Furthermore, the third study 
was designed to investigate whether these inter-organ pathways were acutely regulated by 
different precursor amino acids (arginine vs citrulline) or by the presence of creatine.  
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6.1 Creatine bio-synthesis in PN fed neonates 
 
Suckling neonatal piglets get only 23% of their creatine requirement from milk, but they 
can endogenously synthesize the remainder of their creatine requirement. Following 
preterm birth, PN is often required as a means of nutritional support for infants with 
gastrointestinal disorders or prolonged intolerance of enteral feeding. However, creatine is 
not a component of pediatric PN products. Therefore, the entire creatine requirement needs 
to be synthesized endogenously. Since arginine is one of the precursor amino acids required 
for creatine synthesis, synthesis of arginine and then creatine may be compromised during 
PN feeding. Whether this affects the optimal creatine accretion in neonates was unknown. 
Chapter Three of my thesis was designed to address whether creatine biosynthesis is 
affected by the reduced de novo arginine synthesis as a consequence of gut atrophy during 
PN feeding in neonates. The data from this study determined that the addition of creatine 
into PN increased the creatine concentrations in the plasma and most of the tissue analyzed. 
The enzyme activities were lower in piglets fed creatine compared with piglets fed no 
creatine in PN. That led us to ask: is creatine synthesis limited by substrate availability or 
alternatively by the maximal capacity of the enzymes involve in creatine biosynthesis? In-
vitro enzyme activities and tissue GAA and creatine concentrations may not necessarily 
mimic the in-vivo regulation of creatine biosynthesis. In Chapter Four, my second study, 
this question was addressed by measuring the whole-body precursor to product conversion 
rates via isotope kinetics.  
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In Chapter Three of this thesis, creatine supplementation increased the hepatic and 
kidney fractional protein synthesis rate compared to that in piglets fed a creatine-free diet. 
The amino acid concentrations in the plasma, liver and kidney did not differ between piglets 
fed creatine and control diets. However, the lack of differences in arginine concentrations 
in the plasma and tissues may be explained by the diversion of spared arginine towards 
protein synthesis. Despite no differences in the concentrations of the plasma amino acids, 
the greater tissue protein synthesis suggests that creatine supplementation spared arginine 
for protein synthesis. The changes in the concentrations of the plasma and tissue amino 
acids would not be detectable if the differences in the concentrations are small and amino 
acid fluxes are high. When the fluxes are high, amino acids enter and exit the body pool 
rapidly and a slight change in concentrations of free amino acids would not be detectable 
without isotope tracers.  
 
According to the literature (Wilkinson et al, 2004, Beaumier, 1998), arginine 
turnover in neonates is quite high, such that plasma and tissue free amino acid 
concentrations may not show minor changes during a short study period. Therefore, the 
measurement of free amino acid concentrations in tissues and/or plasma cannot be sensitive 
enough to demonstrate changes in fluxes through the metabolic pathways. Consequently, 
an isotope kinetics investigation was warranted to quantify such changes in-vivo. 
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6.2 Arginine partitioning into GAA/creatine and whole-body proteins 
 
The research presented in Chapter Four was designed to address some of the uncertainties 
arising from the work presented in Chapter Three. Specifically, we wanted to determine 
whether the availability of arginine, GAA, GAA with excess methionine, or creatine affects 
creatine and/or protein synthesis in neonates. We also wanted to determine whether it is 
creatine bio-synthesis or protein synthesis that is prioritized under changing conditions of 
arginine availability in neonatal piglets. We further wanted to quantitatively determine in-
vivo, how much arginine was partitioned into GAA/creatine versus proteins when differing 
amounts of precursors of creatine were available. 
 
Dietary creatine has been shown to repress endogenous GAA/creatine biosynthesis 
in rodent models and in humans (McGuire et al, 1984; Derave et al, 2004; da Silva et al, 
2009; 2014, Deminice et al, 2011). In-vitro enzyme activity (AGAT) involved in creatine 
bio-synthesis has been shown to be down regulated with dietary creatine provision. Similar 
to those data, we observed the reduction in in-vitro AGAT enzyme activity in our piglets. 
However, our in-vivo data did not reflect in-vitro enzyme activities. Therefore, this raised 
the question of whether the amount of dietary GAA/creatine that we provided 
maximized the creatine requirement of our piglets. Furthermore, is there a level of creatine 
that could minimize the conversion of arginine into GAA/creatine in neonatal 
piglets?  Therefore, future studies should focus on determining what amount of creatine 
could spare arginine from creatine synthesis, such that arginine can be partitioned into other 
arginine-requiring metabolic pathways. The arginine that was directed towards creatine was 
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high when large amounts of arginine and methionine were provided. However, what has 
not been determined so far is the amount of arginine that would maximize the creatine 
synthesis. Does this level fall somewhere between 0.6 g.kg-1.d-1 to 1.8 g.kg-1.d-1?  To 
address this question, future work should focus on whether the amount of arginine that is 
partitioned towards creatine synthesis peaks at a specific level of dietary arginine and then 
plateaus, despite increasing the amounts of arginine in the diet.  
 
The arginine requirement for whole-body protein synthesis has been investigated 
via the phenylalanine oxidation technique (Brunton et al, unpublished data). The data from 
that study could not be utilized to estimate a break point from dietary arginine intakes that 
could minimize phenylalanine oxidation which, consequently, would have shown the level 
of arginine that could maximize whole-body protein synthesis. We used our in-vivo data 
(Chapter Four, phenylalanine and arginine tracer data) to estimate the rate of arginine 
partitioning into proteins. The rates did not differ between low arginine and high arginine. 
The minimum amount that could achieve this level of whole-body protein synthesis 
requires further investigation. Furthermore, we do not know whether this is the maximum 
level of whole-body protein synthesis in neonatal piglets or if the whole-body protein 
synthesis could further increase with very high arginine delivered in the diet. 
 
Phenylalanine and tyrosine kinetics allow us to determine whole-body protein 
synthesis. However, whole-body protein synthesis is not indicative of the changes in the 
synthesis of individual proteins or in specific tissues. For example, piglets fed low arginine 
may express more AGAT protein than piglets fed high arginine if the piglets are attempting 
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to maximize GAA and creatine synthesis. This situation would lead to an increase in kidney 
AGAT protein synthesis. However, this specific increase in AGAT synthesis would not 
necessarily correlate with an increase in whole-body protein synthesis. This issue might be 
able to be resolved if we measured the labelled phenylalanine incorporated into specific 
proteins.  
 
In our study, for 4 days, we fed diets with different levels of arginine and 
methionine. We determined on the fourth day that under the condition of low arginine, there 
was no change in whole-body protein synthesis, however, there was lower creatine 
biosynthesis. What we could not determine from this study was whether the whole-body 
protein synthesis was low prior to the fourth day of feeding. Changes in protein synthesis 
in response to the route of feeding (whether intravenous or intragastric) appeared by 24 
hours of the initiation of feeding (Niinikoski et al, 2004). However, there have been no 
studies monitoring the changes in protein synthesis over a period of time. In terms of 
metabolism, three days of life in piglets represents approximately one month for human 
infants. A month is a significant duration for neonates as they are in peak growth phase. 
Low protein synthesis for a one-month period could cause significant impact on growth 
and development of neonates. Therefore, it is important to address whether the protein 
synthesis is not low at any particular time during feeding low concentrations of arginine.  
 
Plasma glutamine concentrations were higher in piglets fed low versus high 
arginine. This is quite normal in an animal fed a diet with a low concentration of an essential 
amino acid. In the condition when one essential amino acid is inadequate, the whole-body 
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protein synthesis will be low. Now, with low whole-body protein synthesis, the other 
essential amino acids will be in excess. These amino acids, to some extent, may be utilized 
by other metabolic pathways in the body. Any excess amounts of essential amino acids 
need to be disposed of via the urea cycle. Arginine is a critical intermediate in the urea 
cycle. The experimental diet is low in arginine; therefore, impaired urea cycle function 
might impede excess nitrogen disposal by that route, and lead to the formation of glutamine 
as a secondary method of regulating ammonia accumulation. Therefore, I expect that the 
plasma glutamine level would go down with the increasing levels of arginine. I speculate 
that the glutamine level in the diet will plateau at the point when arginine in the diet 
maximizes the whole-body protein synthesis. Further investigation will reveal whether 
there is such a relationship between dietary arginine and plasma glutamine. 
 
We determined that dietary GAA can be utilized to meet the creatine needs in 
neonatal piglets when arginine is limited in the diet, but only when GAA is delivered with 
excess dietary methionine. Interestingly, we did not see any increase in plasma or tissue 
GAA concentrations in piglets fed GAA alone. This raised the question of whether GAA 
uptake by the gut was affected by the amount of methionine in the diet. There is no 
information available on the regulation of GAA uptake by gastrointestinal tissues or 
whether it involves a transporter in neonatal piglet. This needs to be addressed in future 
studies. An ex-vivo experiment using an Ussing chamber apparatus would facilitate an 
exploration into the mechanisms of GAA uptake by the gut.   
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6.3 Inter-organ pathways of GAA and creatine bio-synthesis in neonatal piglets  
 
The experiment presented in Chapter Four investigated the effect of arginine availability 
on whole-body GAA and creatine bio-synthesis. GAA/creatine synthesis is an inter-organ 
pathway in adults; therefore, one of my thesis objectives was to investigate whether 
GAA/creatine synthesis occurs as a similar process in neonates. This line of inquiry was 
also driven by the differences in rate of enzyme activities measured in two different tissues; 
although the kidney was identified as the most important organ for GAA synthesis in 
rodents, we measured about double the AGAT activity in the pancreas tissue of our piglet. 
To further investigate this outcome, in Chapter Five we focused on the inter-organ 
pathways of GAA and creatine synthesis in neonatal piglets to elucidate the contribution of 
the pancreas to whole-body GAA/creatine supply. We measured the net flux of creatine 
and its precursors to describe in-vivo the inter-organ synthetic pathways of creatine in sow-
reared piglets. The novel aspect of this study was investigating the role of citrulline as a 
precursor for GAA and creatine. Citrulline can be converted into arginine in the kidney. 
Therefore, we hypothesized that some of the citrulline utilized by the kidney can be 
converted to GAA. We concluded that citrulline is a more effective precursor in the kidney 
for GAA release than arginine from our third study described in Chapter Five of this thesis. 
However, we did not know whether citrulline can be utilized to release GAA/creatine in 
the pancreas or gut. It is an interesting and novel finding that the pancreas and gut cannot 
use citrulline to release GAA and creatine. It is also interesting and novel that the gut has 
the greatest release of creatine among the tissues that we studied. 
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The net release of creatine from the gut indicates that either 1) release is higher than 
uptake or 2) there is no uptake and the release is solely due to endogenous synthesis in gut 
tissues from arginine or from GAA. Unfortunately, we could not determine which is most 
likely from our net balance study. Therefore, we cannot say whether the gut has the capacity 
to take up GAA or creatine from the arterial circulation. A better approach would be to use 
isotope-labelled precursors of GAA and creatine. Isotopic kinetics would allow us to 
measure the disappearance of a precursor isotope (e.g., intravenous arginine tracer) across 
the gut which would be an indicator of arginine uptake from arterial blood. Isotopic kinetics 
then would allow us to determine whether the gut has the capacity to take up, synthesize 
and release GAA and creatine from the systemic circulation. 
 
What could not be compared was the proportion of creatine released via the gut 
versus liver. The liver is considered to be the major organ synthesizing creatine. This 
comparison would help to determine the significance of the gut in creatine synthesis. We 
did not collect the hepatic venous blood to measure the creatine flux across the liver. Future 
studies should focus on determining the quantitative role of the gut for creatine synthesis. 
 
We used an intravenous route for the infusion of the experimental solutions, so the 
first pass intestinal metabolism of dietary derived arginine and GAA was bypassed. The 
next level of study should incorporate this gut metabolism. That would allow us to 
determine how dietary precursors would respond to fluxes of the precursor amino acids, 
GAA and creatine across gastrointestinal tissues.  
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Dietary arginine increases ornithine concentrations in mucosal tissues suggesting 
that either arginase or AGAT activities are significantly higher in the small intestinal 
mucosa (Tennakoon et al, 2013). However, we do not know the contribution of either 
arginases and AGAT for the synthesis of ornithine in the gut. Furthermore, what we do not 
know is whether there is a significant amount of AGAT activity in the neonatal gut. 
According to in-vitro enzyme activity, gut mucosa AGAT activity is insignificant (Brosnan 
et al, 2009). However, in-vitro enzyme activities represent enzyme capacities and do not 
represent in-vivo fluxes.  Therefore, future studies need to focus on the in-vivo flux through 
AGAT in the gut, possibly via isotope kinetics. 
 
Dietary citrulline bypasses the splanchnic citrulline conversion into arginine and a 
portion of whole-body endogenous arginine synthesis occurs in the renal tissues from 
citrulline (Marini et al, 2012). Therefore, arginine synthesized via the kidney from dietary 
citrulline bypasses the first-pass splanchnic arginine catabolism (possibly arginase activity, 
NOS and/or AGAT). Therefore, intragastrically fed citrulline is largely available to 
systemic metabolism. For this reason, feeding citrulline may be more beneficial than 
feeding arginine to neonatal piglets. We also determined that intravenous citrulline is more 
beneficial than arginine as citrulline is a better precursor for GAA/creatine synthesis in the 
kidney than arginine. However, feeding citrulline also bypasses other fates of arginine 
during splanchnic metabolism, such as arginine incorporation into splanchnic proteins, 
nitric oxide synthesis and polyamines synthesis. Therefore, citrulline feeding may be 
detrimental to gut metabolism in neonates (given that the gut is one of the most 
metabolically active organs). We know that the gut also takes up amino acids from the 
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arterial circulation. However, it has been shown that bypassing the first pass metabolism 
by the gut during intravenous feeding causes significant gut atrophy and also that 
intravenous delivery of arginine in neonates does not ameliorate gut atrophy. Therefore, 
supplementation of citrulline enterally needs further investigation to clarify whether a 
consequent lack of arginine in the diet would affect protein synthesis, polyamine synthesis 
and/or nitric oxide synthesis in splanchnic organs. 
 
6.4 Brain creatine synthesis 
 
We analyzed the brain GAA and creatine concentrations in both our IV and enteral (Chapter 
Three and Four) studies. In both these studies, we found no differences in brain GAA or 
creatine concentrations with or without supplementation of creatine or GAA in the diets. 
However, both of our studies were short term. The brain may be taking priority of available 
creatine over other organs to meet its creatine requirement. Therefore, short term changes 
of arginine, methionine, GAA or creatine may not affect brain creatine levels. Long term 
studies are needed in order to determine whether creatine supplementation is effective at 
increasing brain creatine levels. Studies conducted with humans who were suffering from 
creatine deficiency syndrome suggest that the brain takes up arterial creatine, but only very 
slowly. Therefore, changes in brain creatine and GAA concentrations may be undetectable 
(very low) during a short term feeding trials. Under this circumstance, even though the 
changes are very small, such changes are still very important for neonates as brain 
development during the neonatal period is at peak phase. Such short term changes would 
perhaps be visible with more sophisticated analytical methods such as isotopic kinetics. 
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Here, we are limited by the impossibility of measuring precursors and products of GAA 
and creatine across the brain. Isotopically labelled precursors and products of GAA and 
creatine can be measured in cerebrospinal fluid and in brain tissues. Therefore, the 
relationship between brain creatine concentration and dietary and endogenous creatine 
supply via isotopic kinetics are possible and warrant more investigation.  
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APPENDIX A: Body weight and blood flow for the study 
described in Chapter Five 
 
 
 
APPENDIX A1 Body weight of sow-fed (SF) non-fasted piglets or fasted piglets that 
received an infusion of either arginine, citrulline or alanine. Data were analyzed one-way 
ANOVA with Bonferroni’s multiple comparisons test for post hoc analysis. n = 6 per 
infusion groups and n = 4 per SF group. Values are means ± SD of non-transformed data. 
Arginine and methionine: Arg/Met, creatine in Arg/Met: +Cre, citrulline and methionine: 
Cit/Met, alanine: Ala 
 
 
S
F
A
rg
/M
e
t
+
C
re
C
it
/M
e
t
A
la
0
1
2
3
4
B
o
d
y
 w
e
ig
h
t 
a
t 
p
ro
c
e
d
u
re
 (
K
g
)
 191 
 
 
 
APPENDIX A2 Renal, Splenic and portal blood flow in sow-fed (SF) non-fasted piglets 
or fasted piglets that received an infusion of either arginine, citrulline or 
alanine. Data were analyzed one-way ANOVA with Bonferroni’s 
multiple comparisons test for post hoc analysis. n = 6 per infusion groups 
and n = 4 per SF group. Values are means ± SD of non-transformed data. 
Arginine and methionine: Arg/Met, creatine in Arg/Met: +Cre, citrulline 
and methionine: Cit/Met, alanine: Ala 
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Appendix B: Methods 
 
B.1 Determination of tissue and plasma amino acid concentrations 
 
Amino acids concentrations were determined according to the method of Bidlingmeyer et 
al., 1984.  
 
B.1.1 Tissue preparation 
 
Liver tissues and previously pulverized kidney tissue were homogenized with 2% cold 
perchloric acid (1:3 w/v) at 50% speed using a mechanical homogenizer for ~45 s and 
centrifuged at 3000 x g for 15 min to separate tissue-free amino acids from tissue-bound 
amino acids. The supernatant was collected into a scintillation vial. This step was repeated 
3 times to total 1:9 wt./vol. This step facilitated complete separation of tissue free amino 
acids. Norleucine (25 µmol/mL) was added to the scintillation vial as an internal standard 
(1:0.1 w/v) and stored at -80oC until needed.  
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B.1.2 Tissue free amino acid preparation 
 
The supernatant was neutralized with 2.0 M K2CO3 (12.5% v/v) in a plastic tube and 
centrifuged at 5000 x g for 3 min to separate the supernatant from the precipitate. One mL 
of supernatant was added to another plastic tube which was flash frozen in liquid nitrogen 
and placed on a freeze dryer overnight. The dried samples were stored in -20oC freezer until 
the derivatization was performed. Then samples were derivatized as described in B.1.4. 
when ready to run in the HPLC. 
 
B.1.3 Plasma preparation 
 
A 100 µL of aliquot plasma was mixed with 20 µL of 2.5 µmol/mL norleucine internal 
standard (Sigma Aldrich, Oakville, Canada) and 1 mL of 0.5% trifluoroacetic acid (TFA) 
(Sigma Aldrich, Oakville, Canada) in methanol (MeOH) (Fisher Scientific, Whitby, 
Canada) in a micro centrifuge tube, to precipitate proteins. The samples were vortexed and 
centrifuged at 2655 x g for 5 min. Then the supernatant was poured into a plastic tube and 
flash frozen in liquid nitrogen to dry down overnight in a freeze dryer (Thermo Savant, 
Canada).  
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Plasma and tissue-free amino acid concentrations were measured by reverse-phase 
HPLC (C18 column) following derivatization with phenylisothiocyanate (PITC) (Waters, 
Woburn, MA) as per the method of Bidlingmeyer et al (1984). 
 
B.1.4 Derivatization of plasma and tissue free supernatants 
 
100 µL of 2:2:6 TEA (Sigma Aldrich, Oakville, Canada): MeOH: water was added to each 
dried plasma or tissue-free sample followed by freeze drying for ~1 h. Plasma samples were 
then incubated for 35 min at room temperature with 50 µl of 1:1:7:1 solution of water: 
TEA: MeOH: PITC. The labelling with PITC was stopped by flash freezing with liquid 
nitrogen and then placed on a freeze dryer overnight. Plasma samples were re-suspended 
in 200 µL of sample diluent (710 mg of Na2HPO4 (Sigma Aldrich, Oakville, Canada) in 1 
liter of water, pH 7.4 with 10% H3PO4 acid; 5% of the volume was replaced with 
acetonitrile (Fisher Scientific, Whitby, Canada)) while tissue-free samples were 
resuspended in 300 µl of the same sample diluent. 
 
B.1.5 Amino acids by HPLC 
 
Plasma and tissue free amino acid concentrations were measured by reverse-phase HPLC 
following derivatization with phenylisothiocyanate (PITC) (Thermo Scientific, USA) 
(Bidlingmeyer et al., 1984).  
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A 40 µL of aliquot each plasma or tissue free sample was injected into a reverse-
phase C18 Pico-Tag column (Waters, 60Å, 4 µm 3.9 X 300 mm) connected to a HPLC 
system. The HPLC system consisted of a Waters 1525 Binary HPLC pump, Waters 2487 
Dual λ absorbance detector and Waters 717 plus Auto sampler (Waters Corporation, 
Milford, MA, USA). The column temperature was maintained at 46 oC to facilitate the 
separation of amino acids. Buffer A consisted of 70 mM sodium acetate (Fisher Scientific, 
Whitby, Canada) and 2.5% acetonitrile (Fisher Scientific, Whitby, Canada) at pH 6.55 and 
buffer B consisted of 45% acetonitrile and 15% methanol. Buffer was filtered through a 
0.45 µm MAGNA nylon filter (Canadian Life Science, Peterborough, ON, Canada) and 
degassed using a Waters In Line-Degasser AF. The column was allowed to equilibrate with 
buffer A at a rate of 1 mL/min. The phenylthiocarbamyl amino acids were detected at 254 
nm. Peaks were integrated using Breeze Software (Waters, version 3.3, 2002, Waters 
Corporation, Woburn MA, USA) and the amino acid concentrations were determined by 
comparing to the area produced by the internal standard. 
 
B.2 Tissue and plasma guanidinoacetate (GAA) and creatine  
B.2.1 Tissue preparation for GAA and creatine 
 
Tissue (kidney, pancreas, brain, and liver) GAA and creatine concentrations were assayed 
using an HPLC method according to Buchberger and Ferdig (2004) using a C18 reverse 
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phase column (Hypersil ODS 5 U 150x4.6 mm column) with ninhydrin (Sigma Aldrich) 
derivatization and fluorescence detection (Ex/EM 390/470). 
 
Tissue was homogenized with cold 1 M perchloric acid (1:4 w/v) followed by 
centrifugation at 4oC for 20 min at 15,250 x g. Supernatant was transferred to a tube 
quantitatively followed by addition of 50% K2CO3 and 20% KOH to neutralize (pH 6.5 - 
7) the samples. Samples were centrifuged again for 10 min at 10,600 x g at 4oC. Two- 
hundred microliters of supernatant was used for derivatization with ninhydrin (see 
section B.2.3). 
 
B.2.2 Plasma preparation for GAA and creatine 
 
Two-hundred microliters of plasma was mixed with 14 µL of 30% perchloric acid and 
placed on ice for 15 min followed by centrifugation at 15,000 x g for 8 min at 4oC. One-
hundred and fifty microliters of supernatant was transferred to a micro centrifuge 
tube and 22.4 µL of 20% KOH was added. Then samples were placed on ice for 15 min 
followed by centrifugation at 10,000 x g for 5 min. After centrifugation, 150 µl of 
supernatant was used for derivatization with ninhydrin (see section B.2.3). 
 
B.2.3 Derivatization with ninhydrin 
 
To both plasma and tissue samples, 1.3 M KOH and 0.9% ninhydrin (4:3:1.5) were added 
and mixed together and left at room temperature for 15 min. Five percent ascorbic acid and 
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5 M phosphoric acid (1:1) were added to samples and mixed followed by incubation in a 
90oC water bath for 30 min. After derivatization, samples were cooled and filtered using a 
0.45 µm PTFE syringe filter (Canadian Life Science, Peterborough, Canada).  
 
B.2.4 Ninhydrin HPLC separation of GAA and creatine 
 
Ninhydrin derivatised plasma and tissue (kidney, pancreas, brain, and liver) samples were 
run in the HPLC using a C18 reverse phase column (Hypersil ODS 5 U 150x4.6 mm 
column) with fluorescence detection (Ex/EM 390/470) to analyze the GAA and creatine 
concentrations. Detailed method was as follows. 
 
Samples were injected into a YMC-Pack Pro C18 column (150 X 4.6 mm I.D, 
3 µm; YMC America, Inc, Allentown, PA, USA) and derivatized GAA and creatine was 
separated via reverse-phase HPLC using a dual buffer system (Mobile phase A: 50 mM 
formic acid and mobile phase B: 100% methanol). Samples were detected by Waters 474 
scanning fluorescence detector at 470 nm emission and 390 nm excitation. The run time 
for each sample was 32 min with a flow rate of 1 mL/min. A standard curve was used for 
quantification and peaks were determined using Breeze Software (Waters, version 3.3, 
2002, Waters Corporation, Woburn, MA, USA). 
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B.3 Determination of total creatine in gastrocnemius muscle 
 
B.3.1 Tissue preparation 
 
Concentration of gastrocnemius muscle was determined using the simplified method of 
Lamarre et al (2010).  
 
Tissues were homogenized in a 50 mmol.L-1 Tris buffer (pH 7.4) and kept for 30 
min at room temperature to convert phosphocreatine into free creatine. The homogenates 
were then deproteinized with trifluoroacetic acid (TFA) in methanol and micro-centrifuged 
at 3825 x g at 4oC for 10 min. Samples were then filtered using a Bond-Elut C18 solid 
phase extraction cartridge. 
 
B.3.2 HPLC separation of total creatine  
 
The total creatine was separated via HPLC using porous graphitized carbon column 
(Hypercarb, 7 µm, 100 X 4.6 mm, Thermo Scientific, Canada). The peak was detected 
using a Waters 2487 Dual λ absorbance detector at an absorbance of 210 nm. An isocratic 
mobile phase of 0.1% TFA and 3% methanol was used with a flow rate of 1 mL/min and 
run time of 20 min. A standard curve was used for quantification and peaks were 
determined using Breeze Software (Waters, version 3.3, 2002, Waters Corporation, 
Woburn, MA, USA). 
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B.4 In-vitro enzyme activities 
 
B.4.1 AGAT activity 
 
AGAT activity was assayed using a modified method of Van et al (1970) using frozen 
tissues. The assay measured the amount of ornithine converted from arginine due to AGAT 
activity (transamidinase). Detailed methods were as follows. 
 
Whole kidney and pancreas tissues were pulverized, and a representative sample 
was used to measure transamidinase activity. Pulverized frozen kidney tissues were placed 
in 50 mM Potassium Phosphate buffer solution (1:5 w/v) consisting of 0.2 M potassium 
phosphate monobasic and 0.2 M dipotassium phosphate (pH 7.4). Samples were 
homogenized with polytron for 25 seconds. The resulted sample preparation was dilute 
1/20 with phosphate buffer to make 1% homogenate. The tissue homogenate prepared from 
homogenized frozen kidney or pancreas samples were incubated at 37oC in a shaking water 
bath with different substrate buffers containing either arginine (15 mM arginine, 17 mM 
Sodium Fluoride in 50mM Potassium Phosphate) or glycine (23 mM glycine, 17 mM 
Sodium Fluoride in 50mM Potassium Phosphate ) or arginine and glycine 15 mM arginine, 
23 mM glycine and 17 mM Sodium Fluoride in 50mM Potassium Phosphate) or phosphate 
buffer with no substrates (17 mM Sodium Fluoride in 50mM Potassium Phosphate). Each 
preparation was duplicated for the reactions and blank tubes. One of the blank reactions 
was stopped at the beginning of the incubation by adding 1 M PCA (stopped reaction). The 
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remaining blank and the reactions were stopped at the end of 60 minutes of incubation. All 
the tubes were covered with marbles during incubation at 37oC to minimise the evaporation. 
The resulting reactions and the blank and stop reaction were swirled to mix once stopped. 
The content was transferred to a new eppendorf and cooled on ice followed by 
centrifugation at 10,000 rpm for 5 minutes at 4oC. A 0.5 mL aliquot resulting supernatants 
were incubated in a 92oC water bath with ninhydrin colour reagent (6 g) dissolved in 1-
propanol anhydrous (100 mL) (Sigma Aldrich) in order to perform the ornithine assay for 
25 minutes. The preparation of ornithine assay was as follows; 
 
Blank contains 1 M PCA, 100 mM Potassium phosphate, Sodium fluoride, and 
ninhydrin solution while standard contains all the solutions in the blank with ornithine 
standard. The reactions and stopped reactions contain 0.5 mL of the supernatant and the 
ninhydrin solution. The absorbance of the final incubations was read at 505 nm in a 
spectrophotometer. 
 
The remaining tissue homogenates were stored at -70oC for total protein assay. The 
protein content of homogenates was assayed using the PierceTM BCA protein assay kit 
(Thermo Fisher Scientific, Mississauga, Canada). The ornithine produced by AGAT was 
presented as nmol of ornithine per mg of protein per min.  
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Calculation 
 
➢ ΔOD due to AGAT = ΔOD (+arg/+gly) - [{ΔOD (-arg/+gly) + ΔOD (+arg/-gly)} - 
ΔOD (-arg/-gly)] 
➢ (ΔOD AGAT) x nmol ornithine std x 5/ ΔOD x 60 minutes x 5 mg of sample  
= nmol ornithine/min/mg kidney 
 
B.4.2 Hepatic GAMT activity 
 
GAMT activity was assayed using fresh liver samples as described previously by da Silva 
et al (2009) which was modified from Ogawa et al (Ogawa et al., 1983). The reactions stop 
reactions and blanks were prepared from fresh liver samples immediately following 
necropsy and frozen at -80oC for the later analysis of resulting creatine via the ninhydrin 
HPLC method. Liver tissue was homogenized with a buffer solution (1:5 w/v) consisting 
of 0.25 M sucrose, 1 mM EDTA and 10 mM HEPES (pH 7.2). Homogenates were 
centrifuged at 100,000 x g at 4 ºC for 1 h and the supernatant was used to prepare the 
reactions and stop reactions.  
 
The reactions stop reactions and blank preparation was as follows. Briefly, 10 µl 
supernatant was added to 350µl of tris-β-mercaptoethanol solution (100 mM Tris buffer 
(pH 7.4), 20 mM 2-mercaptoethanol) and 50 μL S-adenosylmethionine solution (8.8 mg 
SAM in 1 mL of water and 1 mL of tris-β-mercaptoethanol buffer). The assay was 
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started by addition of 10 µl of GAA (4.68 mg of GAA in 1 mL of water and 1 mL of tris-β-
mercaptoethanol buffer) followed by incubation at 37oC for 20 min. Blanks for the assay 
did not contain supernatant. At the end of 20 min of incubation, the assay was stopped by 
addition of 750 μL of 15% (w/v) trichloroacetic acid and samples were kept on ice for 10 
min. Then 720 μL of 1 M Tris (pH 7.4) was added to neutralize the solutions. The resulting 
solutions were centrifuge at 10,000 x g for 5 min. Creatine synthesized by the enzyme 
GAMT was measured via HPLC and ninhydrin derivatization using 400 µL of supernatant 
as described above (B.2.3 & B.2.4) and activity was expressed per mg of protein per min. 
The protein content in each sample was determined via the biuret reaction. 
 
B.5 Measurement of tissue-specific fractional protein synthesis by gas 
chromatography mass spectrometry (GC-MS) 
 
B.5.1 Tissue preparation 
 
Liver, small intestinal mucosa and kidney samples were prepared for the extraction of cold 
and deuterated phenylalanine as per the method of Lamarre et al (2015).  
 
A 100 mg sample of frozen tissue was homogenized in 2 mL of cold dH2O at 50% 
speed using mechanical homogenizer for ~45 seconds. The resulting homogenate was 
vortexed with 500 µL of cold 2 M perchloric acid (PCA) thoroughly. The homogenates 
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were centrifuged at 3000 rpm for 20 minutes at 4oC to separate acid soluble, tissue-free 
amino acids from acid-insoluble, protein-bound amino acids.   
 
B.5.2 Tissue free amino acid preparation 
 
The supernatant (tissue-free) fraction was applied to a pre-conditioned hydrophobic solid 
phase extraction cartridge (Bond Elute C18, 100 mg 1 mL; Agilent Technologies, Santa 
Clara, CA) to extract phenylalanine. The procedure is as follows. The Bond Elute C18 was 
conditioned with 1 mL of 100% Methanol. One mL of 0.2 M PCA was applied to pre-
conditioned Bond Elute C18. A 0.5 mL sample was applied to the Bond Elute C18. The 
Bond Elute was acid washed with 1 mL of 0.2M PCA. Tissue-free phenylalanine was eluted 
with 1 mL of 100% methanol into a glass tube. This was freeze dried overnight. The dried 
bond eluted tissue-free samples were capped with nitrogen gas and stored in -20oC until 
ready for PFBBR derivatization.  
 
B.5.3 Tissue protein-bound amino acid preparation 
 
The pellet was washed three times as follows to remove all possible tissue-free amino acids 
from the pellet. The washing procedure was as follows. The pellet was homogenized in 5 
mL of 0.2 M PCA and the resulting solution was centrifuged at 3000 rpm for 20 min at 
4oC. This step was repeat for three times and the supernatant was discarded each time. The 
washed pallet was re-suspended in 4 mL of 6N HCL and a glass rod was used to disrupt 
the pellet, followed by transfer of all contents to a Pyrex tube. Then the solution was placed 
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in a 110°C oven for 18 h to hydrolyze the protein. The resulting hydrolysate solution was 
left to cool under the fume-hood. Hydrolysates were transferred into a new screw-capped 
plastic tube using a 0.45 µm PTFE syringe filter (Canadian Life Sciences, Canada). 
 
The hydrolysed (tissue-bound) fraction was applied to a pre-conditioned 
hydrophobic solid phase extraction cartridge (Bond Elute C18, 100 mg 1 mL; Agilent 
Technologies, Santa Clara, CA) to extract bound phenylalanine. The procedure was as 
follows. The Bond Elute C18 was conditioned with 1 mL of 100% Methanol. One mL of 
0.2 M PCA was applied to pre-conditioned Bond Elute C18. One mL tissue-bound sample 
was applied to the Bond Elute C18. The Bond Elute was acid washed with 1 mL of 0.2 M 
PCA. Tissue-free phenylalanine was eluted with 1 mL of 100% methanol into a glass tube. 
The last step was repeated twice. Therefore, the eluted sample was 2 mL in volume. The 
glass tubes were placed in a vacuum oven overnight to dry. The dried bond eluted tissue-
bound samples were capped with nitrogen gas and stored at -20oC until ready for PFBBr 
derivatization.  
  
B.5.4 PFBBr derivatization 
 
The dried tissue-free and tissue-bound eluents were re-suspended in 500 µL of HPLC water 
for the derivatization. The derivatization procedure was as follows. 
 
50 µL of resuspended tissue-free or tissue-bound samples were transferred into a 
glass vial containing 20 µL of 0.5 M phosphate buffer (pH 8.00 and 130 µL of 100 mM 
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pentafluorobenzyl bromide (PFBBr) derivative (Sigma Aldrich) solution in acetone. The 
vial was tightly capped, thoroughly mixed for 1 min and incubated at 60oC for an hour. 
After cooling at room temperature for 5 min, 330 µL of hexane was added and the vial was 
immediately re-capped. The hexane water sample was mixed for 1 min and the organic 
phase was removed and placed into a low volume insert fitted with a GC-MS glass vial for 
mass spectrometry analysis.  
 
B.5.5 GC-MS analysis 
  
The isotopic enrichment of L-[ring-2H5] phenylalanine in tissue-free and protein-bound 
fractions was determined by GC-MS with a model 6890 GC linked to a 5976N quadrupole 
MS (Agilent Technologies) operating in the electron ionization mode (Lamarre et al, 2015). 
A mixed sample of L-[ring-2H5] phenylalanine and unlabeled phenylalanine was run in scan 
mode, in which 91 and 96 ions or 300 and 305 were identified as potential ions. A standard 
curve was run before analyzing samples to identify the linear ranges. Ions with mass-to-
charge ratio of 91 and 96 ions were monitored via selected ion monitoring for liver, small 
intestinal mucosa and muscle tissues; for kidney and pancreas samples, 300 and 305 ions 
were monitored. Percent molar enrichment (mol%) was determined, and fractional 
synthesis rate (FSR, %/d) of protein was calculated as follows: 
 
FSR = IE bound / IE free 1440/t  100 
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Where IE bound and IE free are the isotopic enrichments (mol%) of L-[ring-
2H5] phenylalanine 
of the PCA-insoluble (protein bound) and PCA-soluble (tissue free) phenylalanine pool; t 
is time of labeling in min and 1440 is the number of minutes per day.  
 
B.6 Cholesterol and triglyceride analysis 
 
B.6.1 Tissue cholesterol and triglyceride analysis 
 
Total lipids were extracted from the liver tissues using the method of Folch et al (1957). 
Extracted lipids were used to analyze hepatic cholesterol and triglyceride (TG) 
concentrations via spectrophotometer assays (505 nm and 520 nm respectively) using 
commercially available kits (Genzyme DC-CAL, Triglyceride-SL and Cholesterol-SL) 
from Sekisui Diagnostic (Charlottetown, Canada). 
 
B.6.2 Plasma triglyceride and cholesterol analysis 
 
Plasma samples were also analyzed via spectrophotometer assays (505 nm and 520 nm 
respectively) using a commercially available glycerol standard (Sigma Aldrich) and 
cholesterol standard (Pointe Scientific, Canton, MI), and the same commercial kits as used 
for liver samples (Triglyceride-SL and Cholesterol-SL, Sekisui Diagnostic, Charlottetown, 
Canada). Cholesterol 
 
 207 
 
 
B.7 Plasma homocysteine and cysteine  
 
Plasma homocysteine was determined using a modified method by Vester and Rasmussen 
(1991). A 150 μL aliquot of plasma was combined with 20 μL of tris-(2-carboxyethyl) 
phosphine (100mg/mL) which was vortexed and left at room temperature for 30 minutes.  
50 µL of 0.2 mM 8-amino-naphthalene-1,3,6-trisulfonic acid disodium salt (ANTS) 
(dissolved in 0.1 mM borate buffer with 2mM EDTA at pH = 9.5) and 125 µL of 0.6 M 
perchloric acid were added to samples which were left at room temperature for 10 minutes 
followed by centrifugation at 4°C at 6000 rpm for 5 minutes. 100 μL of supernatant was 
then transferred to dark Eppendorf tubes followed by addition of 200 μL of borate buffer 
(2 M at pH = 10.5) and 100 μL of derivatizing agent 7-flurobenzo-2,1,3-oxadiazole-sulfonic 
acid ammonium salt (SBD-F) solution (1 mg/mL SBDF in 0.1 M borate buffer with 2 mM 
EDTA at pH = 9.5). Samples were covered in aluminum foil and vortexed followed by 
incubation at 60°C in a water bath for 60 minutes.  Samples were then removed and placed 
on ice for 5 minutes followed by centrifugation at 7000 rpm for 5 minutes.  Samples were 
injected into a Waters YMC column (Milford, MA) and homocysteine and cysteine were 
separated via reverse phase HPLC using a dual buffer system (Buffer A: and Buffer B:) 
with a run time of 20 minutes at 1mL/minute. Internal standard ANTS was used for 
quantification and Empower 2 software (Waters, Milford, MA) was used to determine area 
under the curve. 
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Solution preparation: 
 
Solution 1: Dissolve 6.8 g of sodium acetate trihydrate in 500 mL of HPLC water  
Solution 2: Add 11.5 mL glacial acetic acid (99.9%, 17.4 M) to 2 L of HPLC water  
Solution 3: Add Solution 1 for Solution 2 until pH = 4.0 (approximately 400 mL)  
HPLC Buffer A: Combine 980 mL of Solution 3 with 20 mL of methanol 
HPLC Buffer B: Combine 800 mL of Solution 3 with 200 mL of methanol 
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